[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2014055897A2 - Human monoclonal anti-pd-l1 antibodies and methods of use - Google Patents

Human monoclonal anti-pd-l1 antibodies and methods of use Download PDF

Info

Publication number
WO2014055897A2
WO2014055897A2 PCT/US2013/063509 US2013063509W WO2014055897A2 WO 2014055897 A2 WO2014055897 A2 WO 2014055897A2 US 2013063509 W US2013063509 W US 2013063509W WO 2014055897 A2 WO2014055897 A2 WO 2014055897A2
Authority
WO
WIPO (PCT)
Prior art keywords
seq
amino acid
antibody
cdrs
acid sequences
Prior art date
Application number
PCT/US2013/063509
Other languages
French (fr)
Other versions
WO2014055897A3 (en
Inventor
Wayne A. Marasco
Jianhua Sui
Original Assignee
Dana-Farber Cancer Institute, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to KR1020157008757A priority Critical patent/KR101947702B1/en
Priority to CN202111595551.3A priority patent/CN114507282A/en
Priority to MX2015004105A priority patent/MX370848B/en
Priority to JP2015535829A priority patent/JP6461800B2/en
Priority to CA2886433A priority patent/CA2886433C/en
Priority to EP13776696.0A priority patent/EP2903641A2/en
Priority to CN201380063513.0A priority patent/CN104994873B/en
Priority to BR112015007672A priority patent/BR112015007672A2/en
Application filed by Dana-Farber Cancer Institute, Inc. filed Critical Dana-Farber Cancer Institute, Inc.
Priority to AU2013326901A priority patent/AU2013326901B2/en
Priority to US14/433,826 priority patent/US9828434B2/en
Publication of WO2014055897A2 publication Critical patent/WO2014055897A2/en
Publication of WO2014055897A3 publication Critical patent/WO2014055897A3/en
Priority to IL237737A priority patent/IL237737B/en
Priority to HK15112103.2A priority patent/HK1211223A1/en
Priority to US15/821,087 priority patent/US10604581B2/en
Priority to AU2018226425A priority patent/AU2018226425B2/en
Priority to US16/834,901 priority patent/US20200385482A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Definitions

  • This invention relates generally to anti-PD-Ll (also known as programmed cell death 1 ligand 1 or B7H1) antibodies as well as to methods for use thereof.
  • anti-PD-Ll also known as programmed cell death 1 ligand 1 or B7H1
  • T cells are central to preserving this balance, and their proper regulation is primarily coordinated by the B7-CD28 family of molecules. Interactions between B7 family members, which function as ligands, and CD28 family members, which function as receptors, provide critical positive signals that not only initiate, augment and sustain T cell responses, but also contribute key negative signals that limit, terminate and/or attenuate T cell responses when appropriate.
  • a member of the CD28 family, called PD-1 also known as programmed cell death-1 is upregulated on activated T cells, B cells, and monocytes.
  • PD-1 has two identified ligands in the B7 family, PD-L1 (also known as BH71 or programmed cell death-1 ligand 1) and PD-L2. While PD-L2 expression tends to be more restricted, found primarily on activated antigen-presenting cells (APCs), PD-L1 expression is more widespread, including cells of hematopoietic lineage (including activated T cells, B cells, monocytes, dendritic cells and macrophages) and peripheral nonlymphoid tissues (including heart, skeletal, muscle, placenta, lung, kidney and liver tissues). The widespread expression of PD-L1 suggests its significant role in regulating PD-1/PD-L1 -mediated peripheral tolerance.
  • APCs activated antigen-presenting cells
  • Binding between PD-L1 and PD-1 has a profound effect on the regulation of T cell responses. Specifically, PD-Ll/PD-1 interaction inhibits T cell proliferation and production of effector cytokines that mediate T cell activity and immune response, such as IL-2 and IFN- ⁇ . This negative regulatory function is important for preventing T cell- mediated autoimmunity and immunopathology. However, the PD-l/PD-Ll axis has also been shown to play a role in T cell exhaustion, whereby the negative regulatory function inhibits T cell response to the detriment of the host. Prolonged or chronic antigenic stimulation of T cells can induce negative immunological feedback mechanisms which inhibit antigen- specific responses and results in immune evasion of pathogens.
  • T cell exhaustion can also result in progressive physical deletion of the antigen-specific T cells themselves.
  • T cell expression of PD-1 is up-regulated during chronic antigen stimulation, and its binding to PD-L1 results in a blockade of effector function in both CD4+ (T helper cells) and CD8+ (cytotoxic T lymphocytes or CTL) T cells, thus implicating the PD-l/PD-Ll interaction in the induction of T cell exhaustion.
  • PD-1 is highly expressed on HIV-specific CD8+ T cells of HIV infected individuals, indicating that blocking the PD-l/PD-Ll pathway may have therapeutic potential for treatment of HIV infection and AIDS patients.
  • agents that block the PD-l/PD-Ll pathway will provide a new therapeutic approach for a variety of cancers, HIV infection, and/or other diseases and conditions that are associated with T-cell exhaustion. Therefore, there exists an urgent need for agents that can block or prevent PD- l/PD-Ll interaction.
  • the invention is based upon the discovery of monoclonal antibodies which bind PD-L1.
  • the monoclonal antibody is fully human.
  • the antibodies bind PD-L1.
  • the antibodies are referred to herein as huPD-Ll antibodies.
  • PD-L1 is also known as programmed cell death 1 ligand 1, programmed death ligand 1, PDCD1 ligand 1, PDCD1L1, PDL1, B7 homolog 1, B7H1, B7-H, CD274 and CD274 antigen.
  • the present invention provides an isolated humanized monoclonal antibody having a heavy chain with three CDRs comprising the amino acid sequences SYGIS (SEQ ID NO:57), WISAYNGNTNYAQKLED (SEQ ID NO:70), and ALPS GTILVGGWFDP (SEQ ID NO: 86) respectively and a light chain with three CDRs comprising the amino acid sequences TRSSGNIASNYVQ (SEQ ID NO: 101), EDNQRPS (SEQ ID NO: 115), and QSYDSSNLWV (SEQ ID NO: 127) respectively; a heavy chain with three CDRs comprising the amino acid sequences SYALS (SEQ ID NO:58), AISGGGGSTYYADSVKD (SEQ ID NO:71), and DVFPETFSMNYGMDV (SEQ ID NO:87) respectively and a light chain with three CDRs comprising the amino acid sequences QGDSLRSYYAS (SEQ ID NO: 102), GKNNRPS (SEQ ID NO: 102),
  • QVWDNNSDHYV (SEQ ID NO: 129) respectively; a heavy chain with three CDRs comprising the amino acid sequences NYDMS (SEQ ID NO:61),
  • RVNWNGGSTTYADAVKD SEQ ID NO:74
  • EFVGAYDL SEQ ID NO:89
  • a heavy chain with three CDRs comprising the amino acid sequences TGTSSDVGGYNYVS SEQ ID NO: 104
  • DVSNRPS SEQ ID NO: 118
  • SSYTSSTLP SEQ ID NO: 130
  • a heavy chain with three CDRs comprising the amino acid sequences GLYIH SEQ ID NO:62
  • WIIPIFGTANYAQKFED SEQ ID NO:75
  • GLRWGIWGWFDP SEQ ID NO: 90
  • a heavy chain with three CDRs comprising the amino acid sequences RASQSIGNSLA SEQ ID NO: 105
  • GASSRAT SEQ ID NO:119
  • QQHTIPTFS SEQ ID NO:131
  • WIIPIFGKPNYAQKFED SEQ ID NO:76
  • TMVRGFLGVMDV SEQ ID NO:91
  • a heavy chain with three CDRs comprising the amino acid sequences SYAMS SEQ ID NO:64
  • AISGSGGSTYYADSVKD SEQ ID NO:77
  • DQFVTIFGVPRYGMDV SEQ ID NO: 92
  • a light chain with three CDRs comprising the amino acid sequences SGDKLGNKYAY SEQ ID NO: 107
  • QDIKRPS SEQ ID NO: 121
  • QTWDNSVV SEQ ID NO: 133
  • a heavy chain with three CDRs comprising the amino acid sequences SYAIS SEQ ID NO:
  • QSYDSNNRHVI (SEQ ID NO: 134) respectively; a heavy chain with three CDRs comprising the amino acid sequences TYALN (SEQ ID NO:65), RIVPLIGLVNYAHNFED (SEQ ID NO:79), and EVYGGNSDY (SEQ ID NO:94) respectively and a light chain with three CDRs comprising the amino acid sequences TRSSGNIGTNYVQ (SEQ ID NO: 109), EDYRRPS (SEQ ID NO: 122), and QSYHSSGWE (SEQ ID NO: 135) respectively; a heavy chain with three CDRs comprising the amino acid sequences SHGIT (SEQ ID NO: 66),
  • WISAHNGHASNAQKVED SEQ ID NO:80
  • VHAALYYGMDV SEQ ID NO:95
  • a light chain with three CDRs comprising the amino acid sequences GGNNIGS KG VH (SEQ ID NO: 110), DDSDRPS (SEQ ID NO: 123), and
  • QVWDSSSDHWV (SEQ ID NO: 136) respectively; a heavy chain with three CDRs comprising the amino acid sequences RHGMH (SEQ ID NO:67),
  • VISHDGSVKYYADSMKD (SEQ ID NO:81), and GLSYQVSGWFDP (SEQ ID NO:96) respectively and a light chain with three CDRs comprising the amino acid sequences TRSSGSIASNYVQ (SEQ ID NO: 111), EDNQRPS (SEQ ID NO: 115), and QSYDSTTPSV (SEQ ID NO: 137) respectively; a heavy chain with three CDRs comprising the amino acid sequences SYGIS (SEQ ID NO:58), WTSPHNGLTAFAQILED (SEQ ID NO:82), and VHPVFSYALDV (SEQ ID NO: 97) respectively and a light chain with three CDRs comprising the amino acid sequences TRSSGSIASNYVQ (SEQ ID NO: 112), EDNQRPS (SEQ ID NO: 115), and QSYDGITVI (SEQ ID NO: 138) respectively; a heavy chain with three CDRs comprising the amino acid sequences TYAFS (S
  • RIIPILGIANYAQKFED SEQ ID NO:83
  • DGYGSDPVL SEQ ID NO:98
  • a heavy chain with three CDRs comprising the amino acid sequences NYGIS SEQ ID NO:69
  • WISAYNGNTNYAQKVED SEQ ID NO:84
  • GDFRKPFDY SEQ ID NO: 99
  • said antibody binds human PD- Ll.
  • the present invention provides a single chain antibody comprising a V H nucleotide sequence comprising SEQ ID NO: 1 and a V L nucleotide sequence comprising SEQ ID NO: 3 ; a V H nucleotide sequence comprising SEQ ID NO: 5 and a V L nucleotide sequence comprising SEQ ID NO:7; a V H nucleotide sequence comprising SEQ ID NO: 9 and a V L nucleotide sequence comprising SEQ ID NO: 11 ; a V H nucleotide sequence comprising SEQ ID NO: 13 and a V L nucleotide sequence comprising SEQ ID NO: 15; a V H nucleotide sequence comprising SEQ ID NO: 17 and a V L nucleotide sequence comprising SEQ ID NO: 19; a V H nucleotide sequence comprising SEQ ID NO: 21 and a V L nucleotide sequence comprising SEQ ID NO:23 ; a V H nucleotide
  • the present invention provides a single chain antibody comprising a V H amino acid sequence comprising SEQ ID NO: 2 and a V L amino acid sequence comprising SEQ ID NO: 4; a V H amino acid sequence comprising SEQ ID NO: 6 and a V L amino acid sequence comprising SEQ ID NO: 8; a V H amino acid sequence comprising SEQ ID NO: 10 and a V L amino acid sequence comprising SEQ ID NO: 12; a V H amino acid sequence comprising SEQ ID NO: 14 and a V L amino acid sequence comprising SEQ ID NO: 16; a V H amino acid sequence comprising SEQ ID NO: 18 and a V L amino acid sequence comprising SEQ ID NO: 20; a V H amino acid sequence comprising SEQ ID NO: 22 and a V L amino acid sequence comprising SEQ ID NO: 24; a V H amino acid sequence comprising SEQ ID NO: 26 and a V L amino acid sequence comprising SEQ ID NO: 28; a V H amino acid sequence comprising SEQ ID NO:
  • the antibody has a binding affinity within the range of 10 "5 M to 10 "12 M.
  • the antibody is a bi-specific antibody that also binds to a tumor-associated antigen, a cytokine or a cell surface receptor.
  • the tumor- associated antigen is CAIX.
  • the cytokine is IL-10.
  • the cell surface receptor is CCR4, IL21R, BTLA, HVEM or TIM3.
  • the present invention provides an antibody linked to a therapeutic agent.
  • the therapeutic agent is a toxin, a radiolabel, a siRNA, a small molecule, or a cytokine.
  • the present invention provides a cell producing any of the foregoing antibodies.
  • the present invention also provides methods of selectively killing a tumor cell comprising contacting said cell with any of the foregoing antibodies.
  • the selective killing occurs by antibody-dependent cellular toxicity (ADCC), complement- dependent cytotoxicity (CDC), antibody dependent cellular phagocytosis (ADCP).
  • the tumor cell expresses PD-L1.
  • the present invention also provides methods of preventing or reversing T cell exhaustion comprising administering to a subject in need thereof a composition comprising any of the foregoing antibodies.
  • the present invention also provides methods of augmenting an immune response to an antigen comprising administering to a subject in need thereof a composition comprising any of the foregoing antibodies.
  • the antigen is a viral antigen, a bacterial antigen or a tumor associated antigen.
  • the viral antigen is HIV.
  • the tumor associated antigen is CAIX.
  • the antibody is administered prior to or after exposure to the antigen.
  • the administration of said antibody causes an increase in antigen specific T cell activity.
  • the T- cell is an effector T cell.
  • the present invention also provides methods of treating or alleviating a symptom of cancer, comprising administering to a subject in need thereof a composition comprising any of the foregoing antibodies.
  • the cancer is renal cell carcinoma or breast cancer.
  • the cancer is a cancer in which PD-L1 is overexpressed.
  • the cancer is a cancer that induces T cell exhaustion.
  • the present invention also provides methods of treating or alleviating a symptom of a chronic viral infection, comprising administering to a subject in need thereof a composition comprising any of the foregoing antibodies.
  • the chronic viral infection is an HIV infection.
  • the chronic viral infection is a viral infection that induces T cell exhaustion.
  • the present invention provides a nucleic acid sequence comprising the nucleic acid sequence of SEQ ID NO: 1 , 3, 5, 7, 9, 11 , 13. 15. 17, 19, 21 , 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53 or 55.
  • the present invention provides a nucleic acid sequence encoding the polypeptide of SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54 or 56.
  • the present invention provides a polypeptide comprising the amino acid sequence of SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54 or 56.
  • the present invention provides a vector comprising a nucleic acid sequence of SEQ ID NO: 1 , 3, 5, 7, 9, 11 , 13. 15. 17, 19, 21 , 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53 or 55.
  • the present invention provides a vector comprising a nucleic acid sequence of SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54 or 56.
  • the present invention further provides a cell comprising any one of the foregoing vectors.
  • the administration routes include, but are not limited to parenteral, (e.g. , intravenous), intradermal, subcutaneous, oral (e.g. , inhalation), transdermal (i. e., topical), transmucosal, and rectal administration.
  • the subject in any methods of this disclosure is, for example, a mammal.
  • the mammal is, for example, a human.
  • Other features and advantages of the invention will be apparent from and are encompassed by the following detailed description and claims.
  • FIG. 1 Amino acid sequences of anti-PD-Ll scFv-phage clones (14 clones). Framework regions 1-4 (FW1-4), Complementarily determining regions 1-3 (CDR1- 3) and family designations for both the IGHV and IGLV/IGKV are shown. Kabat number is used. Key: “.” AA matches to consensus, "X” no consensus AA, and "-" is a space (i.e. no AA).
  • Ll Ll expressing cells by FACS.
  • Four types of cells were tested, including parental cell line 300.9 and hPD-Ll, hPD-L2 or human C-type lectin domain family 2 member (hCLEC2D) transfected 300.9 cells.
  • GF1538 is a humanized Ab against hPD-Ll.
  • GF1757 is a humanized Ab against hPD-L2.
  • Secondary antibody is PE-goat anti-human IgG.
  • Figure 3 Inhibition of hPD-1 binding to hPD-Ll by anti-PD-Ll phage- antibodies in a competitive FACS analysis. All anti-hPD-Ll Abs in phage-scFv form were tested for inhibition of the binding of hPDl-hFc fusion protein with hPD-Ll expressing 293T cells. 10 12 pfu of phage-scFvs were mixed with -0.25 ⁇ g/mL of soluble hPDl-hFc and added to hPD-Ll expressing-plasmid transfected 293T cells. After washing, the cells were incubated with FITC- anti-human IgG antibody to measure the binding of hPDl-hFc to hPD- Ll on cell surface.
  • Figure 4 Inhibition of hPD- 1 binding to hPD-Ll by anti-PD-Ll soluble antibodies in a competitive FACS analysis. All anti-hPD-Ll Abs were pre-incubated with hPD-Ll expressing-plasmid transfected 300.9 cells at indicated concentrations for 30 mins, 0.125 ⁇ g of hPD-1 -mouse IgG2a was then added to each reaction and incubated for another 30 mins. After washing, PE-goat-anti-mouse IgG2a Ab was added and followed by washing and FACS analysis.
  • GF1538 is a humanized Ab against hPD-Ll.
  • GF1757 is a humanized Ab against hPD-L2.
  • Figure 5 Design and formation of bi-specific antibodies.
  • FIG. 1 Bi-specific antibody (bsAb) construct determination.
  • A) Schematic representation of the bi-specific antibody that recognizes CAIX and PD-L1, and the "knob into hole” approach of linking the CH3 domains.
  • B) Schematic representation of the three types of bsAb constructs with different mutations in the CH2 domain to alter ADCC activity.
  • Figure 7. Generation of bi-specific antibody and its function.
  • A) Protein gel showing the dissociation of engineered (G37 KIHA) antibody under reducing conditions compared to conjugated (non-reduced) control IgG, parental G37 (WT), and bi-specific (G37 KIHA + PD-Ll KIHB) antibodies.
  • FIG. 8 Functional characterization of PD-Ll specific mAb42.
  • PBMCs from four healthy donors D1-D4 were cultured in the presence of ocPDLl (mAb42) or control isotype antibody stimulated with 0.1 ⁇ g/ml SEB for 48 hours and TNFoc production was measured by MSD units. Data presented as means of triplicates *, p ⁇ 0.0005.
  • the present invention provides humanized monoclonal antibodies specific against PD-Ll, also known as B7H1.
  • the antibodies were identified by a method of phage display antibody library selection by using proteoliposome-coupled-PD-Ll as the library selection target. These antibodies represent a new class of human monoclonal antibodies against PD-Ll.
  • T cell exhaustion is a state of T cell dysfunction that can arise in chronic infections and cancer. It is defined by poor effector function, sustained expression of inhibitory receptors and a transcriptional state distinct from that of functional effector or memory T cells. Exhaustion prevents management of infection and tumor progression.
  • PD-Ll overexpression has been detected in different cancers. For example, in breast cancer, PD-Ll is overexpressed and associated with high-risk prognostic factors. In renal cell carcinoma, PD-Ll is upregulated and increased expression of PD-1 has also been found in tumor infiltrating leukocytes. Anti-PD-Ll and anti-PD-1 antibodies have demonstrated some clinical efficacy in phase I trials for renal cell carcinoma.
  • Therapeutic agents that can bind to PD-1 or PD-L1 may be useful for specifically targeting tumor cells. Agents that are capable of blocking the PD-l/PD-Ll interaction may be even more useful in treating cancers that have induced T cell exhaustion to evade anti-tumor T cell activity. Use of such agents, alone or in combination with other anti-cancer therapeutics, can effectively target tumor cells that overexpress PD-L1 and increase anti-tumor T cell activity, thereby augmenting the immune response to target tumor cells.
  • PD-1 and PD-L1 can also be upregulated by T cells after chronic antigen stimulation, for example, by chronic infections.
  • chronic HIV infection HIV-specific CD8+ T cells are functionally impaired, showing a reduced capacity to produce cytokines and effector molecules as well as a diminished ability to proliferate.
  • PD-1 is highly expressed on HIV-specific CD8+ T cells of HIV infected individuals. Therefore, blocking this pathway may enhance the ability of HIV-specific T cells to proliferate and produce cytokines in response to stimulation with HIV peptides, thereby augmenting the immune response against HIV.
  • Other chronic infections may also benefit from the use of PD-l/PD-Ll blocking agents, such as chronic viral, bacterial or parasitic infections.
  • the present invention provides a human monoclonal antibody that specifically binds PD-L1 proteins. Binding of the antibody of the present invention to PD-L1 interrupts the ligand's ability to bind to its receptor PD1. By a variety of mechanisms, the huPD-Ll antibody prevents the negative feedback mechanisms that inhibit T cell responses. In some cases, the huPD-Ll antibody prevents, inhibits or reverses T cell exhaustion. Administration of the huPD-Ll antibody may result in increased T cell proliferation, increased antigen- specific T cell activity, and increased production of effector cytokines. In some instances, the huPD-Ll antibody promotes or augments the antigen- specific immune response. This immune response may be mediated by effector T cells.
  • the huPD-Ll antibody is monovalent or bivalent and comprises a single or double chain. Functionally, the binding affinity of the huPD-Ll antibody is within the range of 10 ⁇ 5 M to 10 ⁇ 12 M.
  • the binding affinity of the huPD-Ll antibody is from 10 ⁇ 6 M to 10 ⁇ 12 M, from 10 "7 M to 10 ⁇ 12 M, from 10 ⁇ 8 M to 10 "12 M, from 10 ⁇ 9 M to 10 "12 M, from 10 "5 M to 10 ⁇ n M, from 10 "6 M to 10 ⁇ n M, from 10 "7 M to 10 ⁇ n M, from 10 ⁇ 8 M to 10 ⁇ n M, from 10 "9 M to 10 "11 M, from 10 "10 M to 10 "11 M, from 10 "5 M to 10 "10 M, from 10 "6 M to 10 "10 M, from 10 "7 M to 10 "10 M, from 10 "8 M to 10 “10 M, from 10 "9 M to 10 "10 M, from 10
  • the antibody of the present invention comprises a therapeutic agent including, but not limited to, a toxin, a radiolabel, a siRNA, or a cytokine.
  • the huPD-Ll antibody is capable of inducing cell death.
  • Cell death is induced by either direct or indirect mechanisms.
  • PD-Ll binding by the huPD-Ll antibody can lead to complement-dependent cytotoxicity (CDC).
  • CDC complement-dependent cytotoxicity
  • the huPD-Ll antibody binds PD-Ll, and leads to the recruitment of a second cell type that will kill the PD- L14-expressing target cell.
  • Exemplary mechanisms by which the huPD-Ll antibody mediates cell death by recruitment of a second cell type include, but are not limited to, antibody- dependent cellular toxicity (ADCC) and antibody dependent cellular phagocytosis (ADCP).
  • Target PD-Ll -expressing cell types comprise tumor and T cells, such as activated T cells.
  • huPD-Ll antibodies Fourteen unique monoclonal huPD-Ll antibodies were identified. These include Ab-14, Ab-16, Ab-22, Ab-30, Ab-31, Ab-32, Ab-38, Ab-42, Ab-46, Ab-50, Ab-52, Ab-55, Ab-56 and Ab-65.
  • nucleic acid and amino acid sequence of the monoclonal huPD-Ll antibodies are provided below:
  • V H chain of Ab-14 (SEQ ID NO: l)
  • V L chain of Ab-14 (SEQ ID NO:3)
  • V H chain of Ab-14 (SEQ ID NO:2)
  • V L chain of Ab-14 (SEQ ID NO:4)
  • V H chain of Ab-16 (SEQ ID NO:5)
  • V L chain of Ab-16 (SEQ ID NO:7)
  • V H chain of Ab-16 (SEQ ID NO: 6)
  • V L chain of Ab-16 (SEQ ID NO: 8)
  • V H chain of Ab-22 (SEQ ID NO:9)
  • V L chain of Ab-22 (SEQ ID NO: 11)
  • V H chain of Ab-22 (SEQ ID NO: 10)
  • V L chain of Ab-22 (SEQ ID NO: 12)
  • V L chain of Ab-30 (SEQ ID NO: 15)
  • V H chain of Ab-30 (SEQ ID NO: 14)
  • V L chain of Ab-30 (SEQ ID NO: 16)
  • V H chain of Ab-31 (SEQ ID NO: 17)
  • V L chain of Ab-31 (SEQ ID NO: 19)
  • V H chain of Ab-31 (SEQ ID NO: 18)
  • V L chain of Ab-31 (SEQ ID NO:20)
  • V H chain of Ab-32 (SEQ ID NO:21)
  • V H chain of Ab-32 (SEQ ID NO:22)
  • V L chain of Ab-32 (SEQ ID NO:24)
  • V H chain of Ab-38 (SEQ ID NO:25)
  • V L chain of Ab-38 (SEQ ID NO:27)
  • V H chain of Ab-38 (SEQ ID NO:26)
  • V L chain of Ab-38 (SEQ ID NO:28)
  • V H chain of Ab-42 (SEQ ID NO:29)
  • V L chain of Ab-42 (SEQ ID NO:31)
  • V H chain of Ab-42 (SEQ ID NO: 30)
  • V L chain of Ab-42 (SEQ ID NO: 32)
  • V H chain of Ab-46 (SEQ ID NO:33)
  • V L chain of Ab-46 (SEQ ID NO: 35)
  • V H chain of Ab-46 (SEQ ID NO: 34)
  • V L chain of Ab-46 (SEQ ID NO:36)
  • V H chain of Ab-50 (SEQ ID NO: 37)
  • V L chain of Ab-50 (SEQ ID NO: 39)
  • V H chain of Ab-50 (SEQ ID NO:38)
  • V L chain of Ab-50 (SEQ ID NO:40)
  • V H chain of Ab-52 (SEQ ID NO:41)
  • V L chain of Ab-52 (SEQ ID NO:43)
  • V H chain of Ab-52 (SEQ ID NO:42)
  • V L chain of Ab-52 (SEQ ID NO:44)
  • V H chain of Ab-55 (SEQ ID NO:45)
  • V L chain of Ab-55 (SEQ ID NO:47)
  • V H chain of Ab-55 (SEQ ID NO:46)
  • V L chain of Ab-55 (SEQ ID NO:48)
  • V H chain of Ab-56 (SEQ ID NO:49)
  • V L chain of Ab-56 (SEQ ID NO:51)
  • V H chain of Ab-56 (SEQ ID NO:50)
  • V L chain of Ab-56 (SEQ ID NO:52)
  • V H chain of Ab-65 (SEQ ID NO:53)
  • V L chain of Ab-65 (SEQ ID NO:55)
  • V H chain of Ab-65 (SEQ ID NO:54)
  • V L chain of Ab-65 (SEQ ID NO:56)
  • Table 15B Amino acid sequences of the complementary determining regions of the light chain.
  • the huPD-Ll antibodies described herein bind to PD-Ll.
  • the huPD-Ll antibodies have high affinity and high specificity for PD-Ll.
  • the huPD-Ll antibodies can bind the PD-1 receptor and prevent, inhibit, or block the ligand PD- Ll from binding its receptor PD-1.
  • the huPD-Ll antibodies may have some cross-reactivity with PD-L2.
  • the huPD-Ll antibodies do not exhibit any cross-reactivity with PD-L2.
  • the huPD-Ll antibodies bind to PD-L1 with higher affinity and/or higher specificity than to PD-L2.
  • the present invention also features antibodies that have a specified percentage identity or similarity to the amino acid or nucleotide sequences of the huPD-Ll antibodies described herein.
  • the antibodies may have 60% , 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or higher identity when compared a specified region or the full length of any one of the huPD-Ll antibodies described herein.
  • Sequence identity or similarity to the nucleic acids and proteins of the present invention can be determined by sequence comparison and/or alignment by methods known in the art. For example, sequence comparison algorithms (i.e. BLAST or BLAST 2.0), manual alignment or visual inspection can be utilized to determine percent sequence identity or similarity for the nucleic acids and proteins of the present invention.
  • amino acid sequences one of skill in the art will readily recognize that individual substitutions, deletions or additions to a nucleic acid, peptide, polypeptide, or protein sequence which alters, adds, deletes, or substitutes a single amino acid or a small percentage of amino acids in the encoded sequence is collectively referred to herein as a "conservatively modified variant".
  • the alteration results in the substitution of an amino acid with a chemically similar amino acid.
  • Conservative substitution tables providing functionally similar amino acids are well known in the art.
  • Such conservatively modified variants of the huPD-Ll antibody disclosed herein may exhibit increased cross-reactivity to PD-L2 in comparison to an unmodified huPD-Ll antibody.
  • antibody refers to immunoglobulin molecules and immunologically active portions of immunoglobulin (Ig) molecules, i.e. , molecules that contain an antigen binding site that specifically binds (immunoreacts with) an antigen.
  • Ig immunoglobulin
  • immunoglobulin molecules molecules that contain an antigen binding site that specifically binds (immunoreacts with) an antigen.
  • specifically binds or “immunoreacts with” is meant that the antibody reacts with one or more antigenic determinants of the desired antigen and does not react with other
  • Antibodies include, but are not limited to, polyclonal, monoclonal, chimeric, dAb (domain antibody), single chain, F a , F a - and F( ab ') 2 fragments, scFvs, and F a expression libraries.
  • a single chain Fv (“scFv”) polypeptide molecule is a covalently linked VH:VL heterodimer, which can be expressed from a gene fusion including VH- and " VY-encoding genes linked by a peptide-encoding linker. (See Huston et al. (1988) Proc Nat Acad Sci USA 85(16):5879-5883).
  • antibody molecules obtained from humans relate to any of the classes IgG, IgM, IgA, IgE and IgD, which differ from one another by the nature of the heavy chain present in the molecule. Certain classes have subclasses as well, such as IgGi, IgG 2 , and others.
  • the light chain may be a kappa chain or a lambda chain.
  • the term "antigen-binding site,” or “binding portion” refers to the part of the immunoglobulin molecule that participates in antigen binding. The antigen binding site is formed by amino acid residues of the N-terminal variable ("V") regions of the heavy (“H”) and light (“L”) chains.
  • FR refers to amino acid sequences which are naturally found between, and adjacent to, hypervariable regions in immunoglobulins.
  • the three hypervariable regions of a light chain and the three hypervariable regions of a heavy chain are disposed relative to each other in three dimensional space to form an antigen-binding surface.
  • the antigen-binding surface is complementary to the three-dimensional surface of a bound antigen, and the three hypervariable regions of each of the heavy and light chains are referred to as
  • CDRs complementarity-determining regions
  • epitopic determinants includes any protein determinant capable of specific binding to an immunoglobulin, a scFv, or a T-cell receptor.
  • Epitopic determinants usually consist of chemically active surface groupings of molecules such as amino acids or sugar side chains and usually have specific three dimensional structural characteristics, as well as specific charge characteristics.
  • antibodies may be raised against N- terminal or C-terminal peptides of a polypeptide.
  • immunological binding refers to the non-covalent interactions of the type which occur between an immunoglobulin molecule and an antigen for which the immunoglobulin is specific.
  • the strength, or affinity of immunological binding interactions can be expressed in terms of the dissociation constant (K ⁇ of the interaction, wherein a smaller K ⁇ j represents a greater affinity.
  • Immunological binding properties of selected polypeptides can be quantified using methods well known in the art. One such method entails measuring the rates of antigen- binding site/antigen complex formation and dissociation, wherein those rates depend on the concentrations of the complex partners, the affinity of the interaction, and geometric parameters that equally influence the rate in both directions.
  • both the "on rate constant” (K on ) and the “off rate constant” (K cff ) can be determined by calculation of the concentrations and the actual rates of association and dissociation. (See Nature 361: 186-87 (1993)).
  • the ratio of K cff /K on enables the cancellation of all parameters not related to affinity, and is equal to the dissociation constant K ⁇ j. (See, generally, Davies et al. (1990) Annual Rev Biochem 59:439-473).
  • An antibody of the present invention is said to specifically bind to a PD-L1 epitope when the equilibrium binding constant (K ⁇ is ⁇ 10 ⁇ , preferably ⁇ 10 nM, more preferably ⁇ 10 nM, and most preferably ⁇ 100 pM to about 1 pM, as measured by assays such as radioligand binding assays or similar assays known to those skilled in the art.
  • K ⁇ is ⁇ 10 ⁇ , preferably ⁇ 10 nM, more preferably ⁇ 10 nM, and most preferably ⁇ 100 pM to about 1 pM, as measured by assays such as radioligand binding assays or similar assays known to those skilled in the art.
  • An PD-L1 protein of the invention may be utilized as an immunogen in the generation of antibodies that immunospecifically bind these protein components.
  • a PD-L1 protein or a derivative, fragment, analog, homolog, or ortholog thereof, coupled to a proteoliposome may be utilized as an immunogen in the generation of antibodies that immunospecifically bind these protein components.
  • a human monoclonal antibody has the same specificity as a human monoclonal antibody of the invention by ascertaining whether the former prevents the latter from binding to PD-L1. If the human monoclonal antibody being tested competes with the human monoclonal antibody of the invention, as shown by a decrease in binding by the human monoclonal antibody of the invention, then it is likely that the two monoclonal antibodies bind to the same, or to a closely related, epitope.
  • Another way to determine whether a human monoclonal antibody has the specificity of a human monoclonal antibody of the invention is to pre-incubate the human monoclonal antibody of the invention with the PD-L1 protein, with which it is normally reactive, and then add the human monoclonal antibody being tested to determine if the human monoclonal antibody being tested is inhibited in its ability to bind PD-L1. If the human monoclonal antibody being tested is inhibited then, in all likelihood, it has the same, or functionally equivalent, epitopic specificity as the monoclonal antibody of the invention. Screening of human monoclonal antibodies of the invention can be also carried out by utilizing PD-L1 and determining whether the test monoclonal antibody is able to neutralize PD-L1.
  • Antibodies can be purified by well-known techniques, such as affinity chromatography using protein A or protein G, which provide primarily the IgG fraction of immune serum. Subsequently, or alternatively, the specific antigen which is the target of the immunoglobulin sought, or an epitope thereof, may be immobilized on a column to purify the immune specific antibody by immunoaffinity chromatography. Purification of
  • immunoglobulins is discussed, for example, by D. Wilkinson (The Engineer, published by The Engineer, Inc., Philadelphia PA, Vol. 14, No. 8 (April 17, 2000), pp. 25-28).
  • the complementarity determining regions (CDRs) of the monoclonal antibody are identical in all the molecules of the population.
  • MAbs contain an antigen binding site capable of immunoreacting with a particular epitope of the antigen characterized by a unique binding affinity for it.
  • Monoclonal antibodies can be prepared using hybridoma methods, such as those described by Kohler and Milstein, Nature, 256:495 (1975).
  • a hybridoma method a mouse, hamster, or other appropriate host animal, is typically immunized with an immunizing agent to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the immunizing agent.
  • the lymphocytes can be immunized in vitro.
  • the immunizing agent will typically include the protein antigen, a fragment thereof or a fusion protein thereof.
  • peripheral blood lymphocytes are used if cells of human origin are desired, or spleen cells or lymph node cells are used if non-human mammalian sources are desired.
  • the lymphocytes are then fused with an immortalized cell line using a suitable fusing agent, such as polyethylene glycol, to form a hybridoma cell (Coding, Monoclonal Antibodies: Principles and Practice, Academic Press, (1986) pp.
  • Immortalized cell lines are usually transformed mammalian cells, particularly myeloma cells of rodent, bovine and human origin. Usually, rat or mouse myeloma cell lines are employed.
  • the hybridoma cells can be cultured in a suitable culture medium that preferably contains one or more substances that inhibit the growth or survival of the unfused, immortalized cells.
  • a suitable culture medium that preferably contains one or more substances that inhibit the growth or survival of the unfused, immortalized cells.
  • the parental cells lack the enzyme hypoxanthine guanine phosphoribosyl transferase (HGPRT or HPRT)
  • HGPRT or HPRT hypoxanthine guanine phosphoribosyl transferase
  • the culture medium for the hybridomas typically will include hypoxanthine, aminopterin, and thymidine ("HAT medium”), which substances prevent the growth of HGPRT-deficient cells.
  • Preferred immortalized cell lines are those that fuse efficiently, support stable high level expression of antibody by the selected antibody-producing cells, and are sensitive to a medium such as HAT medium. More preferred immortalized cell lines are murine myeloma lines, which can be obtained, for instance, from the Salk Institute Cell Distribution Center, San Diego, California and the American Type Culture Collection, Manassas, Virginia. Human myeloma and mouse-human heteromyeloma cell lines also have been described for the production of human monoclonal antibodies. (See Kozbor, J. Immunol., 133:3001 (1984); Brodeur et al., Monoclonal Antibody Production Techniques and
  • the culture medium in which the hybridoma cells are cultured can then be assayed for the presence of monoclonal antibodies directed against the antigen.
  • the binding specificity of monoclonal antibodies produced by the hybridoma cells is determined by immunoprecipitation or by an in vitro binding assay, such as
  • RIA radioimmunoassay
  • ELISA enzyme-linked immunoabsorbent assay
  • the clones can be subcloned by limiting dilution procedures and grown by standard methods. (See Coding, Monoclonal Antibodies: Principles and Practice, Academic Press, (1986) pp. 59-103). Suitable culture media for this purpose include, for example, Dulbecco's Modified Eagle's Medium and RPMI-1640 medium. Alternatively, the hybridoma cells can be grown in vivo as ascites in a mammal.
  • the monoclonal antibodies secreted by the subclones can be isolated or purified from the culture medium or ascites fluid by conventional immunoglobulin purification procedures such as, for example, protein A-Sepharose, hydroxylapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography.
  • Monoclonal antibodies can also be made by recombinant DNA methods, such as those described in U.S. Patent No. 4,816,567.
  • DNA encoding the monoclonal antibodies of the invention can be readily isolated and sequenced using conventional procedures (e.g. , by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of murine antibodies).
  • the hybridoma cells of the invention serve as a preferred source of such DNA.
  • the DNA can be placed into expression vectors, which are then transfected into host cells such as simian COS cells, Chinese hamster ovary (CHO) cells, or myeloma cells that do not otherwise produce immunoglobulin protein, to obtain the synthesis of monoclonal antibodies in the recombinant host cells.
  • host cells such as simian COS cells, Chinese hamster ovary (CHO) cells, or myeloma cells that do not otherwise produce immunoglobulin protein, to obtain the synthesis of monoclonal antibodies in the recombinant host cells.
  • the DNA also can be modified, for example, by substituting the coding sequence for human heavy and light chain constant domains in place of the homologous murine sequences (see U.S. Patent No. 4,816,567; Morrison, Nature 368, 812-13 (1994)) or by covalently joining to the immunoglobulin coding sequence all or part of the coding sequence for a
  • non-immunoglobulin polypeptide can be substituted for the constant domains of an antibody of the invention, or can be substituted for the variable domains of one antigen-combining site of an antibody of the invention to create a chimeric bivalent antibody.
  • Fully human antibodies are antibody molecules in which the entire sequence of both the light chain and the heavy chain, including the CDRs, arise from human genes. Such antibodies are termed “humanized antibodies”, “human antibodies”, or “fully human antibodies” herein.
  • Human monoclonal antibodies can be prepared by using trioma technique; the human B-cell hybridoma technique (see Kozbor, et al., 1983 Immunol Today 4: 72); and the EBV hybridoma technique to produce human monoclonal antibodies (see Cole, et al., 1985 In: MONOCLONAL ANTIBODIES AND CANCER THERAPY, Alan R. Liss, Inc., pp. 77-96).
  • Human monoclonal antibodies may be utilized and may be produced by using human hybridomas (see Cote, et al., 1983. Proc Natl Acad Sci USA 80: 2026-2030) or by transforming human B-cells with Epstein Barr Virus in vitro (see Cole, et al., 1985 In:
  • human antibodies can also be produced using additional techniques, including phage display libraries. (See Hoogenboom and Winter, J. Mol. Biol., 227:381 (1991); Marks et al., J. Mol. Biol., 222:581 (1991)).
  • human antibodies can be made by introducing human immunoglobulin loci into transgenic animals, e.g. , mice in which the endogenous immunoglobulin genes have been partially or completely inactivated. Upon challenge, human antibody production is observed, which closely resembles that seen in humans in all respects, including gene rearrangement, assembly, and antibody repertoire. This approach is described, for example, in U.S. Patent Nos.
  • Human antibodies may additionally be produced using transgenic nonhuman animals which are modified so as to produce fully human antibodies rather than the animal's endogenous antibodies in response to challenge by an antigen.
  • transgenic nonhuman animals which are modified so as to produce fully human antibodies rather than the animal's endogenous antibodies in response to challenge by an antigen.
  • the endogenous genes encoding the heavy and light immunoglobulin chains in the nonhuman host have been incapacitated, and active loci encoding human heavy and light chain immunoglobulins are inserted into the host's genome.
  • the human genes are incorporated, for example, using yeast artificial chromosomes containing the requisite human DNA segments. An animal which provides all the desired modifications is then obtained as progeny by crossbreeding intermediate transgenic animals containing fewer than the full complement of the modifications.
  • nonhuman animal is a mouse, and is termed the XenomouseTM as disclosed in PCT publications WO 96/33735 and WO 96/34096.
  • This animal produces B cells which secrete fully human immunoglobulins.
  • the antibodies can be obtained directly from the animal after immunization with an immunogen of interest, as, for example, a preparation of a polyclonal antibody, or alternatively from immortalized B cells derived from the animal, such as hybridomas producing monoclonal antibodies.
  • the genes encoding the immunoglobulins with human variable regions can be recovered and expressed to obtain the antibodies directly, or can be further modified to obtain analogs of antibodies such as, for example, single chain Fv (scFv) molecules.
  • scFv single chain Fv
  • U.S. Patent No. 5,939,598 An example of a method of producing a nonhuman host, exemplified as a mouse, lacking expression of an endogenous immunoglobulin heavy chain is disclosed in U.S. Patent No. 5,939,598. It can be obtained by a method, which includes deleting the J segment genes from at least one endogenous heavy chain locus in an embryonic stem cell to prevent rearrangement of the locus and to prevent formation of a transcript of a rearranged immunoglobulin heavy chain locus, the deletion being effected by a targeting vector containing a gene encoding a selectable marker; and producing from the embryonic stem cell a transgenic mouse whose somatic and germ cells contain the gene encoding the selectable marker.
  • One method for producing an antibody of interest is disclosed in U.S. Patent No. 5,916,771.
  • This method includes introducing an expression vector that contains a nucleotide sequence encoding a heavy chain into one mammalian host cell in culture, introducing an expression vector containing a nucleotide sequence encoding a light chain into another mammalian host cell, and fusing the two cells to form a hybrid cell.
  • the hybrid cell expresses an antibody containing the heavy chain and the light chain.
  • the antibody can be expressed by a vector containing a DNA segment encoding the single chain antibody described above.
  • Vectors can include vectors, liposomes, naked DNA, adjuvant-assisted DNA, gene gun, catheters, etc.
  • Vectors include chemical conjugates such as described in WO 93/64701, which has targeting moiety (e.g. a ligand to a cellular surface receptor), and a nucleic acid binding moiety (e.g. polylysine), viral vector (e.g. a DNA or RNA viral vector), fusion proteins such as described in PCT/US 95/02140 (WO 95/22618) which is a fusion protein containing a target moiety (e.g. an antibody specific for a target cell) and a nucleic acid binding moiety (e.g. a protamine), plasmids, phage, etc.
  • the vectors can be
  • chromosomal chromosomal, non-chromosomal or synthetic.
  • Retroviral vectors include moloney murine leukemia viruses.
  • DNA viral vectors are preferred.
  • These vectors include pox vectors such as orthopox or avipox vectors, herpesvirus vectors such as a herpes simplex I virus (HSV) vector (see Geller, A. I. et al., J. Neurochem, 64:487 (1995); Lim, F., et al., in DNA Cloning: Mammalian Systems, D.
  • HSV herpes simplex I virus
  • Pox viral vectors introduce the gene into the cells cytoplasm.
  • Avipox virus vectors result in only a short term expression of the nucleic acid.
  • Adenovirus vectors, adeno- associated virus vectors and herpes simplex virus (HSV) vectors are preferred for introducing the nucleic acid into neural cells.
  • the adenovirus vector results in a shorter term expression (about 2 months) than adeno-associated virus (about 4 months), which in turn is shorter than HSV vectors.
  • the particular vector chosen will depend upon the target cell and the condition being treated.
  • the introduction can be by standard techniques, e.g. infection, transfection, transduction or transformation. Examples of modes of gene transfer include e.g., naked DNA, CaP0 4 precipitation, DEAE dextran, electroporation, protoplast fusion, lipofection, cell microinjection, and viral vectors.
  • the vector can be employed to target essentially any desired target cell.
  • stereotaxic injection can be used to direct the vectors (e.g. adenovirus, HSV) to a desired location.
  • the particles can be delivered by intracerebroventricular (icv) infusion using a minipump infusion system, such as a SynchroMed Infusion System.
  • icv intracerebroventricular
  • a method based on bulk flow, termed convection has also proven effective at delivering large molecules to extended areas of the brain and may be useful in delivering the vector to the target cell.
  • convection A method based on bulk flow, termed convection, has also proven effective at delivering large molecules to extended areas of the brain and may be useful in delivering the vector to the target cell.
  • Other methods that can be used include catheters, intravenous, parenteral, intraperitoneal and subcutaneous injection, and oral or other known routes of administration.
  • These vectors can be used to express large quantities of antibodies that can be used in a variety of ways. For example, to detect the presence of PD-L1 in a sample. The antibody can also be used to try to bind to and disrupt a PD-L1 activity.
  • Techniques can be adapted for the production of single-chain antibodies specific to an antigenic protein of the invention (see e.g. , U.S. Patent No. 4,946,778).
  • methods can be adapted for the construction of F ab expression libraries (see e.g. , Huse, et al., 1989 Science 246: 1275-1281) to allow rapid and effective identification of monoclonal F a b fragments with the desired specificity for a protein or derivatives, fragments, analogs or homologs thereof.
  • Antibody fragments that contain the idiotypes to a protein antigen may be produced by techniques known in the art including, but not limited to: (i) an F(ab')2 fragment produced by pepsin digestion of an antibody molecule; (ii) an F a fragment generated by reducing the disulfide bridges of an F( a )2 fragment; (iii) an F a b fragment generated by the treatment of the antibody molecule with papain and a reducing agent and (iv) F v fragments.
  • Heteroconjugate antibodies are also within the scope of the present invention.
  • Heteroconjugate antibodies are composed of two covalently joined antibodies. Such antibodies have, for example, been proposed to target immune system cells to unwanted cells (see U.S. Patent No. 4,676,980), and for treatment of HIV infection (see WO 91/00360; WO 92/200373; EP 03089). It is contemplated that the antibodies can be prepared in vitro using known methods in synthetic protein chemistry, including those involving crosslinking agents. For example, immunotoxins can be constructed using a disulfide exchange reaction or by forming a thioether bond. Examples of suitable reagents for this purpose include
  • cysteine residue(s) can be introduced into the Fc region, thereby allowing interchain disulfide bond formation in this region.
  • the homodimeric antibody thus generated can have improved internalization capability and/or increased complement-mediated cell killing and antibody-dependent cellular cytotoxicity (ADCC).
  • ADCC complement-mediated cell killing and antibody-dependent cellular cytotoxicity
  • an antibody can be engineered that has dual Fc regions and can thereby have enhanced complement lysis and ADCC capabilities. (See Stevenson et al., Anti-Cancer Drug Design, 3: 219-230 (1989)).
  • the invention also pertains to immunoconjugates comprising an antibody conjugated to a cytotoxic agent such as a toxin (e.g. , an enzymatically active toxin of bacterial, fungal, plant, or animal origin, or fragments thereof), or a radioactive isotope (i.e. , a radioconjugate).
  • a cytotoxic agent such as a toxin (e.g. , an enzymatically active toxin of bacterial, fungal, plant, or animal origin, or fragments thereof), or a radioactive isotope (i.e. , a radioconjugate).
  • Enzymatically active toxins and fragments thereof that can be used include diphtheria A chain, nonbinding active fragments of diphtheria toxin, exotoxin A chain (from Pseudomonas aeruginosa), ricin A chain, abrin A chain, modeccin A chain, alpha-sarcin, Aleurites fordii proteins, dianthin proteins, Phytolaca americana proteins (PAPI, PAPII, and PAP-S), momordica charantia inhibitor, curcin, crotin, sapaonaria officinalis inhibitor, gelonin, mitogellin, restrictocin, phenomycin, enomycin, and the tricothecenes.
  • a variety of radionuclides are available for the production of radioconjugated antibodies. Examples include 212 Bi, m I, m In, 90 Y, and 186 Re.
  • Conjugates of the antibody and cytotoxic agent are made using a variety of bifunctional protein-coupling agents such as N-succinimidyl-3-(2-pyridyldithiol) propionate (SPDP), iminothiolane (IT), bifunctional derivatives of imidoesters (such as dimethyl adipimidate HCL), active esters (such as disuccinimidyl suberate), aldehydes (such as glutareldehyde), bis-azido compounds (such as bis (p-azidobenzoyl) hexanediamine), bis-diazonium derivatives (such as bis-(p-diazoniumbenzoyl)-ethylenediamine),
  • SPDP N-succinimidyl-3-(2-pyridyldithiol) propionate
  • IT iminothiolane
  • bifunctional derivatives of imidoesters such as dimethyl adipimidate HCL
  • a ricin immunotoxin can be prepared as described in Vitetta et al., Science 238: 1098 (1987). Carbon- 14-labeled
  • MX-DTPA l-isothiocyanatobenzyl-3-methyldiethylene triaminepentaacetic acid
  • Covalent binding can be achieved either by direct condensation of existing side chains or by the incorporation of external bridging molecules.
  • Many bivalent or polyvalent linking agents are useful in coupling protein molecules, such as the antibodies of the present invention, to other molecules.
  • representative coupling agents can include organic compounds such as thioesters, carbodiimides, succinimide esters, diisocyanates, glutaraldehyde, diazobenzenes and hexamethylene diamines. This listing is not intended to be exhaustive of the various classes of coupling agents known in the art but, rather, is exemplary of the more common coupling agents. (See Killen and Lindstrom, Jour. Immun.
  • linkers include: (i) EDC (l-ethyl-3- (3-dimethylamino-propyl) carbodiimide hydrochloride; (ii) SMPT (4- succinimidyloxycarbonyl-alpha-methyl-alpha-(2-pridyl-dithio)-toluene (Pierce Chem. Co., Cat.
  • linkers described above contain components that have different attributes, thus leading to conjugates with differing physio-chemical properties.
  • sulfo- NHS esters of alkyl carboxylates are more stable than sulfo-NHS esters of aromatic carboxylates.
  • NHS-ester containing linkers are less soluble than sulfo-NHS esters.
  • the linker SMPT contains a sterically hindered disulfide bond, and can form conjugates with increased stability.
  • Disulfide linkages are in general, less stable than other linkages because the disulfide linkage is cleaved in vitro, resulting in less conjugate available.
  • Sulfo-NHS in particular, can enhance the stability of carbodimide couplings.
  • Carbodimide couplings (such as EDC) when used in conjunction with sulfo-NHS, forms esters that are more resistant to hydrolysis than the carbodimide coupling reaction alone.
  • the antibodies disclosed herein can also be formulated as immunoliposomes.
  • Liposomes containing the antibody are prepared by methods known in the art, such as described in Epstein et al., Proc. Natl. Acad. Sci. USA, 82: 3688 (1985); Hwang et al., Proc. Natl Acad. Sci. USA, 77: 4030 (1980); and U.S. Pat. Nos. 4,485,045 and 4,544,545.
  • Particularly useful liposomes can be generated by the reverse-phase evaporation method with a lipid composition comprising phosphatidylcholine, cholesterol, and PEG-derivatized phosphatidylethanolamine (PEG-PE). Liposomes are extruded through filters of defined pore size to yield liposomes with the desired diameter.
  • Fab' fragments of the antibody of the present invention can be conjugated to the liposomes as described in Martin et al., J. Biol. Chem., 257: 286-288 (1982) via a disulfide-interchange reaction.
  • Antibodies specifically binding a PD-Ll protein or a fragment thereof of the invention can be administered for the treatment of cancer or other proliferative disorders.
  • Many cancers overexpress PD-Ll and the upregulation of PD-Ll is associated with high risk prognostic factors.
  • Overexpression fo PD-Ll in tumor cells can also indicate a mechanism by which the tumor cells evade anti-tumor immunity, such as by inducing T cell exhaustion.
  • Such cancers include renal cell carcinoma and breast cancer.
  • Other exemplary cancers are those cancers that are associated with or utilize T cell exhaustion to evade anti-tumor T cell activity.
  • Use of the antibody of the invention can enhance the ability of tumor antigen- specific T cells to proliferate and produce cytokines in response to stimulation with tumor antigen peptides, thereby augmenting T cell activity or anti-tumor immune response.
  • Antibodies specifically binding a PD-Ll protein or fragment thereof of the invention can be administered for the treatment of a chronic infection.
  • Such chronic infections include, for example, viral, bacterial and parasitic infections.
  • An exemplary chronic viral infection is HIV.
  • HIV-specific CD8+ T cells are functionally impaired, showing a reduced capacity to produce cytokines and effector molecules as well as a diminished ability to proliferate.
  • PD-1 is highly expressed on HIV- specific CD8+ T cells of HIV infected individuals.
  • Use of the antibody of the invention can enhance the ability of HIV-specific T cells to proliferate and produce cytokines in response to stimulation with HIV peptides, thereby augmenting T cell activity or anti- viral immune response.
  • Antibodies of the invention may be used as therapeutic agents. Such agents will generally be employed to treat or prevent cancer in a subject, increase vaccine efficiency or augment a natural immune response.
  • An antibody preparation preferably one having high specificity and high affinity for its target antigen, is administered to the subject and will generally have an effect due to its binding with the target. Administration of the antibody may abrogate or inhibit or interfere with an activity of the PD-L1 protein.
  • Antibodies of the invention are capable of inducing cell death.
  • Cell death is induced by either direct or indirect mechanisms.
  • PD-L1 binding by the huPD- Ll antibody can lead to complement-dependent cytotoxicity (CDC).
  • the huPD- Ll antibody binds PD-L1, and leads to the recruitment of a second cell type that will kill the PD-L14-expressing target cell.
  • Exemplary mechanisms by which the huPD-Ll antibody mediates cell death by recruitment of a second cell type include, but are not limited to, antibody-dependent cellular toxicity (ADCC) and antibody dependent cellular phagocytosis (ADCP).
  • Target PD-L1 -expressing cell types comprise tumor and T cells, for example, activated T cells.
  • Antibodies specifically binding a PD-L1 protein or fragment thereof of the invention can be administered for the treatment of a cancer or chronic infection in the form of pharmaceutical compositions.
  • Principles and considerations involved in preparing therapeutic compositions comprising the antibody, as well as guidance in the choice of components are provided, for example, in Remington: The Science And Practice Of
  • a therapeutically effective amount of an antibody of the invention relates generally to the amount needed to achieve a therapeutic objective. As noted above, this may be a binding interaction between the antibody and its target antigen that, in certain cases, interferes with the functioning of the target.
  • the amount required to be administered will furthermore depend on the binding affinity of the antibody for its specific antigen, and will also depend on the rate at which an administered antibody is depleted from the free volume other subject to which it is administered.
  • Common ranges for therapeutically effective dosing of an antibody or antibody fragment of the invention may be, by way of nonlimiting example, from about 0.1 mg/kg body weight to about 50 mg/kg body weight. Common dosing frequencies may range, for example, from twice daily to once a week.
  • the smallest inhibitory fragment that specifically binds to the binding domain of the target protein is preferred.
  • peptide molecules can be designed that retain the ability to bind the target protein sequence.
  • Such peptides can be synthesized chemically and/or produced by recombinant DNA technology. (See, e.g. , Marasco et al., Proc. Natl. Acad. Sci. USA, 90: 7889-7893 (1993)).
  • the formulation can also contain more than one active compound as necessary for the particular indication being treated, preferably those with complementary activities that do not adversely affect each other.
  • the composition can comprise an agent that enhances its function, such as, for example, a cytotoxic agent, cytokine, chemotherapeutic agent, or growth-inhibitory agent.
  • an agent that enhances its function such as, for example, a cytotoxic agent, cytokine, chemotherapeutic agent, or growth-inhibitory agent.
  • Such molecules are suitably present in combination in amounts that are effective for the purpose intended.
  • the active ingredients can also be entrapped in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization, for example, hydroxymethylcellulose or gelatin-microcapsules and poly-(methylmethacrylate)
  • microcapsules respectively, in colloidal drug delivery systems (for example, liposomes, albumin microspheres, microemulsions, nano-particles, and nanocapsules) or in
  • formulations to be used for in vivo administration must be sterile. This is readily accomplished by filtration through sterile filtration membranes.
  • sustained-release preparations can be prepared. Suitable examples of sustained-release preparations include semipermeable matrices of solid hydrophobic polymers containing the antibody, which matrices are in the form of shaped articles, e.g. , films, or microcapsules. Examples of sustained-release matrices include polyesters, hydrogels (for example, poly(2-hydroxyethyl-methacrylate), or poly(vinylalcohol)), polylactides (U.S. Pat. No. 3,773,919), copolymers of L-glutamic acid and ⁇
  • ethyl-L-glutamate non-degradable ethylene-vinyl acetate
  • degradable lactic acid-glycolic acid copolymers such as the LUPRON DEPOTTM (injectable microspheres composed of lactic acid-glycolic acid copolymer and leuprolide acetate)
  • poly-D-(-)-3-hydroxybutyric acid While polymers such as ethylene- vinyl acetate and lactic acid-glycolic acid enable release of molecules for over 100 days, certain hydrogels release proteins for shorter time periods.
  • An antibody according to the invention can be used as an agent for detecting the presence of PD-L1 (or a protein or a protein fragment thereof) in a sample.
  • the antibody contains a detectable label.
  • Antibodies can be polyclonal, or more preferably, monoclonal.
  • An intact antibody, or a fragment thereof e.g. , F ab , scFv, or F (ab)2
  • the term "labeled" with regard to the probe or antibody is intended to encompass direct labeling of the probe or antibody by coupling (i. e.
  • biological sample is intended to include tissues, cells and biological fluids isolated from a subject, as well as tissues, cells and fluids present within a subject. Included within the usage of the term “biological sample”, therefore, is blood and a fraction or component of blood including blood serum, blood plasma, or lymph.
  • the detection method of the invention can be used to detect an analyte mRNA, protein, or genomic DNA in a biological sample in vitro as well as in vivo.
  • in vitro techniques for detection of an analyte mRNA includes Northern hybridizations and in situ hybridizations.
  • in vitro techniques for detection of an analyte protein include enzyme linked immunosorbent assays (ELISAs), Western blots, immunoprecipitations, and immunofluorescence.
  • ELISAs enzyme linked immunosorbent assays
  • Western blots Western blots
  • immunoprecipitations immunoprecipitations
  • immunofluorescence immunofluorescence
  • in vitro techniques for detection of an analyte genomic DNA include Southern hybridizations.
  • ELISA Theory and Practice: Methods in Molecular Biology
  • Vol. 42 J. R. Crowther (Ed.) Human Press, Totowa, NJ, 1995
  • Immunoassay E. Diamandis and T. Christopoulus, Academic Press, Inc., San Diego, CA, 1996
  • Practice and Theory of Enzyme Immunoassays P. Tijssen, Elsevier Science Publishers, Amsterdam, 1985.
  • in vivo techniques for detection of an analyte protein include introducing into a subject a labeled anti- analyte protein antibody.
  • the antibody can be labeled with a radioactive marker whose presence and location in a subject can be detected by standard imaging techniques.
  • Antibodies directed against a PD-L1 protein may be used in methods known within the art relating to the localization and/or quantitation of a PD- LI protein (e.g., for use in measuring levels of the PD-Ll protein within appropriate physiological samples, for use in diagnostic methods, for use in imaging the protein, and the like).
  • antibodies specific to a PD-Ll protein, or derivative, fragment, analog or homolog thereof, that contain the antibody derived antigen binding domain are utilized as pharmacologically active compounds (referred to hereinafter as "Therapeutics").
  • An antibody specific for a PD-Ll protein of the invention can be used to isolate a PD-Ll polypeptide by standard techniques, such as immunoaffinity,
  • Antibodies directed against a PD-Ll protein can be used diagnostically to monitor protein levels in tissue as part of a clinical testing procedure, e.g., to, for example, determine the efficacy of a given treatment regimen. Detection can be facilitated by coupling (i.e., physically linking) the antibody to a detectable substance.
  • detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, and radioactive materials.
  • suitable enzymes include horseradish peroxidase, alkaline phosphatase, ⁇ -galactosidase, or acetylcholinesterase;
  • suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin;
  • suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol;
  • bioluminescent materials include
  • radioactive material examples include I, 131 1, 35 S or 3 H.
  • compositions suitable for administration can be incorporated into pharmaceutical compositions suitable for administration.
  • Such compositions typically comprise the antibody or agent and a pharmaceutically acceptable carrier.
  • pharmaceutically acceptable carrier is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. Suitable carriers are described in the most recent edition of Remington' s Pharmaceutical Sciences, a standard reference text in the field, which is incorporated herein by reference.
  • Such carriers or diluents include, but are not limited to, water, saline, ringer's solutions, dextrose solution, and 5% human serum albumin. Liposomes and non-aqueous vehicles such as fixed oils may also be used.
  • the use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the compositions is contemplated. Supplementary active compounds can also be incorporated into the compositions.
  • a pharmaceutical composition of the invention is formulated to be compatible with its intended route of administration.
  • routes of administration include parenteral, e.g. , intravenous, intradermal, subcutaneous, oral (e.g. , inhalation), transdermal (i.e., topical), transmucosal, and rectal administration.
  • Solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid (EDTA); buffers such as acetates, citrates or phosphates, and agents for the adjustment of tonicity such as sodium chloride or dextrose.
  • the pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide.
  • the parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.
  • compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion.
  • suitable carriers include physiological saline, bacteriostatic water, Cremophor
  • the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof.
  • the proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants.
  • Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like.
  • isotonic agents for example, sugars, polyalcohols such as manitol, sorbitol, sodium chloride in the composition.
  • Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.
  • Sterile injectable solutions can be prepared by incorporating the active compound in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization.
  • dispersions are prepared by incorporating the active compound into a sterile vehicle that contains a basic dispersion medium and the required other ingredients from those enumerated above.
  • methods of preparation are vacuum drying and freeze-drying that yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.
  • Oral compositions generally include an inert diluent or an edible carrier. They can be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and used in the form of tablets, troches, or capsules. Oral compositions can also be prepared using a fluid carrier for use as a mouthwash, wherein the compound in the fluid carrier is applied orally and swished and expectorated or swallowed. Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition.
  • the tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.
  • a binder such as microcrystalline cellulose, gum tragacanth or gelatin
  • an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch
  • a lubricant such as magnesium stearate or Sterotes
  • a glidant such as colloidal silicon dioxide
  • the compounds are delivered in the form of an aerosol spray from pressured container or dispenser which contains a suitable propellant, e.g. , a gas such as carbon dioxide, or a nebulizer.
  • a suitable propellant e.g. , a gas such as carbon dioxide, or a nebulizer.
  • Systemic administration can also be by transmucosal or transdermal means.
  • penetrants appropriate to the barrier to be permeated are used in the formulation.
  • penetrants are generally known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives.
  • Transmucosal administration can be accomplished through the use of nasal sprays or suppositories.
  • the active compounds are formulated into ointments, salves, gels, or creams as generally known in the art.
  • the compounds can also be prepared in the form of suppositories (e.g. , with conventional suppository bases such as cocoa butter and other glycerides) or retention enemas for rectal delivery.
  • suppositories e.g. , with conventional suppository bases such as cocoa butter and other glycerides
  • retention enemas for rectal delivery.
  • the active compounds are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems.
  • a controlled release formulation including implants and microencapsulated delivery systems.
  • Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, poly anhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art.
  • the materials can also be obtained commercially from Alza Corporation and Nova Pharmaceuticals, Inc.
  • Liposomal suspensions (including liposomes targeted to infected cells with monoclonal antibodies to viral antigens) can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Patent No. 4,522,811.
  • Dosage unit form refers to physically discrete units suited as unitary dosages for the subject to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier.
  • the specification for the dosage unit forms of the invention are dictated by and directly dependent on the unique characteristics of the active compound and the particular therapeutic effect to be achieved, and the limitations inherent in the art of compounding such an active compound for the treatment of individuals.
  • compositions can be included in a container, pack, or dispenser together with instructions for administration.
  • the huPD-Ll antibody of the invention when joined to a detectable moiety, provides a way for detecting "cancerous tissue" or tissue subject to aberrant cell proliferation and therefore at risk for cancer.
  • the antibody-detectable moiety conjugates also provides a method of detecting cancerous metastatic tissue present in distal organs and/or tissues.
  • tissue may be detected by contacting tissue suspected of being cancerous with the antibody- detectable moiety under appropriate conditions to cause the detectable moiety to be detected in cancerous tissue, thereby detecting the presence of cancerous tissue.
  • the huPD-Ll antibody of the invention when joined to a detectable moiety, provides a way for detecting T cell exhaustion in a subject suffering from a cancer or a chronic infection.
  • the huPD-Ll antibody can be used to detect the levels of PD- Ll in a subject, wherein the levels in comparison to a reference level can indicate whether the subject is suffering from T cell exhaustion.
  • this method can also be used to determine whether or not treatment using the huPD-Ll antibody to augment the immune response by reversing or inhibiting T cell exhaustion would be beneficial to the subject.
  • the detectable moieties can be conjugated directly to the antibodies or fragments, or indirectly by using, for example, a fluorescent secondary antibody. Direct conjugation can be accomplished by standard chemical coupling of, for example, a fluorophore to the antibody or antibody fragment, or through genetic engineering. Chimeras, or fusion proteins can be constructed which contain an antibody or antibody fragment coupled to a fluorescent or bioluminescent protein.
  • Casadei, et al. describe a method of making a vector construct capable of expressing a fusion protein of aequorin and an antibody gene in mammalian cells.
  • the term "labeled”, with regard to the probe or antibody, is intended to encompass direct labeling of the probe or antibody by coupling (i.e. , physically linking) a detectable substance to the probe or antibody, as well as indirect labeling of the probe or antibody by reactivity with another reagent that is directly labeled.
  • indirect labeling include detection of a primary antibody using a fluorescently-labeled secondary antibody and end-labeling of a DNA probe with biotin such that it can be detected with fluorescently-labeled streptavidin.
  • biological sample is intended to include tissues, cells and biological fluids isolated from a subject (such as a biopsy), as well as tissues, cells and fluids present within a subject.
  • the detection method of the invention can be used to detect cancer, a cancer cell, or a cancer-associated cell (such as a stromal cell associated with a tumor or cancer cell) in a biological sample in vitro as well as in vivo.
  • in vitro techniques for detection of PD-L1 include enzyme linked immunosorbent assays (ELISAs), Western blots, immunoprecipitations, and immunofluorescence.
  • in vivo techniques for detection of PD-L1 include introducing into a subject a labeled anti-PD-Ll antibody.
  • the antibody can be labeled with a radioactive marker whose presence and location in a subject can be detected by standard imaging techniques.
  • the invention provides a non-invasive method of detecting a tumor or cancer cell in a subject.
  • the subject is administered an antibody or scFv antibody of the invention, where the antibody is linked to a detectable moiety (i.e. , any moiety capable of being detected by, e.g., fluorescent, chemical, chemiluminescent, radioactive, or other means known in the art), the antibody is allowed to localize to the tumor then is detected by observation of the detectable moiety.
  • a detectable moiety i.e. , any moiety capable of being detected by, e.g., fluorescent, chemical, chemiluminescent, radioactive, or other means known in the art
  • targeted conjugates that is, conjugates which contain a targeting moiety-a molecule or feature designed to localize the conjugate within a subject or animal at a particular site or sites
  • localization refers to a state when an equilibrium between bound, "localized", and unbound, "free” entities within a subject has been essentially achieved. The rate at which such equilibrium is achieved depends upon the route of administration. For example, a conjugate administered by intravenous injection to localize thrombi may achieve localization, or accumulation at the thrombi, within minutes of injection. On the other hand, a conjugate administered orally to localize an infection in the intestine may take hours to achieve localization. Alternatively, localization may simply refer to the location of the entity within the subject or animal at selected time periods after the entity is administered. By way of another example, localization is achieved when an moiety becomes distributed following administration.
  • the state of localization as a function of time may be followed by imaging the detectable moiety (e.g., a light-emitting conjugate) according to the methods of the invention, such as with a photodetector device.
  • the "photodetector device” used should have a high enough sensitivity to enable the imaging of faint light from within a mammal in a reasonable amount of time, and to use the signal from such a device to construct an image.
  • a pair of "night- vision" goggles or a standard high- sensitivity video camera such as a Silicon Intensified Tube (SIT) camera (e.g., from Hammamatsu Photonic Systems, Bridgewater, N.J.), may be used. More typically, however, a more sensitive method of light detection is required.
  • SIT Silicon Intensified Tube
  • the photon flux per unit area becomes so low that the scene being imaged no longer appears continuous. Instead, it is represented by individual photons which are both temporally and spatially distinct form one another. Viewed on a monitor, such an image appears as scintillating points of light, each representing a single detected photon. By accumulating these detected photons in a digital image processor over time, an image can be acquired and constructed. In contrast to conventional cameras where the signal at each image point is assigned an intensity value, in photon counting imaging the amplitude of the signal carries no significance. The objective is to simply detect the presence of a signal (photon) and to count the occurrence of the signal with respect to its position over time.
  • At least two types of photodetector devices can detect individual photons and generate a signal which can be analyzed by an image processor.
  • Reduced-Noise Photodetection devices achieve sensitivity by reducing the background noise in the photon detector, as opposed to amplifying the photon signal. Noise is reduced primarily by cooling the detector array.
  • the devices include charge coupled device (CCD) cameras referred to as "backthinned", cooled CCD cameras. In the more sensitive instruments, the cooling is achieved using, for example, liquid nitrogen, which brings the temperature of the CCD array to approximately -120°C.
  • “Backthinned” refers to an ultra- thin backplate that reduces the path length that a photon follows to be detected, thereby increasing the quantum efficiency.
  • a particularly sensitive backthinned cryogenic CCD camera is the "TECH 512", a series 200 camera available from Photometries, Ltd. (Tucson, Ariz.).
  • Photon amplification devices amplify photons before they hit the detection screen.
  • This class includes CCD cameras with intensifiers, such as microchannel intensifiers.
  • a microchannel intensifier typically contains a metal array of channels perpendicular to and co-extensive with the detection screen of the camera.
  • the microchannel array is placed between the sample, subject, or animal to be imaged, and the camera. Most of the photons entering the channels of the array contact a side of a channel before exiting.
  • a voltage applied across the array results in the release of many electrons from each photon collision. The electrons from such a collision exit their channel of origin in a "shotgun" pattern, and are detected by the camera.
  • Image processors process signals generated by photodetector devices which count photons in order to construct an image which can be, for example, displayed on a monitor or printed on a video printer. Such image processors are typically sold as part of systems which include the sensitive photon-counting cameras described above, and accordingly, are available from the same sources.
  • the image processors are usually connected to a personal computer, such as an IBM-compatible PC or an Apple Macintosh (Apple Computer, Cupertino, Calif.), which may or may not be included as part of a purchased imaging system.
  • a personal computer such as an IBM-compatible PC or an Apple Macintosh (Apple Computer, Cupertino, Calif.), which may or may not be included as part of a purchased imaging system.
  • image processing programs such as "ADOBE PHOTOSHOP", Adobe Systems, Adobe Systems, Mt. View, Calif.
  • the biological sample contains protein molecules from the test subject.
  • One preferred biological sample is a peripheral blood leukocyte sample isolated by conventional means from a subject.
  • the invention also encompasses kits for detecting the presence of PD-Ll or a
  • the kit can comprise: a labeled compound or agent capable of detecting a cancer or tumor cell (e.g., an anti-PD-Ll scFv or monoclonal antibody) in a biological sample; means for determining the amount of PD-Ll in the sample; and means for comparing the amount of PD-Ll in the sample with a standard.
  • the standard is, in some embodiments, a non-cancer cell or cell extract thereof.
  • the compound or agent can be packaged in a suitable container.
  • the kit can further comprise instructions for using the kit to detect cancer in a sample.
  • a bi-specific antibody is an antibody comprising two variable domains or scFv units such that the resulting antibody recognizes two different antigens.
  • the present invention provides for bi-specific antibodies that recognize PD-L1 and a second antigen.
  • Exemplary second antigens include tumor associated antigens, cytokines and cell surface receptors.
  • the second antigen can be CAIX (carbonic anhydrase IX, or G250), IL-10 or CCR4.
  • the second antigen can be a cell surface receptor, wherein the cell surface receptor is CCR4, IL21R, BTLA, HVEM or TIM3.
  • a bi-specific antibody of the present invention comprises a heavy chain and a light chain combination or scFv of the huPD-Ll antibodies disclosed herein.
  • Bi-specific antibodies of the present invention can be constructed using methods known art.
  • the bi-specific antibody is a single polypeptide wherein the two scFv fragments are joined by a long linker polypeptide, of sufficient length to allow intramolecular association between the two scFv units to form an antibody.
  • the bi-specific antibody is more than one polypeptide linked by covalent or non-covalent bonds.
  • the bi-specific antibody is constructed using the
  • the bi-specific antibody can be constructed through exchange of heavy-light chain dimers from two or more different antibodies to generate a hybrid antibody where the first heavy-light chain dimer recognizes PD-L1 and the second heavy-light chain dimer recognizes a second antigen.
  • the mechanism for heavy-light chain dimer is similar to the formation of human IgG4, which also functions as a bispecific molecule. Dimerization of IgG heavy chains is driven by intramolecular force, such as the pairing the CH3 domain of each heavy chain and disulfide bridges. Presence of a specific amino acid in the CH3 domain (R409) has been shown to promote dimer exchange and construction of the IgG4 molecules.
  • Heavy chain pairing is also stabilized further by interheavy chain disulfide bridges in the hinge region of the antibody.
  • the hinge region contains the amino acid sequence Cys-Pro-Ser-Cys (in comparison to the stable IgGl hinge region which contains the sequence Cys-Pro-Pro-Cys) at amino acids 226- 230.
  • This sequence difference of Serine at position 229 has been linked to the tendency of IgG4 to form novel intrachain disulfides in the hinge region (Van der Neut Kolfschoten, M. et al., 2007, Science 317: 1554-1557 and Labrijn, A.F. et al, 2011, Journal ofimmunol 187:3238-3246).
  • bi-specific antibodies of the present invention can be created through introduction of the R409 residue in the CH3 domain and the Cys-Pro-Ser-Cys sequence in the hinge region of antibodies that recognize PD-Ll or a second antigen, so that the heavy-light chain dimers exchange to produce an antibody molecule with one heavy-light chain dimer recognizing PD-Ll and the second heavy-light chain dimer recognizing a second antigen, wherein the second antigen is any antigen disclosed herein.
  • the bi- specific antibody contains one anti-PD-Ll heavy-light chain dimer conjugated to one anti- CAIX (carbonic anhydrase IX, or 250) heavy-light chain dimer, as discussed in Examples 3 and 4.
  • Heavy-light chain dimer exchange can also be enhanced with addition of a reducing agent, such as reduced glutathione, to promote the exchange.
  • a reducing agent such as reduced glutathione
  • Known IgG4 molecules may also be altered such that the heavy and light chains recognize PD-Ll or a second antigen, as disclosed herein.
  • Use of this method for constructing the bi-specific antibodies of the present invention may be beneficial due to the intrinsic characteristic of IgG4 molecules wherein the Fc region differs from other IgG subtypes in that it interacts poorly with effector systems of the immune response, such as complement and Fc receptors expressed by certain white blood cells. This specific property makes these IgG4-based bi-specific antibodies attractive for therapeutic applications, in which the antibody is required to bind the target(s) and functionally alter the signaling pathways associated with the target(s), however not trigger effector activities.
  • mutations are introduced to the constant regions of the bsAb such that the antibody dependent cell-mediated cytotoxicity (ADCC) activity of the bsAb is altered.
  • ADCC antibody dependent cell-mediated cytotoxicity
  • the mutation is an LALA mutation in the CH2 domain.
  • the bsAb contains mutations on one scFv unit of the heterodimeric bsAb, which reduces the ADCC activity.
  • the bsAb contains mutations on both chains of the heterodimeric bsAb, which completely ablates the ADCC activity.
  • the mutations introduced one or both scFv units of the bsAb are LALA mutations in the CH2 domain.
  • bsAbs with variable ADCC activity can be optimized such that the bsAbs exhibits maximal selective killing towards cells that express one antigen that is recognized by the bsAb, however exhibits minimal killing towards the second antigen that is recognized by the bsAb.
  • the present invention provides for bi-specific antibodies that recognize PD-Ll and a second antigen.
  • the second antigen is a tumor associated antigen.
  • the tumor associated antigen is carbonic anhydrase IX (CAIX).
  • CAIX carbonic anhydrase IX
  • a CAIX/PD-L1 bi-specific antibody may be constructed, comprising one heavy and one light chain combination of the huPD-Ll antibodies described herein and one heavy and one light chain combination that recognizes CAIX ( Figure 5A).
  • CAFX has been described as a prognostic marker for disease progression and a target for immunotherapy with IL-2.
  • CAFX is a tumor-associated antigen that is highly expressed in cancers, such as renal cell carcinoma.
  • activation of the PDl/PD-Ll axis by tumor cells may induce T cell exhaustion for certain tumor-specific antigens, such as CAIX, whereby tumor cells expressing CAIX escape recognition by the immune system.
  • the bsAb targeting both CAFX and PD-Ll serves as a novel cancer therapeutic.
  • Treatment with a CAIX/PD-L1 bsAb would inhibit or reverse the PD-1/PD-L1 -mediated T-cell exhaustion for CAIX, and promote tumor surveillance and an immune response against CAIX-expressing tumor cells.
  • treatment with a CAIX/PD-L1 bsAb would promote an antigen-specific immune response against tumor cells, where the antigen targeted is CAIX.
  • mutations may be introduced to the CAIX or the PD-Ll chains at the constant regions (e.g., CH2 domain) to reduce ADCC activity (Figure 5B).
  • mutations may be introduced into both the CAIX and the PD-Ll chains in the constant regions to completely ablate ADCC activity.
  • Mutated bsAbs with variable ADCC activity can be assayed by methods known in the art for their specificity of killing tumor cells.
  • the CAFX/PD-L1 bsAb will exhibit maximal selective killing of CAIX- expressing tumor cells but exhibits only minimal killing of PD-Ll -expressing endogenous peripheral blood mononuclear cells (PBMCs).
  • PBMCs peripheral blood mononuclear cells
  • the second antigen is a cell surface receptor, wherein the cell surface receptor is interleukin 21 receptor (IL21R).
  • IL21R interleukin 21 receptor
  • an IL21R/PD-L1 bi-specific antibody may be constructed, comprising one heavy and one light chain combination of the huPD-Ll antibodies described herein and one heavy and one light chain combination that binds IL21R in an agonistic manner.
  • the cytokine IL21 is secreted by CD4+ T helper cells and binds to IL21R to promote several immune activation pathways, particularly, promoting the antigen- specific cytotoxicity of CTLs and the maturation, proliferation and cytotoxicity of NK cells (Sondergaard, H et al., 2009 Tissue antigens 74:467-479; Kasaian, M. T. et al, 2002 Immunity 16:559-569; and Coquet, J. M. et al, 2008 J Immunol 178:2827- 2834).
  • IL21 has been shown to promote activation and cytotoxic capacity against melanoma antigens (Li, Y.
  • the IL21R/PD-L1 bsAb of the present invention binds to IL21R in an agonistic manner, thereby acting as a mimic or surrogate for the cytokine IL21. Binding by the IL21R/PD-L1 bsAb can result in activation of the IL21R-mediated pathways and subsequent promotion of antigen- specific cytotoxic immune responses against tumor cells that have induced PD-L1 -mediated T-cell exhaustion.
  • One particular benefit of treatment with the bi-specific antibody of the invention is the localization of the IL21R activation to areas where PD-1/PD-L1 -mediated T cell exhaustion has occurred, for example, in the tumor microenvironment, for example near or within tumors that have induced T cell exhaustion to evade anti-tumor immune responses.
  • the ILR/PD-L1 bsAb promotes antitumor immune response in a two-pronged mechanism: 1) by reversing or inhibiting PD-l/PD- Ll-mediated T cell exhaustion, and 2) by promoting IL21/IL21R-mediated activation of cytotoxic immune response, thereby inducing antigen-specific or anti-tumor immune responses and cytotoxicity.
  • the IL21R/PD-L1 bi-specific antibody may also have use in a vaccine for vaccination of a subject, or as a vaccine adjuvant.
  • OCR germinal center reaction
  • PD1 is expressed by follicular T helper cells (TFH) while PDL1 is expressed by germinal center B cells (Crotty, S. et al, 2011, Annual review of Immunology, 29:621- 623).
  • T helper cells follicular T helper cells
  • IL21R/PD-L1 bi-specific antibody wherein the PD-L1 portion of the antibody inhibits the P D1/PD-L1 axis, would result in the preferential expansion of only high affinity antibodies.
  • IL-21 strongly promotes the transition of antigen-specific B cells to antibody- secreting plasma cells, as well as the formation and persistence of TFH activity (Crotty, S. et al, 2011, Annual review of Immunology , 29:621-623)
  • a bsAb against PDL1 with IL21 surrogate or agonistic activity could act as a GCR-specific adjuvant towards promotion of high affinity antibody production against particular antigens, such as antigens administered through a vaccine, or antigens of infectious agents.
  • the second antigen is BTLA (B and T lymphocyte attenuator protein) or HVEM (Herpesvirus entry mediator, also known as TNFRSF14).
  • BTLA B and T lymphocyte attenuator protein
  • HVEM Herpesvirus entry mediator, also known as TNFRSF14.
  • a BTLA/PD-L1 bi-specific antibody may be constructed, comprising one heavy and one light chain combination of the huPD-Ll antibodies described herein and one heavy and one light chain combination that binds BTLA.
  • an HVEM/PD-L1 bi-specific antibody may be constructed, comprising one heavy and one light chain combination of the huPD-Ll antibodies described herein and one heavy and one light chain combination that binds HVEM, preferably, to those regions of HVEM that mediate binding with BTLA.
  • BTLA binding to HVEM results in T cell inhibition, similar to PD1/PD-L1 interactions.
  • the BTLA/PD-L1 or HVEM/PD-L1 bi-specific antibodies of the present invention would inhibit or prevent the association between BTLA and HVEM, and prevent BTLA/HVE-mediated T cell inhibition.
  • BTLA inhibition promotes tumor- specific T cell responses. Therefore, treatment with the bi-specific antibodies of the present invention results in the simultaneous blockade of two distinct inhibitor pathways that limit T cell activity.
  • the HVEM/PD-L1 bsAb antibody would also prevent the association between HVEM and another HVEM ligand, CD 160, which has been shown to be an agonist for the survival of B cell chronic lymphocytic leukemia (BCLL) cells, and strongly inhibits CD4+ T-cell activation and function.
  • CD 160 another HVEM ligand
  • B cell chronic lymphocytic leukemia (BCLL) cells B cell chronic lymphocytic leukemia (BCLL) cells
  • B cell chronic lymphocytic leukemia (BCLL) cells B cell chronic lymphocytic leukemia
  • Treatment with the HVEM/PD-L1 bi-specific antibody that also prevents HVEM/CD160 binding of the present invention results in the simultaneous blockade of two inhibitor pathways that limit T cell activity and inhibition of CD160-mediated tumor survival pathways.
  • the second antigen is TIM3 (T-cell immunoglobulin and mucin domain 3).
  • a TIM3/PD-L1 bi-specific antibody may be constructed, comprising one heavy and one light chain combination of the huPD-Ll antibodies described herein and one heavy and one light chain combination that binds TIM3.
  • the antibodies of the present invention prevent or inhibit TIM3 binding with galectin-9 (GAL9). Interaction between TIM3 and GAL9 results in inhibition of T cell function and activation of macrophages (Sakuishi, K. et al, 2010, The Journal of experimental medicine, 207:2187-2194 and Zhang, Y.
  • TIM3 has also been shown to promote the activity of myeloid derived suppressor cells (MDSC) (Dardalhon, V. et al., 2012 Journal of leukocyte biology, 185: 1383-1392). Therefore, treatment with a bispecific antibody of the present invention, such as the TIM3/PD-L1 bsAb, would reverse and prevent T-cell exhaustion, promote tumor surveillance and inhibit generation of MDSC.
  • a bispecific antibody of the present invention such as the TIM3/PD-L1 bsAb
  • Use of the TIM3/PD-L1 bsAb may be particularly beneficial for treatment of subjects that suffer from cancers with polymorphisms in TIM3, such as renal cell carcinoma and metastatic renal cell carcinoma.
  • the bi-specific antibodies disclosed herein may be useful in treatment of diseases or medical conditions, for example, cancer.
  • the bi-specific antibodies of the present invention may be particularly useful in diseases or medical conditions that are associated with T cell exhaustion.
  • the bi-specific antibodies disclosed herein may be used as a vaccine for promoting antigen-specific immune responses.
  • the bi-specific antibodies of the present invention will target tumors that induce T-cell exhaustion.
  • the invention provides for both prophylactic and therapeutic methods of treating a subject at risk of (or susceptible to) a cancer, or other cell proliferation-related diseases or disorders.
  • diseases or disorders include but are not limited to, e.g., those diseases or disorders associated with aberrant expression of PD-L1.
  • the methods are used to treat, prevent or alleviate a symptom of renal cell carcinoma or breast cancer.
  • the methods are used to treat, prevent or alleviate a symptom of a cancer in which PD-L1 plays a negative regulatory role in T cell response.
  • the methods are used to treat, prevent or alleviate a symptom of a solid tumor such as breast cancer, lung cancer, ovarian cancer, prostate cancer, colon cancer, cervical cancer, brain cancer, liver cancer, pancreatic cancer or stomach cancer.
  • the methods are used to treat, prevent or alleviate a symptom of a cancer that has metastasized.
  • the invention provides for both prophylactic and therapeutic methods of treating a subject at risk of (or susceptible to) a chronic viral, bacterial or parasitic infection.
  • the invention provides for both prophylactic and therapeutic methods of treating a subject at risk of (or susceptible to) HIV infection or AIDS.
  • the invention also provides for therapeutic methods for both prophylactic and therapeutic methods of treating a subject at risk of a disease or disorder or condition associated with T-cell exhaustion or a risk of developing T-cell exhaustion.
  • the invention also provides for therapeutic methods for both prophylactic and therapeutic methods of treating a subject at risk of a disease or disorder or condition associated with T-cell exhaustion or a risk of developing T-cell exhaustion.
  • diseases or disorder include, but are not limited to HIV, AIDS, and chronic bacterial, viral or parasitic infections.
  • Other such chronic infections include those caused by, for example, hepatitis B virus (HBV), hepatitis C virus (HCV), herpes simplex virus 1 (HSV-1), H. pylori, or Toxoplasma gondii.
  • the invention provides methods for preventing, treating or alleviating a symptom cancer or a cell proliferative disease or disorder in a subject by administering to the subject a monoclonal antibody or scFv antibody of the invention.
  • a huPD-Ll antibody may be administered in therapeutically effective amounts.
  • Subjects at risk for cancer or cell proliferation-related diseases or disorders include patients who have a family history of cancer or a subject exposed to a known or suspected cancer-causing agent. Administration of a prophylactic agent can occur prior to the manifestation of cancer such that the disease is prevented or, alternatively, delayed in its progression.
  • tumor cell growth is inhibited or suppressor T cell activity is decreased by contacting a cell with a PD-L1 antibody of the invention.
  • the cell is any cell that expresses PD-L1.
  • the cell is T cell.
  • an immune response is increased or enhanced by administering to the subject a monoclonal antibody or scFv antibody of the invention.
  • the immune response is augmented for example by augmenting antigen specific T effector function.
  • the antigen is a viral (e.g. HIV), bacterial, parasitic or tumor antigen.
  • the immune response is a natural immune response.
  • natural immune response is meant an immune response that is a result of an infection.
  • the infection is a chronic infection.
  • Increasing or enhancing an immune response to an antigen can be measured by a number of methods known in the art. For example, an immune response can be measured by measuring any one of the following: T cell activity, T cell proliferation, T cell activation, production of effector cytokines, and T cell transcriptional profile.
  • the immune response is a response induced due to a vaccination.
  • the invention provides a method of increasing vaccine efficiency by administering to the subject a monoclonal antibody or scFv antibody of the invention and a vaccine.
  • the antibody and the vaccine are administered sequentially or concurrently.
  • the vaccine is a tumor vaccine a bacterial vaccine or a viral vaccine.
  • the invention provides treating cancer in a patient by administering two antibodies that bind to the same epitope of the PD-Ll protein or, alternatively, two different epitopes of the PD-Ll protein.
  • the cancer is treated by administering a first antibody that binds to PD-Ll and a second antibody that binds to a protein other than PD-Ll.
  • the other protein other than PD-Ll may include, but is not limited to, CAIX, CCR4 and IL-10.
  • the other protein other than PD-Ll is a tumor-associated antigen.
  • the invention provides administration of a huPD-Ll antibody alone or with an additional antibody that recognizes another protein other than PD- Ll, with cells that are capable of effecting or augmenting an immune response.
  • these cells may be peripheral blood mononuclear cells (PBMC), or any cell type that is found in PBMC, e.g., cytotoxic T cells, macrophages, and natural killer (NK) cells.
  • PBMC peripheral blood mononuclear cells
  • NK natural killer
  • the invention provides administration of an antibody that binds to the PD-Ll protein and an anti-neoplastic agent, such a small molecule, a growth factor, a cytokine or other therapeutics including biomolecules such as peptides, peptidomimetics, peptoids, polynucleotides, lipid-derived mediators, small biogenic amines, hormones, neuropeptides, and proteases.
  • an anti-neoplastic agent such as a small molecule, a growth factor, a cytokine or other therapeutics including biomolecules such as peptides, peptidomimetics, peptoids, polynucleotides, lipid-derived mediators, small biogenic amines, hormones, neuropeptides, and proteases.
  • Small molecules include, but are not limited to, inorganic molecules and small organic molecules.
  • Suitable growth factors or cytokines include an IL- 2, GM-CSF, IL-12, and TNF-alpha
  • EXAMPLE 1 GENERATION OF HUMAN MABS AGAINST PD-Ll
  • Human mAbs against human PD-Ll were generated by panning against a 27- billion member human scFv phage display library. Using full length PD-Ll in the form of paramagnetic proteoliposomes (PMPL), which assure proper orientation of the extracellular domain of PD-Ll for presentation to the library, 14 unique scFv-phage were identified that bind PD-Ll. Human IgG constructs were constructed for these 14 unique scFv-phage: Ab- 14, Ab-16, Ab-22, Ab-30, Ab-31, Ab-32, Ab-38, Ab-42, Ab-46, Ab-50, Ab-52, Ab-55, Ab- 56 and Ab-65.
  • PMPL paramagnetic proteoliposomes
  • EXAMPLE 2 CHARACTERIZATION OF HUPD-L1 MABS BINDING TO PD-Ll
  • Binding analysis of huPD-Ll antibodies were performed using PD-Ll - expressing cells.
  • Four types of cells were tested, including parental cell line 300.19, and transfected cell lines expressing human PD-Ll (hPD-Ll), human PD-L2 (HPD-L2), and human C-type lectin domain family 2 member (hCLEC2D).
  • the binding assays were performed in duplicate, with the results summarized below in Tables 16-19 and Figure 2.
  • Antibody affinity was tested by using four antibody concentrations: 10 g/ml, 1 g/ml, 0.1 ⁇ g/ml and 0.01 ⁇ g/ml.
  • GF1538 and GF1757 antibodies were used as controls: GF1538 is a humanized Ab against hPD-Ll, and GF1757 is a humanized Ab against hPD-L2.
  • the secondary antibody utilized was PE-goat anti-human IgG. All values represent mean fluorescence intensity (GMFI), as detected by FACs analysis.
  • Results from the binding assay show that the tested huPD-Ll antibodies show highly affinity and specificity for binding PD-Ll.
  • MFI mean fluorescence intensity
  • the MFI values were not significantly higher than the basal levels, indicating that the huPD-Ll antibodies did not have high affinity or specificity for PD-L2 or CLE2D.
  • a few huPD-Ll antibodies, for example Ab-42 demonstrated some cross-reactivity with PD-L2, the antibodies have significantly higher affinity and specificity for PD-Ll.
  • Table 17A Staining using huPD-Ll on hPD-Ll-transfected 300.19 cells, assay 1 results.
  • Table 17B Staining using huPD-Ll on hPD-Ll-transfected 300.19 cells, assay 2 results.
  • Table 18A Staining using huPD-Ll on hPD-L2-transfected 300.19 cells, assay 1 results.
  • Table 18B Staining using huPD-Ll on hPD-L2-transfected 300.19 cells, assay 2 results.
  • Table 19A Staining using huPD-Ll on hCLEC2D-transfected 300.19 cells, assay 1.
  • EXAMPLE 2 CHARACTERIZATION OF ANTI-PD-L1 PHAGE-ANTIBODIES BLOCKING PD/PD-L1 BINDING
  • a competitive FACS analysis was performed to characterize the inhibition of hPDl binding to hPD-Ll by anti-PD-Ll phage antibodies. All anti-hPD-Ll antibodies were in phage-scFv form. 293T cells were transfected with a vector encoding human PD-L1 fused to human Fc region for expression of hPD-Ll-Fc. In this assay, 10 12 plaque-forming units (pfu) of phage-scFvs were mixed with about 0.25 mg/ml of soluble hPD-l-hFc fusion protein and then added to the hPD-Ll -expressing 293T cells. After washing, the cells were incubated with FITC- anti-human IgG antibody and analyzed by FACS to measure the binding of hPDl-hFc to hPD-Ll on the cell surface.
  • pfu plaque-forming units
  • Fluorescence values were obtained by FACS analysis and used to generate a percentage of inhibition of binding of hPD-1 to hPD-Ll+ cells. These values are displayed in Figure 3. Almost all anti-PD-Ll phage scFvs demonstrated some ability to inhibit the binding of hPD-1 to hPD-Ll. Particularly, Ab-14, Ab-16, Ab-30, Ab-31, Ab-42, Ab-50, Ab- 52, and Ab-55 phage-scFvs demonstrated significant inhibition of hPD-l/hPD-Ll binding.
  • EXAMPLE 3 CHARACTERIZATION OF HUPD-L1 SOLUBLE MABS BLOCKING
  • a competitive FACS analysis was performed to characterize the inhibition of hPDl binding to hPD-Ll by the soluble huPD-Ll antibodies of the present invention. All huPD-Ll antibodies were tested for their ability to inhibit the binding of hPDl-IgG fusion protein with hPD-Ll -expressing 300.19 cells. In this assay, 50,000 cells expressing hPD-Ll were pre-incubated with the huPD-Ll or control antibodies for 30 minutes at the following concentrations: 10 g/ml, 1 g/ml, 0.1 ⁇ g/ml and 0.01 ⁇ g/ml.
  • EXAMPLE 4 FORMATION OF BI-SPECIFIC ANTIBODIES
  • bispecific antibodies were achieved in the following steps. First, the two parental antibodies carrying the bispecific mutations were expressed and purified separately. Then the antibodies were mixed in the presence of a mild reducing agent. The mild reduction of the antibodies caused dissociation of the antibodies into two monomers, each with a variable heavy and light chain. The monomers were then mixed together, followed by an oxidation step which causes the formation of bi-specific antibody molecules.
  • Anti-PD-Ll parental (PD-L1 wild type, PDL-1WT) and engineered
  • EXAMPLE 5 BI-SPECIFIC ANTIBODY FUNCTION
  • the bi-specific antibodies generated in Example 3 were next tested for their ability to recognize both antigens, for example, PD-L1 and G250.
  • the function of the PD-L1 and G250 bi-specific antibodies was tested using flow cytometry.
  • CAIX + PD-L1 " SKRC-52 express CALX (250) but not PD-L1, and therefore it was expected that cells could be recognized by only anti-CAIX antibody G37 and not PD-L1. To avoid the saturation of antibody binding, the concentration of antibody was low and in a reduced dose manner. Indeed, parental anti-G37 recognized SKRC-52 cells, while parental anti-PD-Ll did not (levels same as control).
  • the bi-specific antibody containing conjugated anti-G37 and anti- PD-Ll monomers, recognized SKRC-52 cells in a half reduced concentration compared to the parental G37 antibody, thereby demonstrating the functionality of a bi-specific antibody generated using the methods and antibodies described herein.
  • mAb42 Peripheral blood mononuclear cells
  • D1-D4 Different healthy donors
  • PBMCs peripheral blood mononuclear cells
  • PMBCs were stimulated with 0. ⁇ g/ml SEB (staphylococcal enterotoxin B) and TNFoc production was measured using MSD (Meso Scale Delivery). Sample analyses were performed in triplicate.
  • culturing PBMCs in the presence of mAb42 caused an increase in production of TNFa in response to SEB when cultured in the presence of anti-PD- Ll antibody (mAb42) compared to control antibody in all four donor samples. Furthermore, the increase in TNFa production was statistically significant, with a p ⁇ 0.0005. Thus, treatment with anti-PD-Ll antibody augments the immune response in response to an antigen, or infection, in humans.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Microbiology (AREA)

Abstract

The present invention comprises human monoclonal antibodies that bind to PD-L1 (also known as programmed death ligand 1 or B7H1). Binding of the invented antibody to PD-L1 inhibits binding to its receptor, PD1 (programmed death 1), and ligand-mediated activities and can be used to treat cancer and chronic viral infections.

Description

HUMAN MONOCLONAL ANTI-PD-L1 ANTIBODIES AND METHODS OF USE
RELATED APPLICATIONS
[0001] This application claims priority to and benefit of U.S. Provisional Application
No. 61/709,731, filed on October 4, 2012, and U.S. Provisional Application No. 61/779,969 filed on March 13, 2013; the contents of which are each hereby incorporated by reference in their entireties.
FIELD OF THE INVENTION
[0002] This invention relates generally to anti-PD-Ll (also known as programmed cell death 1 ligand 1 or B7H1) antibodies as well as to methods for use thereof.
BACKGROUND OF THE INVENTION
[0003] The immune system must achieve a balance between effective responses to eliminate pathogenic entities and maintaining tolerance to prevent autoimmune disease. T cells are central to preserving this balance, and their proper regulation is primarily coordinated by the B7-CD28 family of molecules. Interactions between B7 family members, which function as ligands, and CD28 family members, which function as receptors, provide critical positive signals that not only initiate, augment and sustain T cell responses, but also contribute key negative signals that limit, terminate and/or attenuate T cell responses when appropriate. A member of the CD28 family, called PD-1 (also known as programmed cell death-1) is upregulated on activated T cells, B cells, and monocytes. PD-1 has two identified ligands in the B7 family, PD-L1 (also known as BH71 or programmed cell death-1 ligand 1) and PD-L2. While PD-L2 expression tends to be more restricted, found primarily on activated antigen-presenting cells (APCs), PD-L1 expression is more widespread, including cells of hematopoietic lineage (including activated T cells, B cells, monocytes, dendritic cells and macrophages) and peripheral nonlymphoid tissues (including heart, skeletal, muscle, placenta, lung, kidney and liver tissues). The widespread expression of PD-L1 suggests its significant role in regulating PD-1/PD-L1 -mediated peripheral tolerance.
[0004] Binding between PD-L1 and PD-1 has a profound effect on the regulation of T cell responses. Specifically, PD-Ll/PD-1 interaction inhibits T cell proliferation and production of effector cytokines that mediate T cell activity and immune response, such as IL-2 and IFN-γ. This negative regulatory function is important for preventing T cell- mediated autoimmunity and immunopathology. However, the PD-l/PD-Ll axis has also been shown to play a role in T cell exhaustion, whereby the negative regulatory function inhibits T cell response to the detriment of the host. Prolonged or chronic antigenic stimulation of T cells can induce negative immunological feedback mechanisms which inhibit antigen- specific responses and results in immune evasion of pathogens. T cell exhaustion can also result in progressive physical deletion of the antigen-specific T cells themselves. T cell expression of PD-1 is up-regulated during chronic antigen stimulation, and its binding to PD-L1 results in a blockade of effector function in both CD4+ (T helper cells) and CD8+ (cytotoxic T lymphocytes or CTL) T cells, thus implicating the PD-l/PD-Ll interaction in the induction of T cell exhaustion.
[0005] More recently, it has been shown that some chronic viral infections and cancers have developed immune evasion tactics that specifically exploit the PD-l/PD-Ll axis by causing PD-l/PD-Ll -mediated T cell exhaustion. Many human tumor cells and tumor- associated antigen presenting cells express high levels of PD-L1, which suggests that the tumors induce T cell exhaustion to evade anti-tumor immune responses. During chronic HIV infection, HIV-specific CD8+ T cells are functionally impaired, showing a reduced capacity to produce cytokines and effector molecules as well as a diminished ability to proliferate. Studies have shown that PD-1 is highly expressed on HIV-specific CD8+ T cells of HIV infected individuals, indicating that blocking the PD-l/PD-Ll pathway may have therapeutic potential for treatment of HIV infection and AIDS patients. Taken together, agents that block the PD-l/PD-Ll pathway will provide a new therapeutic approach for a variety of cancers, HIV infection, and/or other diseases and conditions that are associated with T-cell exhaustion. Therefore, there exists an urgent need for agents that can block or prevent PD- l/PD-Ll interaction.
SUMMARY OF THE INVENTION
[0006] The invention is based upon the discovery of monoclonal antibodies which bind PD-L1. The monoclonal antibody is fully human. The antibodies bind PD-L1. The antibodies are referred to herein as huPD-Ll antibodies.
[0007] PD-L1 is also known as programmed cell death 1 ligand 1, programmed death ligand 1, PDCD1 ligand 1, PDCD1L1, PDL1, B7 homolog 1, B7H1, B7-H, CD274 and CD274 antigen. [0008] The present invention provides an isolated humanized monoclonal antibody having a heavy chain with three CDRs comprising the amino acid sequences SYGIS (SEQ ID NO:57), WISAYNGNTNYAQKLED (SEQ ID NO:70), and ALPS GTILVGGWFDP (SEQ ID NO: 86) respectively and a light chain with three CDRs comprising the amino acid sequences TRSSGNIASNYVQ (SEQ ID NO: 101), EDNQRPS (SEQ ID NO: 115), and QSYDSSNLWV (SEQ ID NO: 127) respectively; a heavy chain with three CDRs comprising the amino acid sequences SYALS (SEQ ID NO:58), AISGGGGSTYYADSVKD (SEQ ID NO:71), and DVFPETFSMNYGMDV (SEQ ID NO:87) respectively and a light chain with three CDRs comprising the amino acid sequences QGDSLRSYYAS (SEQ ID NO: 102), GKNNRPS (SEQ ID NO:116), and NSRDSSGNHYV (SEQ ID NO:128) respectively; a heavy chain with three CDRs comprising the amino acid sequences DYAMH (SEQ ID NO:60), LISGDGGSTYYADSVKD (SEQ ID NO:73), and VLLPCSSTSCYGSVGAFDI (SEQ ID NO:88) respectively and a light chain with three CDRs comprising the amino acid sequences GGSDIGRKSVH (SEQ ID NO: 103), SDRDRPS (SEQ ID NO: 117), and
QVWDNNSDHYV (SEQ ID NO: 129) respectively; a heavy chain with three CDRs comprising the amino acid sequences NYDMS (SEQ ID NO:61),
RVNWNGGSTTYADAVKD (SEQ ID NO:74), and EFVGAYDL (SEQ ID NO:89) respectively and a light chain with three CDRs comprising the amino acid sequences TGTSSDVGGYNYVS (SEQ ID NO: 104), DVSNRPS (SEQ ID NO: 118), and SSYTSSTLP (SEQ ID NO: 130) respectively; a heavy chain with three CDRs comprising the amino acid sequences GLYIH (SEQ ID NO:62), WIIPIFGTANYAQKFED (SEQ ID NO:75), and GLRWGIWGWFDP (SEQ ID NO: 90) respectively and a light chain with three CDRs comprising the amino acid sequences RASQSIGNSLA (SEQ ID NO: 105), GASSRAT (SEQ ID NO:119), and QQHTIPTFS (SEQ ID NO:131) respectively; a heavy chain with three CDRs comprising the amino acid sequences DNAIS (SEQ ID NO:63),
WIIPIFGKPNYAQKFED (SEQ ID NO:76), and TMVRGFLGVMDV (SEQ ID NO:91) respectively and a light chain with three CDRs comprising the amino acid sequences RASQGIGSYLA (SEQ ID NO: 106), AASTLQS (SEQ ID NO: 120), and QQLNNYPIT (SEQ ID NO: 132) respectively; a heavy chain with three CDRs comprising the amino acid sequences SYAMS (SEQ ID NO:64), AISGSGGSTYYADSVKD (SEQ ID NO:77), and DQFVTIFGVPRYGMDV (SEQ ID NO: 92) respectively and a light chain with three CDRs comprising the amino acid sequences SGDKLGNKYAY (SEQ ID NO: 107), QDIKRPS (SEQ ID NO: 121), and QTWDNSVV (SEQ ID NO: 133) respectively; a heavy chain with three CDRs comprising the amino acid sequences SYAIS (SEQ ID NO: 57), WIIPIFGTANYAQKFED (SEQ ID NO:78), and GRQMFGAGIDF (SEQ ID NO:93) respectively and a light chain with three CDRs comprising the amino acid sequences TRSSGSIDSNYVQ (SEQ ID NO: 108), EDNQRPS (SEQ ID NO: 115), and
QSYDSNNRHVI (SEQ ID NO: 134) respectively; a heavy chain with three CDRs comprising the amino acid sequences TYALN (SEQ ID NO:65), RIVPLIGLVNYAHNFED (SEQ ID NO:79), and EVYGGNSDY (SEQ ID NO:94) respectively and a light chain with three CDRs comprising the amino acid sequences TRSSGNIGTNYVQ (SEQ ID NO: 109), EDYRRPS (SEQ ID NO: 122), and QSYHSSGWE (SEQ ID NO: 135) respectively; a heavy chain with three CDRs comprising the amino acid sequences SHGIT (SEQ ID NO: 66),
WISAHNGHASNAQKVED (SEQ ID NO:80), and VHAALYYGMDV (SEQ ID NO:95) respectively and a light chain with three CDRs comprising the amino acid sequences GGNNIGS KG VH (SEQ ID NO: 110), DDSDRPS (SEQ ID NO: 123), and
QVWDSSSDHWV (SEQ ID NO: 136) respectively; a heavy chain with three CDRs comprising the amino acid sequences RHGMH (SEQ ID NO:67),
VISHDGSVKYYADSMKD (SEQ ID NO:81), and GLSYQVSGWFDP (SEQ ID NO:96) respectively and a light chain with three CDRs comprising the amino acid sequences TRSSGSIASNYVQ (SEQ ID NO: 111), EDNQRPS (SEQ ID NO: 115), and QSYDSTTPSV (SEQ ID NO: 137) respectively; a heavy chain with three CDRs comprising the amino acid sequences SYGIS (SEQ ID NO:58), WTSPHNGLTAFAQILED (SEQ ID NO:82), and VHPVFSYALDV (SEQ ID NO: 97) respectively and a light chain with three CDRs comprising the amino acid sequences TRSSGSIASNYVQ (SEQ ID NO: 112), EDNQRPS (SEQ ID NO: 115), and QSYDGITVI (SEQ ID NO: 138) respectively; a heavy chain with three CDRs comprising the amino acid sequences TYAFS (SEQ ID NO:68),
RIIPILGIANYAQKFED (SEQ ID NO:83), and DGYGSDPVL (SEQ ID NO:98) respectively and a light chain with three CDRs comprising the amino acid sequences TRSSGSIASHYVQ (SEQ ID NO: 113), EDNKRPS (SEQ ID NO: 124), and QSYDSSNRWV (SEQ ID NO: 139) respectively; or a heavy chain with three CDRs comprising the amino acid sequences NYGIS (SEQ ID NO:69), WISAYNGNTNYAQKVED (SEQ ID NO:84), and GDFRKPFDY (SEQ ID NO: 99) respectively and a light chain with three CDRs comprising the amino acid sequences TLRSGLNVGSYRIY (SEQ ID NO: 114), YKSDSNKQQAS (SEQ ID NO: 125), and MPWYSSAVV (SEQ ID NO: 140) respectively; wherein said antibody binds human PD- Ll. [0009] In one aspect, the antibody is monovalent or bivalent. In another aspect, the antibody is a single chain antibody.
[0010] The present invention provides a single chain antibody comprising a VH nucleotide sequence comprising SEQ ID NO: 1 and a VL nucleotide sequence comprising SEQ ID NO: 3 ; a VH nucleotide sequence comprising SEQ ID NO: 5 and a VL nucleotide sequence comprising SEQ ID NO:7; a VH nucleotide sequence comprising SEQ ID NO: 9 and a VL nucleotide sequence comprising SEQ ID NO: 11 ; a VH nucleotide sequence comprising SEQ ID NO: 13 and a VL nucleotide sequence comprising SEQ ID NO: 15; a VH nucleotide sequence comprising SEQ ID NO: 17 and a VL nucleotide sequence comprising SEQ ID NO: 19; a VH nucleotide sequence comprising SEQ ID NO: 21 and a VL nucleotide sequence comprising SEQ ID NO:23 ; a VH nucleotide sequence comprising SEQ ID NO: 25 and a VL nucleotide sequence comprising SEQ ID NO: 27; a VH nucleotide sequence comprising SEQ ID NO: 29 and a VL nucleotide sequence comprising SEQ ID NO:31 ; a VH nucleotide sequence comprising SEQ ID NO: 33 and a VL nucleotide sequence comprising SEQ ID NO:35 ; a VH nucleotide sequence comprising SEQ ID NO: 37 and a VL nucleotide sequence comprising SEQ ID NO:39; a VH nucleotide sequence comprising SEQ ID NO: 41 and a VL nucleotide sequence comprising SEQ ID NO: 43 ; a VH nucleotide sequence comprising SEQ ID NO: 45 and a VL nucleotide sequence comprising SEQ ID NO:47; a VH nucleotide sequence comprising SEQ ID NO: 49 and a VL nucleotide sequence comprising SEQ ID NO:51 ; or a VH nucleotide sequence comprising SEQ ID NO: 53 and a VL nucleotide sequence comprising SEQ ID NO:55.
[0011] In another aspect, the present invention provides a single chain antibody comprising a VH amino acid sequence comprising SEQ ID NO: 2 and a VL amino acid sequence comprising SEQ ID NO: 4; a VH amino acid sequence comprising SEQ ID NO: 6 and a VL amino acid sequence comprising SEQ ID NO: 8; a VH amino acid sequence comprising SEQ ID NO: 10 and a VL amino acid sequence comprising SEQ ID NO: 12; a VH amino acid sequence comprising SEQ ID NO: 14 and a VL amino acid sequence comprising SEQ ID NO: 16; a VH amino acid sequence comprising SEQ ID NO: 18 and a VL amino acid sequence comprising SEQ ID NO: 20; a VH amino acid sequence comprising SEQ ID NO: 22 and a VL amino acid sequence comprising SEQ ID NO: 24; a VH amino acid sequence comprising SEQ ID NO: 26 and a VL amino acid sequence comprising SEQ ID NO: 28; a VH amino acid sequence comprising SEQ ID NO: 30 and a VL amino acid sequence comprising SEQ ID NO: 32; a VH amino acid sequence comprising SEQ ID NO: 34 and a VL amino acid sequence comprising SEQ ID NO: 36; a VH amino acid sequence comprising SEQ ID NO: 38 and a VL amino acid sequence comprising SEQ ID NO: 40; a VH amino acid sequence comprising SEQ ID NO: 42 and a VL amino acid sequence comprising SEQ ID NO: 44; a VH amino acid sequence comprising SEQ ID NO: 46 and a VL amino acid sequence comprising SEQ ID NO: 48; a VH amino acid sequence comprising SEQ ID NO: 50 and a VL amino acid sequence comprising SEQ ID NO: 52; or a VH amino acid sequence comprising SEQ ID NO: 54 and a VL amino acid sequence comprising SEQ ID NO: 56.
[0012] In some aspects, the antibody has a binding affinity within the range of 10"5 M to 10"12 M.
[0013] In another aspect, the antibody is a bi-specific antibody that also binds to a tumor-associated antigen, a cytokine or a cell surface receptor. For example, the tumor- associated antigen is CAIX. For example, the cytokine is IL-10. For example, the cell surface receptor is CCR4, IL21R, BTLA, HVEM or TIM3.
[0014] The present invention provides an antibody linked to a therapeutic agent. For example, the therapeutic agent is a toxin, a radiolabel, a siRNA, a small molecule, or a cytokine.
[0015] The present invention provides a cell producing any of the foregoing antibodies.
[0016] The present invention also provides methods of selectively killing a tumor cell comprising contacting said cell with any of the foregoing antibodies. In one aspect, the selective killing occurs by antibody-dependent cellular toxicity (ADCC), complement- dependent cytotoxicity (CDC), antibody dependent cellular phagocytosis (ADCP). In another aspect, the tumor cell expresses PD-L1.
[0017] The present invention also provides methods of preventing or reversing T cell exhaustion comprising administering to a subject in need thereof a composition comprising any of the foregoing antibodies.
[0018] The present invention also provides methods of augmenting an immune response to an antigen comprising administering to a subject in need thereof a composition comprising any of the foregoing antibodies. In one aspect, the antigen is a viral antigen, a bacterial antigen or a tumor associated antigen. In another aspect, the viral antigen is HIV. In a further aspect, the tumor associated antigen is CAIX. In another aspect, the antibody is administered prior to or after exposure to the antigen. In another aspect, the administration of said antibody causes an increase in antigen specific T cell activity. In another aspect, the T- cell is an effector T cell.
[0019] The present invention also provides methods of treating or alleviating a symptom of cancer, comprising administering to a subject in need thereof a composition comprising any of the foregoing antibodies. For example, the cancer is renal cell carcinoma or breast cancer. For example, the cancer is a cancer in which PD-L1 is overexpressed. In another example, the cancer is a cancer that induces T cell exhaustion.
[0020] The present invention also provides methods of treating or alleviating a symptom of a chronic viral infection, comprising administering to a subject in need thereof a composition comprising any of the foregoing antibodies. For example, the chronic viral infection is an HIV infection. For example, the chronic viral infection is a viral infection that induces T cell exhaustion.
[0021] The present invention provides a nucleic acid sequence comprising the nucleic acid sequence of SEQ ID NO: 1 , 3, 5, 7, 9, 11 , 13. 15. 17, 19, 21 , 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53 or 55.
[0022] In another aspect, the present invention provides a nucleic acid sequence encoding the polypeptide of SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54 or 56.
[0023] In another aspect, the present invention provides a polypeptide comprising the amino acid sequence of SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54 or 56.
[0024] In another aspect, the present invention provides a vector comprising a nucleic acid sequence of SEQ ID NO: 1 , 3, 5, 7, 9, 11 , 13. 15. 17, 19, 21 , 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53 or 55. The present invention provides a vector comprising a nucleic acid sequence of SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54 or 56. The present invention further provides a cell comprising any one of the foregoing vectors.
[0025] The administration routes, in any methods of this disclosure, include, but are not limited to parenteral, (e.g. , intravenous), intradermal, subcutaneous, oral (e.g. , inhalation), transdermal (i. e., topical), transmucosal, and rectal administration.
[0026] The subject in any methods of this disclosure is, for example, a mammal. The mammal is, for example, a human. [0027] Other features and advantages of the invention will be apparent from and are encompassed by the following detailed description and claims.
BRIEF DESCRIPTION OF THE DRAWINGS
[0028] Figure 1. Amino acid sequences of anti-PD-Ll scFv-phage clones (14 clones). Framework regions 1-4 (FW1-4), Complementarily determining regions 1-3 (CDR1- 3) and family designations for both the IGHV and IGLV/IGKV are shown. Kabat number is used. Key: "." AA matches to consensus, "X" no consensus AA, and "-" is a space (i.e. no AA).
[0029] Figure 2. Binding analysis of huPD-Ll antibodies with human PD-L1 (hPD-
Ll) expressing cells by FACS. Four types of cells were tested, including parental cell line 300.9 and hPD-Ll, hPD-L2 or human C-type lectin domain family 2 member (hCLEC2D) transfected 300.9 cells. GF1538 is a humanized Ab against hPD-Ll. GF1757 is a humanized Ab against hPD-L2. Secondary antibody is PE-goat anti-human IgG.
[0030] Figure 3. Inhibition of hPD-1 binding to hPD-Ll by anti-PD-Ll phage- antibodies in a competitive FACS analysis. All anti-hPD-Ll Abs in phage-scFv form were tested for inhibition of the binding of hPDl-hFc fusion protein with hPD-Ll expressing 293T cells. 1012 pfu of phage-scFvs were mixed with -0.25 μg/mL of soluble hPDl-hFc and added to hPD-Ll expressing-plasmid transfected 293T cells. After washing, the cells were incubated with FITC- anti-human IgG antibody to measure the binding of hPDl-hFc to hPD- Ll on cell surface.
[0031] Figure 4. Inhibition of hPD- 1 binding to hPD-Ll by anti-PD-Ll soluble antibodies in a competitive FACS analysis. All anti-hPD-Ll Abs were pre-incubated with hPD-Ll expressing-plasmid transfected 300.9 cells at indicated concentrations for 30 mins, 0.125 μg of hPD-1 -mouse IgG2a was then added to each reaction and incubated for another 30 mins. After washing, PE-goat-anti-mouse IgG2a Ab was added and followed by washing and FACS analysis. GF1538 is a humanized Ab against hPD-Ll. GF1757 is a humanized Ab against hPD-L2.
[0032] Figure 5. Design and formation of bi-specific antibodies.
[0033] Figure 6. Bi-specific antibody (bsAb) construct determination. A) Schematic representation of the bi-specific antibody that recognizes CAIX and PD-L1, and the "knob into hole" approach of linking the CH3 domains. B) Schematic representation of the three types of bsAb constructs with different mutations in the CH2 domain to alter ADCC activity. [0034] Figure 7. Generation of bi-specific antibody and its function. A) Protein gel showing the dissociation of engineered (G37 KIHA) antibody under reducing conditions compared to conjugated (non-reduced) control IgG, parental G37 (WT), and bi-specific (G37 KIHA + PD-Ll KIHB) antibodies. B) Protein gel showing the dissociation of engineered (PD-Ll KIHB) antibody under reducing conditions compared to control IgG, parental PDL-1 (WT), and bi-specific (G37 KIHA + PD-Ll KIHB) antibodies. C) Analysis of bi-specific antibody binding to CAIX+PDL-1" SKRC-52 cells by flow cytometry.
[0035] Figure 8. Functional characterization of PD-Ll specific mAb42. PBMCs from four healthy donors (D1-D4) were cultured in the presence of ocPDLl (mAb42) or control isotype antibody stimulated with 0.1 μg/ml SEB for 48 hours and TNFoc production was measured by MSD units. Data presented as means of triplicates *, p<0.0005.
DETAILED DESCRIPTION
[0036] The present invention provides humanized monoclonal antibodies specific against PD-Ll, also known as B7H1. The antibodies were identified by a method of phage display antibody library selection by using proteoliposome-coupled-PD-Ll as the library selection target. These antibodies represent a new class of human monoclonal antibodies against PD-Ll.
[0037] These anti-PD-Ll human monoclonal antibodies are referred to herein as
"huPD-Ll antibodies".
[0038] Binding of PD-Ll to PD-1 negatively regulates T cell antigen-specific responses, which is critical for tolerance and prevention of autoimmunity and
immunopathology. However, excessive PD-Ll/PD-1 interaction, which can be caused by chronic antigenic stimulation, can result in inhibition of T cell antigen-specific responses and loss of T cells, which are characteristics of T cell exhaustion. T cell exhaustion is a state of T cell dysfunction that can arise in chronic infections and cancer. It is defined by poor effector function, sustained expression of inhibitory receptors and a transcriptional state distinct from that of functional effector or memory T cells. Exhaustion prevents management of infection and tumor progression.
[0039] PD-Ll overexpression has been detected in different cancers. For example, in breast cancer, PD-Ll is overexpressed and associated with high-risk prognostic factors. In renal cell carcinoma, PD-Ll is upregulated and increased expression of PD-1 has also been found in tumor infiltrating leukocytes. Anti-PD-Ll and anti-PD-1 antibodies have demonstrated some clinical efficacy in phase I trials for renal cell carcinoma. Therapeutic agents that can bind to PD-1 or PD-L1 may be useful for specifically targeting tumor cells. Agents that are capable of blocking the PD-l/PD-Ll interaction may be even more useful in treating cancers that have induced T cell exhaustion to evade anti-tumor T cell activity. Use of such agents, alone or in combination with other anti-cancer therapeutics, can effectively target tumor cells that overexpress PD-L1 and increase anti-tumor T cell activity, thereby augmenting the immune response to target tumor cells.
[0040] PD-1 and PD-L1 can also be upregulated by T cells after chronic antigen stimulation, for example, by chronic infections. During chronic HIV infection, HIV- specific CD8+ T cells are functionally impaired, showing a reduced capacity to produce cytokines and effector molecules as well as a diminished ability to proliferate. PD-1 is highly expressed on HIV-specific CD8+ T cells of HIV infected individuals. Therefore, blocking this pathway may enhance the ability of HIV-specific T cells to proliferate and produce cytokines in response to stimulation with HIV peptides, thereby augmenting the immune response against HIV. Other chronic infections may also benefit from the use of PD-l/PD-Ll blocking agents, such as chronic viral, bacterial or parasitic infections.
[0041] The present invention provides a human monoclonal antibody that specifically binds PD-L1 proteins. Binding of the antibody of the present invention to PD-L1 interrupts the ligand's ability to bind to its receptor PD1. By a variety of mechanisms, the huPD-Ll antibody prevents the negative feedback mechanisms that inhibit T cell responses. In some cases, the huPD-Ll antibody prevents, inhibits or reverses T cell exhaustion. Administration of the huPD-Ll antibody may result in increased T cell proliferation, increased antigen- specific T cell activity, and increased production of effector cytokines. In some instances, the huPD-Ll antibody promotes or augments the antigen- specific immune response. This immune response may be mediated by effector T cells.
[0042] The huPD-Ll antibody is monovalent or bivalent and comprises a single or double chain. Functionally, the binding affinity of the huPD-Ll antibody is within the range of 10~5M to 10~12 M. For example, the binding affinity of the huPD-Ll antibody is from 10~6 M to 10~12 M, from 10"7 M to 10~12 M, from 10~8 M to 10"12 M, from 10~9 M to 10"12 M, from 10"5 M to 10~n M, from 10"6 M to 10~n M, from 10"7 M to 10~n M, from 10~8 M to 10~n M, from 10"9 M to 10"11 M, from 10"10 M to 10"11 M, from 10"5 M to 10"10 M, from 10"6 M to 10"10 M, from 10"7 M to 10"10 M, from 10"8 M to 10"10 M, from 10"9 M to 10"10 M, from 10"5 M to 10"9 M, from 10"6 M to 10"9 M, from 10"7 M to 10"9 M, from 10"8 M to 10"9 M, from 10"5 M to 10"8 M, from 10"6 M to 10"8 M, from 10"7 M to 10"8 M, from 10~5 M to 10"7 M, from 10~6 M to 10"7 M or from 10"5 M to 10~6 M.
[0043] Furthermore, the antibody of the present invention comprises a therapeutic agent including, but not limited to, a toxin, a radiolabel, a siRNA, or a cytokine.
[0044] The huPD-Ll antibody is capable of inducing cell death. Cell death is induced by either direct or indirect mechanisms. For instance, PD-Ll binding by the huPD-Ll antibody can lead to complement-dependent cytotoxicity (CDC). Alternatively, the huPD-Ll antibody binds PD-Ll, and leads to the recruitment of a second cell type that will kill the PD- L14-expressing target cell. Exemplary mechanisms by which the huPD-Ll antibody mediates cell death by recruitment of a second cell type include, but are not limited to, antibody- dependent cellular toxicity (ADCC) and antibody dependent cellular phagocytosis (ADCP). Target PD-Ll -expressing cell types comprise tumor and T cells, such as activated T cells.
[0045] Fourteen unique monoclonal huPD-Ll antibodies were identified. These include Ab-14, Ab-16, Ab-22, Ab-30, Ab-31, Ab-32, Ab-38, Ab-42, Ab-46, Ab-50, Ab-52, Ab-55, Ab-56 and Ab-65.
[0046] The nucleic acid and amino acid sequence of the monoclonal huPD-Ll antibodies are provided below:
[0047]
Table 1A. Ab-14 Variable Region nucleic acid sequences
VH chain of Ab-14 (SEQ ID NO: l)
CAGGTGCAGCTGGTGCAGTCTGGAGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTCTCCTGCAAGGCTTC TGGTTACACCTTTACCAGCTATGGTATCAGCTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGAT GGATCAGCGCTTACAATGGTAACACAAACTATGCACAGAAGCTCCAGGGCAGAGTCACCATGACCACAGACACA TCCACGAGCACAGCCTACATGGAGCTGAGGAGCCTGAGATCTGACGACACGGCCGTGTATTACTGTGCGAGAGC TCTACCTAGTGGGAC TATACTGGTCGGAGGTTGGTTCGACCCCTGGGGCCAGGGAACCCTGGTCACCGTCTCCT CA
VL chain of Ab-14 (SEQ ID NO:3)
AATTTTATGCTGACTCAGCCCCACTCTGTGTCGGAGTCTCCGGGGAAGACGGTAACCATCTCCTGCACCCGCAG CAGTGGCAACATTGCCAGCAATTATGTGCAGTGGTACCAACAGCGCCCGGGCAGTGCCCCCACCACTGTGATCT ATGAGGATAACCAAAGACCCTCTGGGGTCCCTGATCGGTTCTCTGGCTCCATCGACAGCTCCTCCAACTCTGCC TCCCTCACCATCTCTGGACTGAAGACTGAGGACGAGGCTGACTACTACTGTCAGTCTTATGATAGCAGCAATCT TTGGGTGTTCGGCGGAGGGACCAAGCTGACCGTCCTA
[0048]
Table IB. Ab-14 Variable Region amino acid sequences
VH chain of Ab-14 (SEQ ID NO:2)
QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYG I SWVRQAPGQGLEWMGWI SAYNGNTNYAQKLQGRVTMTTDT S TSTAYMELRS LRSDDTAVYYCARALPSGT I LVGGWF DPWGQGTLVTVSS
VL chain of Ab-14 (SEQ ID NO:4)
NFMLTQPHSVSESPGKTVT I SCTRSSGN IASNYVQWYQQRPGSAPTTVIYE DNQRPSGVPDRF SGS I DSS SNSA S LT I SGLKTEDEADYYCQSYDS SNLWVFGGGTKLTVL
[0049] Table 2A. Ab-16 Variable Region nucleic acid sequences
VH chain of Ab-16 (SEQ ID NO:5)
GAGGTGCAGCTGGTGCAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGTGCAGCCTC TGGATTCACCTTTAGCAGCTATGCCCTGAGCTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTCTCAG CTATTAGTGGTGGTGGTGGTAGCACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCAGAGACAAT TCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCCGTATATTACTGTGCGAAAGA CGTGTTTCCAGAGACTTTTTCGATGAACTACGGTATGGACGTCTGGGGCCAAGGAACCCTGGTCACCGTCTCCT CA
VL chain of Ab-16 (SEQ ID NO:7)
TCTTCTGAGCTGACTCAGGACCCTGCTGTGTCTGTGGCCTTGGGACAGACAGTCAGGATCACATGCCAAGGAGA CAGCCTCAGAAGCTATTATGCAAGCTGGTACCAGCAGAAGCCAGGACAGGCCCCTGTACTTGTCATCTATGGTA AAAACAACCGGCCCTCAGGGATCCCAGACCGATTCTCTGGCTCCAGCTCAGGAAACACAGCTTCCTTGACCATC ACTGGGGCTCAGGCGGAAGATGAGGCTGACTATTACTGTAACTCCCGGGACAGCAGTGGTAACCATTATGTCTT CGGAACTGGGACCAAGGTCACCGTCCTA
[0050]
Table 2B. Ab-16 Variable Region amino acid sequences
VH chain of Ab-16 (SEQ ID NO: 6)
EVQLVQSGGGVVQPGRSLRLSCAASGFTFSSYALSWVRQAPGKGLEWVSAISGGGGSTYYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAKDVFPETFSMNYGMDVWGQGTLVTVSS
VL chain of Ab-16 (SEQ ID NO: 8)
SSELTQDPAVSVALGQTVRITCQGDSLRSYYASWYQQKPGQAPVLVIYGKNNRPSGIPDRFSGSSSGNTASLTI TGAQAEDEADYYCNSRDSSGNHYVFGTGTKVTVL
[0051]
Table 3A. Ab-22 Variable Region nucleic acid sequences
VH chain of Ab-22 (SEQ ID NO:9)
CAGGTGCAGCTGGTGCAGTCTGGGGGAGGCGTGGTACAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTC TGGATTCACCTTTGATGATTATGCCATGCACTGGGTCCGTCAAGCTCCAGGGAAGGGTCTGGAGTGGGTCTCTC TTATTAGTGGGGATGGTGGTAGCACATACTATGCAGACTCTGTGAAGGGCCGATTCACCATCTCCAGAGACAAC AGCAAAAACTCCCTGTATCTGCAAATGAACAGTCTGAGAACTGAGGACACCGCCTTGTATTACTGTGCAAAAGT GCTCCTCCCCTGTAGTAGTACCAGCTGCTATGGAAGCGTCGGTGCTTTTGATATCTGGGGCCAAGGGACCACGG TCACCGTCTCCTCA
VL chain of Ab-22 (SEQ ID NO: 11)
TAGGACGATGAGCTCGGTCCCAGCTCCGAAGACATAATGATCACTATTATTATCCCACACCTGACAGTAATAAT CGGCCTCATCACCGGCTTCGACCCTGCTGATGGTCAGGGTGGCCGTGTTCCCAGAGTTGGAGCCAGAGAATCGC TCAGAGATCCCTGAGGGCCGGTCCCTATCAGAGTAGATGACCAACGCAGGGGCCTGGCCTGGCTTCTGCTGGTA CCAGTGCACACTCTTCCTTCCAATGTCGCTTCCCCCACAGGTAATCCTGGCCGTCTTTCCTGGGGCCACTGACA CTGAGGGTGCCTGAGTCAGCACAGGCAG
[0052]
Table 3B. Ab-22 Variable Region amino acid sequences
VH chain of Ab-22 (SEQ ID NO: 10)
QVQLVQSGGGVVQPGGSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSLISGDGGSTYYADSVKGRFTISRDN SKNSLYLQMNSLRTEDTALYYCAKVLLPCSSTSCYGSVGAFDIWGQGTTVTVSS
VL chain of Ab-22 (SEQ ID NO: 12)
LPVLTQAPSVSVAPGKTARITCGGSDIGRKSVHWYQQKPGQAPALVIYSDRDRPSGISERFSGSNSGNTATLTI SRVEAGDEADYYCQVWDNNSDHYVFGAGTELIVL
[0053]
Table 4A. Ab-30 Variable Region nucleic acid sequences
VH chain of Ab-30 (SEQ ID NO: 13) CAGGTGCAGCTGGTGCAGTCTGGGGGAAGTGTGGTACGGCCTGGGGAATCCCTCAGACTCTCCTGTGTAGCCTC TGGATTCATCTTTGATAATTATGACATGAGTTGGGTCCGCCAAGTTCCAGGGAAGGGGCTGGAGTGGGTCTCTC GTGTTAATTGGAATGGTGGTAGCACAACTTATGCAGACGCTGTGAAGGGCCGATTCACCATCTCCAGAGACAAC ACCAAGAACTCCCTGTATCTACAAATGAACAACCTGAGAGCCGAAGACACGGCCGTGTATTACTGTGTGCGCGA GTTTGTCGGTGCTTATGATCTCTGGGGCCAGGGGACCACGGTCACCGTCTCCTCA
VL chain of Ab-30 (SEQ ID NO: 15)
CAGTCTGCCCTGACTCAGCCTGCCTCCGTGTCTGGGTCTCCTGGACAGTCGATCACCATCTCCTGCACTGGAAC CAGCAGTGACGTTGGTGGTTATAACTATGTCTCCTGGTACCAACAACACCCAGGCAAAGCCCCCAAACTCATGA TTTATGATGTCAGTAATCGGCCCTCAGGGGTTTCTAATCGCTTCTCTGGCTCCAAGTCTGGCAACACGGCCTCC CTGACCATCTCTGGGCTCCAGGCTGAGGACGAGGCTGATTATTACTGCAGCTCATATACAAGCAGCACTCTGCC GTTCGGCGGAgGGACCAAGCTGACCGTCCTA
[0054]
Table 4B. Ab-30 Variable Region amino acid sequences
VH chain of Ab-30 (SEQ ID NO: 14)
QVQLVQSGGSVVRPGESLRLSCVASGFIFDNYDMSWVRQVPGKGLEWVSRVNWNGGSTTYADAVKGRFTISRDN TKNSLYLQMNNLRAEDTAVYYCVREFVGAYDLWGQGTTVTVSS
VL chain of Ab-30 (SEQ ID NO: 16)
QSALTQPASVSGSPGQS ITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSNRPSGVSNRFSGSKSGNTAS LTISGLQAEDEADYYCSSYTSSTLPFGGGTKLTVL
[0055]
Table 5A. Ab-31 Variable Region nucleic acid sequences
VH chain of Ab-31 (SEQ ID NO: 17)
CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCAGGGGCCACAGTGAAGGTCTCCTGCAAGGTTTT TGGAGACACCTTCCGCGGCCTCTATATACACTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGAG GGATCATCCCTATCTTTGGTACAGCAAACTACGCACAGAAGTTCCAGGGCAGAGTCACGATTACCACGGACGAA TCCACGAGCACAGCCTACATGGAGCTGAGCAGCCTGAGATCTGAGGACACGGCCGTGTATTACTGTGCGAGCGG ACTACGTTGGGGGATCTGGGGCTGGTTCGACCCCTGGGGCCAGGGCACCCTGGTCACCGTCTCCTCA
VL chain of Ab-31 (SEQ ID NO: 19)
GAAATTGTGTTGACGCAGTCTCCAGCCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGGGC CAGTCAGAGTATTGGCAACAGCTTAGCCTGGTACCAGCAGAAACCTGGCCAGGCTCCCAGGCTCCTCATGTATG GTGCATCCAGCAGGGCCACTGGCATCCCAGACAGGTTCAGTGGCAGTGGGGCTGGGACAGACTTCACTCTCACC ATCAGCAGCCTAGAGCCTGAAGATTTTGCAACGTATTACTGTCAGCAGCATACTATCCCAACATTCTCTTTCGG CCCTGGGACCAAAGTGGAAGTCAAA
[0056]
Table 5B. Ab-31 Variable Region amino acid sequences
VH chain of Ab-31 (SEQ ID NO: 18)
QVQLVQSGAEVKKPGATVKVSCKVFGDTFRGLYIHWVRQAPGQGLEWMGGI IPIFGTANYAQKFQGRVTITTDE STSTAYMELSSLRSEDTAVYYCASGLRWGIWGWFDPWGQGTLVTVSS
VL chain of Ab-31 (SEQ ID NO:20)
E IVLTQSPATLSLSPGERATLSCRASQS IGNSLAWYQQKPGQAPRLLMYGASSRATGIPDRFSGSGAGTDFTLT ISSLEPEDFATYYCQQHTIPTFSFGPGTKVEVK
[0057]
Table 6A. Ab-32 Variable Region nucleic acid sequences
VH chain of Ab-32 (SEQ ID NO:21)
GAGGTGCAGCTGGTGCAGTCTGGGGCTGAGCTGAAGAAGCCTGGGTCCTCGGTGAAGGTCTCCTGCAAGGCTTT TGGAGGCACCTTCAGTGACAATGCTATCAGCTGGGTGCGACAGGCCCCTGGACAAGGGCCTGAGTGGATGGGGG GCATCATTCCTATCTTTGGAAAACCAAACTACGCACAGAAGTTCCAGGGCAGAGTCACGATTACCGCGGACGAA TCCACGAGCACTGCCTACATGGTCCTGAGCAGCCTGAGATCTGAGGACACGGCCGTATATTACTGTGCGAGAAC TATGGTTCGGGGCTTTCTTGGGGTTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCA VL chain of Ab-32 (SEQ ID NO:23)
GATATTGTGATGACCCAGACTCCATCCTTCCTGTCCGCATCCATAGGAGACAGAGTCACCATCACTTGCCGGGC CAGTCAGGGCATTGGCAGTTATTTAGCCTGGTATCAGCAAAGACCAGGGGAAGCCCCTAAGCTCCTGATCTATG CTGCATCGACTTTGCAAAGTGGAGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACGGACTTCACTCTCACA ATCAGCAACCTGCAGCCTGAAGATTTTGCAACTTATTACTGTCAACAGCTTAATAATTACCCGATCACCTTCGG CCAAGGGACACGACTGGAGATTAAA
[0058]
Table 6B. Ab-32 Variable Region amino acid sequences
VH chain of Ab-32 (SEQ ID NO:22)
EVQLVQSGAELKKPGSSVKVSCKAFGGTFSDNAISWVRQAPGQGPEWMGGI IPIFGKPNYAQKFQGRVTITADE STSTAYMVLSSLRSEDTAVYYCARTMVRGFLGVMDVWGQGTTVTVSS
VL chain of Ab-32 (SEQ ID NO:24)
DIVMTQTPSFLSASIGDRVTITCRASQGIGSYLAWYQQRPGEAPKLLIYAASTLQSGVPSRFSGSGSGTDFTLT ISNLQPEDFATYYCQQLNNYPITFGQGTRLE IK
[0059]
Table 7A. Ab-38 Variable Region nucleic acid sequences
VH chain of Ab-38 (SEQ ID NO:25)
CAGGTGCAGCTGGTGCAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTC TGGATTCACCTTTAGCAGCTATGCCATGAGCTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTCTCAG CTATTAGTGGTAGTGGTGGTAGCACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCAGAGACAAT TCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCCGTATATTACTGTGCGAAAGA TCAGTTCGTTACGATTTTTGGAGTGCCAAGATACGGTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCT CCTCA
VL chain of Ab-38 (SEQ ID NO:27)
CAGTCTGCCCTGACTCAGCCACCCTCAGTGTCCGTGTCCCCAGGACAGACAGCCAACATCCCCTGCTCTGGAGA TAAATTGGGGAATAAATATGCTTACTGGTATCAGCAGAAGCCAGGCCAGTCCCCTGTACTGCTCATCTATCAAG ATATCAAGCGGCCCTCAAGGATCCCTGAGCGATTCTCTGGCTCCAACTCTGCGGACACAGCCACTCTGACCATC AGCGGGACCCAGGCTATGGATGAGGCTGACTATTACTGTCAGACGTGGGACAACAGCGTGGTCTTCGGCGGCGG GACCAAGCTGACCGTCCTC
[0060]
Table 7B. Ab-38 Variable Region amino acid sequences
VH chain of Ab-38 (SEQ ID NO:26)
QVQLVQSGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAKDQFVTIFGVPRYGMDVWGQGTTVTVSS
VL chain of Ab-38 (SEQ ID NO:28)
QSALTQPPSVSVSPGQTANIPCSGDKLGNKYAYWYQQKPGQSPVLLIYQDIKRPSRIPERFSGSNSADTATLTI SGTQAMDEADYYCQTWDNSVVFGGGTKLTVL
[0061]
Table 8A. Ab-42 Variable Region nucleic acid sequences
VH chain of Ab-42 (SEQ ID NO:29)
CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGTCCTCGGTGAAGGTCTCCTGCAAGGCTTC TGGAGGCACCTTCAGCAGCTATGCTATCAGCTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGAG GGATCATCCCTATCTTTGGTACAGCAAACTACGCACAGAAGTTCCAGGGCAGAGTCACGATTACCGCGGACAAA TCCACGAGCACAGCCTACATGGAGCTGAGCAGCCTGAGATCTGAGGACACGGCCGTCTATTACTGTGCGAGAGG GCGTCAAATGTTCGGTGCGGGAATTGATTTCTGGGGCCCGGGCACCCTGGTCACCGTCTCCTCA
VL chain of Ab-42 (SEQ ID NO:31)
AATTTTATGCTGACTCAGCCCCACTCTGTGTCGGAGTCTCCGGGGAAGACGGTAACCATCTCCTGCACCCGCAG CAGTGGCAGCATTGACAGCAACTATGTGCAGTGGTACCAGCAGCGCCCGGGCAGCGCCCCCACCACTGTGATCT ATGAGGATAACCAAAGACCCTCTGGGGTCCCTGATCGGTTCTCTGGCTCCATCGACAGCTCCTCCAACTCTGCC TCCCTCACCATCTCTGGACTGAAGACTGAGGACGAGGCTGACTACTACTGTCAGTCTTATGATAGCAACAATCG TCATGTGATATTCGGCGGAGGGACCAAGCTGACCGTCCTA
[0062] Table 8B. Ab-42 Variable Region amino acid sequences
VH chain of Ab-42 (SEQ ID NO: 30)
QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGI IPIFGTANYAQKFQGRVTITADK STSTAYMELSSLRSEDTAVYYCARGRQMFGAGIDFWGPGTLVTVSS
VL chain of Ab-42 (SEQ ID NO: 32)
NFMLTQPHSVSESPGKTVTISCTRSSGS IDSNYVQWYQQRPGSAPTTVIYEDNQRPSGVPDRFSGS IDSSSNSA SLTISGLKTEDEADYYCQSYDSNNRHVIFGGGTKLTVL
[0063]
Table 9A. Ab-46 Variable Region nucleic acid sequences
VH chain of Ab-46 (SEQ ID NO:33)
GAGGTGCAGCTGGTGGAGTCTGGGGCTGAAGTAAAGAAGCCTGGGTCCTCGGTGAAAGTCTCCTGCAAGGTTTC AGGAGGCACATTCGGCACCTATGCTCTCAACTGGGTGCGCCAGGCCCCTGGACAAGGGCTTGAGTGGATGGGAA GGATCGTCCCTCTCATTGGTCTAGTAAACTACGCACATAACTTTGAGGGCAGAATCTCGATTACCGCGGACAAG TCCACGGGCACAGCCTACATGGAACTGAGCAACCTGAGATCTGACGACACGGCCGTGTATTACTGTGCGAGAGA GGTCTACGGTGGTAACTCCGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCA
VL chain of Ab-46 (SEQ ID NO: 35)
AATTTTATGCTGACTCAGCCCCACTCAGTGTCGGAGTCTCCGGGGAAGACGGTAACCATCTCCTGCACTCGCAG TAGTGGCAACATTGGCACCAACTATGTGCAGTGGTACCAGCAGCGCCCGGGCAGTGCCCCCGTCGCTTTGATCT ACGAGGATTATCGAAGACCCTCTGGGGTCCCTGATCGGTTCTCTGGCTCCATCGACAGCTCCTCCAACTCTGCC TCCCTCATCATCTCTGGACTGAAGCCTGAGGACGAGGCTGACTACTACTGTCAGTCTTATCATAGCAGCGGTTG GGAATTCGGCGGAGGGACCAAGCTGACCGTCCTC
[0064]
Table 9B. Ab-46 Variable Region amino acid sequences
VH chain of Ab-46 (SEQ ID NO: 34)
EVQLVESGAEVKKPGSSVKVSCKVSGGTFGTYALNWVRQAPGQGLEWMGRIVPLIGLVNYAHNFEGRISITADK STGTAYMELSNLRSDDTAVYYCAREVYGGNSDYWGQGTLVTVSS
VL chain of Ab-46 (SEQ ID NO:36)
NFMLTQPHSVSESPGKTVTISCTRSSGNIGTNYVQWYQQRPGSAPVALIYEDYRRPSGVPDRFSGS IDSSSNSA SLI ISGLKPEDEADYYCQSYHSSGWEFGGGTKLTVL
[0065]
Table 10A. Ab-50 Variable Region nucleic acid sequences
VH chain of Ab-50 (SEQ ID NO: 37)
CAGGTGCAGCTGGTGCAGTCTGGAGGTGAGGTGAAGAAGCCGGGGGCCTCAGTGAAGGTCTCCTGCAAGGCTTC TGGTTACACCTTGAGCAGTCATGGTATAACCTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGAT GGATCAGCGCTCACAATGGTCACGCTAGCAATGCACAGAAGGTGGAGGACAGAGTCACTATGACTACTGACACA TCCACGAACACAGCCTACATGGAACTGAGGAGCCTGACAGCTGACGACACGGCCGTGTATTACTGTGCGAGAGT ACATGCTGCCCTCTACTATGGTATGGACGTCTGGGGCCAAGGAACCCTGGTCACCGTCTCCTCA
VL chain of Ab-50 (SEQ ID NO: 39)
CAGTCTGTGCTGACTCAGCCACCCTCGGTGTCAGTGGCCCCAGGACAGACGGCCAGGATTACCTGTGGGGGAAA CAACATTGGAAGTAAAGGTGTGCACTGGTATCAGCAGAAGCCAGGCCAGGCCCCTGTACTGGTCGTCTATGATG ATAGTGACCGGCCCTCAGGGATCCCTGAGCGATTCTCTGGCTCCAACTCTGGGAACACGGCCACCCTGACCATC AGCAGGGTCGAAGCCGGGGATGAGGCCGACTATTACTGTCAGGTGTGGGATAGTAGTAGTGATCATTGGGTGTT CGGCGGAGGGACCAAGCTGACCGTCCTA
[0066]
Table 10B. Ab-50 Variable Region amino acid sequences
VH chain of Ab-50 (SEQ ID NO:38)
QVQLVQSGGEVKKPGASVKVSCKASGYTLSSHGITWVRQAPGQGLEWMGWISAHNGHASNAQKVEDRVTMTTDT STNTAYMELRSLTADDTAVYYCARVHAALYYGMDVWGQGTLVTVSS
VL chain of Ab-50 (SEQ ID NO:40)
QSVLTQPPSVSVAPGQTARITCGGNNIGSKGVHWYQQKPGQAPVLVVYDDSDRPSGIPERFSGSNSGNTATLTI SRVEAGDEADYYCQVWDSSSDHWVFGGGTKLTVL
[0067]
Table 11A. Ab-52 Variable Region nucleic acid sequences
VH chain of Ab-52 (SEQ ID NO:41)
CAGGTGCAGCTGCAGGAGTCGGGGGGAGGCGTGGTGCAGCCTGGGAGGTCCCTGAGACTCTCCTGTTCAGCCTC TGGATTCACCTTCAGCAGACATGGCATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCAG TGATATCACATGATGGAAGTGTAAAATACTATGCAGACTCCATGAAGGGCCGATTCAGCATCTCCAGAGACAAT TCCAACAACACACTGTATCTCCAAATGGACAGCCTGAGAGCTGACGACACGGCCGTTTATTACTGTGCGAGAGG ACTGTCGTACCAGGTGTCGGGGTGGTTCGACCCCTGGGGCCAGGGCACCCTGGTCACCGTCTCCTCA
VL chain of Ab-52 (SEQ ID NO:43)
AATTTTATGCTGACTCAGCCCCACTCTGTGTCGGAGTCTCCGGGGAAGACGGTAACCATCTCCTGCACCCGCAG CAGTGGCAGCATTGCCAGCAACTATGTGCAGTGGTACCAGCAGCGCCCGGGCAGTGCCCCCACCACTGTGATCT ATGAGGATAACCAAAGACCCTCTGGGGTCCCTGATCGGTTCTCTGGCTCCATCGACAGCTCCTCCAACTCTGCC TCCCTCACCATCTCTGGACTGAAGACTGAGGACGAGGCTGACTACTACTGTCAGTCTTATGATAGCACCACCCC TTCGGTGTTCGGCGGCGGGACCAAGCTGACCGTCCTA
[0068]
Table 11B. Ab-52 Variable Region amino acid sequences
VH chain of Ab-52 (SEQ ID NO:42)
QVQLQESGGGVVQPGRSLRLSCSASGFTFSRHGMHWVRQAPGKGLEWVAVISHDGSVKYYADSMKGRFSISRDN SNNTLYLQMDSLRADDTAVYYCARGLSYQVSGWFDPWGQGTLVTVSS
VL chain of Ab-52 (SEQ ID NO:44)
NFMLTQPHSVSESPGKTVTISCTRSSGS IASNYVQWYQQRPGSAPTTVIYEDNQRPSGVPDRFSGS IDSSSNSA SLTISGLKTEDEADYYCQSYDSTTPSVFGGGTKLTVL
[0069]
Table 12A. Ab-55 Variable Region nucleic acid sequences
VH chain of Ab-55 (SEQ ID NO:45)
CAGGTGCAGCTGGTGCAGTCTGGAGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTCTCCTGCAAGGCTTC TGGTTACACCTTTACCAGCTATGGTATCAGCTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGAT GGACCAGCCCTCATAATGGTCTCACAGCATTTGCACAGATCCTAGAGGGCCGAGTCACCATGACCACAGACACA TCCACGAACACAGCCTACATGGAATTGAGGAACCTGACATTTGATGACACGGCCGTTTATTTCTGTGCGAAAGT ACATCCTGTCTTCTCTTATGCGTTGGACGTCTGGGGCCAAGGCACCCTGGTCACCGTCTCCTCA
VL chain of Ab-55 (SEQ ID NO:47)
AATTTTATGCTGACTCAGCCCCACTCTGTGTCGGAGTCCCCGGGGAAGACGGTAACCATCTCCTGCACCCGCAG CAGTGGCAGCATTGCCAGCAACTATGTACAGTGGTACCAGCAGCGCCCGGGCAGTTCCCCCACCACTGTGATCT ATGAAGATAACCAAAGACCCTCTGGGGTCCCTGATCGGTTCTCTGGCTCCATCGACACCTCCTCCAACTCTGCC TCCCTCACCATCTCTGGACTGAAGACTAAGGACGAGGCGGACTACTACTGTCAGTCTTATGATGGCATCACTGT GATTTTCGGCGGAGGGACCAAGTTGACCGTCCTA
[0070]
Table 12B. Ab-55 Variable Region amino acid sequences
VH chain of Ab-55 (SEQ ID NO:46)
QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWTSPHNGLTAFAQILEGRVTMTTDT STNTAYMELRNLTFDDTAVYFCAKVHPVFSYALDVWGQGTLVTVSS
VL chain of Ab-55 (SEQ ID NO:48)
NFMLTQPHSVSESPGKTVTISCTRSSGS IASNYVQWYQQRPGSSPTTVIYEDNQRPSGVPDRFSGS IDTSSNSA SLTISGLKTKDEADYYCQSYDGITVIFGGGTKLTVL
[0071]
Table 13A. Ab-56 Variable Region nucleic acid sequences
VH chain of Ab-56 (SEQ ID NO:49)
GAGGTGCAGCTGGTGGAGTCTGGAGCTGAGGTGATGAACCCTGGGTCCTCGGTGAGGGTCTCCTGCAGGGGTTC TGGAGGCGACTTCAGTACCTATGCTTTCAGCTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGAA GGATCATCCCTATCCTTGGTATAGCAAACTACGCACAGAAGTTCCAGGGCAGGGTCACGATTACCGCGGACAAA TCCACGAGCACAGCCTACATGGAGCTGAGCAGCCTGAGATCTGACGATACGGCCGTGTATTACTGTGCGAGAGA TGGCTATGGTTCGGACCCGGTGCTATGGGGCCAGGGCACCCTGGTCACCGTCTCCTCA
VL chain of Ab-56 (SEQ ID NO:51)
AATTTTATGCTGACTCAGCCCCACTCTGTGTCGGGGTCTCCGGGGAAGACGGTAACCCTCCCCTGCACCCGCAG CAGTGGCAGCATTGCCAGCCACTATGTCCAGTGGTACCAGCAGCGCCCGGGCAGTGCCCCCACCACTGTGATCT ATGAGGATAACAAGAGACCCTCTGGGGTCCCTGATCGGTTCTCTGGCTCCATCGACAGCTCCTCCAACTCTGCC TCCCTCAGCATCTCTGGACTGAAGACTGAGGACGAGGCTGACTACTACTGTCAGTCTTATGATAGCAGCAATCG TTGGGTGTTCGGCGGAGGGACCAAGCTGACCGTCCTA
[0072]
Table 13B. Ab-56 Variable Region amino acid sequences
VH chain of Ab-56 (SEQ ID NO:50)
EVQLVESGAEVMNPGSSVRVSCRGSGGDFSTYAFSWVRQAPGQGLEWMGRI IPILGIANYAQKFQGRVTITADK STSTAYMELSSLRSDDTAVYYCARDGYGSDPVLWGQGTLVTVSS
VL chain of Ab-56 (SEQ ID NO:52)
NFMLTQPHSVSGSPGKTVTLPCTRSSGS IASHYVQWYQQRPGSAPTTVIYEDNKRPSGVPDRFSGS IDSSSNSA SLSISGLKTEDEADYYCQSYDSSNRWVFGGGTKLTVL
[0073]
Table 14A. Ab-65 Variable Region nucleic acid sequences
VH chain of Ab-65 (SEQ ID NO:53)
GAGGTGCAGCTGGTGCAGTCTGGAGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTCTCCTGCAAGGCTTC TGGTTACACCTTTACCAACTATGGTATCAGCTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGAT GGATCAGCGCTTACAATGGTAACACAAACTATGCACAGAAGGTCCAGGGCAGAGTCACCATGACCACAGACACA TCCACGAGCACAGGCTACATGGAGCTGAGGAGCCTGAGATCTGACGACACGGCCGTGTATTACTGTGCGAGAGG AGATTTTCGGAAACCCTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCA
VL chain of Ab-65 (SEQ ID NO:55)
CTGCCTGTGCTGACTCAGCCGGCTTCCCTCTCTGCATCCCCCGGAGCATCAGCCAGTCTCACCTGCACCTTACG CAGTGGCCTCAATGTTGGTTCCTACAGGATATACTGGTACCAGCAGAAGCCAGGGAGTCGTCCCCAGTATCTCC TGAACTACAAATCAGACTCAAATAAACAGCAGGCCTCTGGAGTCCCCAGCCGCTTCTCTGGATCCAAGGATGCT TCGGCCAATGCAGGGATTTTACTCATCTCCGGGCTCCAGTCTGAGGATGAGGCTGACTATTACTGTATGATTTG GTACAGCAGCGCTGTGGTATTCGGCGGAGGGACCAAGCTGACCGTCCTA
[0074]
Table 14B. Ab-65 Variable Region amino acid sequences
VH chain of Ab-65 (SEQ ID NO:54)
EVQLVQSGAEVKKPGASVKVSCKASGYTFTNYGISWVRQAPGQGLEWMGWISAYNGNTNYAQKVQGRVTMTTDT STSTGYMELRSLRSDDTAVYYCARGDFRKPFDYWGQGTLVTVSS
VL chain of Ab-65 (SEQ ID NO:56)
LPVLTQPASLSASPGASASLTCTLRSGLNVGSYRIYWYQQKPGSRPQYLLNYKSDSNKQQASGVPSRFSGSKDA SANAGILLISGLQSEDEADYYCMIWYSSAVVFGGGTKLTVL
[0075] The amino acid sequences of the heavy and light chain complementary determining regions of the huPD-Ll antibodies are shown in Table 15A and 15B below.
[0076]
Table 15A. Amino acid sequences of the complementary determining regions of the heavy chain.
Figure imgf000018_0001
NO: NO: NO:
Consensus SYAIS 57 WISPIGGSTNYAQKVQG 70 GLXXXXXXXXXXXXXXXDV 85
Ab-14 SYGIS 58 WISAYNGNTNYAQKLED 71 ALPSGTILVGGWFDP 86
Ab-16 SYALS 59 AISGGGGSTYYADSVKD 72 DVFPETFSMNYGMDV 87
Ab-22 DYAMH 60 LISGDGGSTYYADSVKD 73 VLLPCSSTSCYGSVGAFDI 88
Ab-30 NYDMS 61 RVNWNGGSTTYADAVKD 74 EFVGAYDL 89
Ab-31 GLYIH 62 WI IPIFGTANYAQKFED 75 GLRWGIWGWFDP 90
Ab-32 DNAIS 63 WIIPIFGKPNYAQKFED 76 TMVRGFLGVMDV 91
Ab-38 SYAMS 64 AISGSGGSTYYADSVKD 77 DQFVTIFGVPRYGMDV 92
Ab-42 SYAIS 57 WI IPIFGTANYAQKFED 78 GRQMFGAGIDF 93
Ab-46 TYALN 65 RIVPLIGLVNYAHNFED 79 EVYGGNSDY 94
Ab-50 SHGIT 66 WISAHNGHASNAQKVED 80 VHAALYYGMDV 95
Ab-52 RHGMH 67 VISHDGSVKYYADSMKD 81 GLSYQVSGWFDP 96
Ab-55 SYGIS 58 WTSPHNGLTAFAQILED 82 VHPVFSYALDV 97
Ab-56 TYAFS 68 RIIPILGIANYAQKFED 83 DGYGSDPVL 98
Ab-65 NYGIS 69 WISAYNGNTNYAQKVED 84 GDFRKPFDY 99
[0077] Table 15B. Amino acid sequences of the complementary determining regions of the light chain.
Figure imgf000019_0001
[0078] The huPD-Ll antibodies described herein bind to PD-Ll. In one aspect, the huPD-Ll antibodies have high affinity and high specificity for PD-Ll. In another aspect, the huPD-Ll antibodies can bind the PD-1 receptor and prevent, inhibit, or block the ligand PD- Ll from binding its receptor PD-1. In some instances, the huPD-Ll antibodies may have some cross-reactivity with PD-L2. In some instances, the huPD-Ll antibodies do not exhibit any cross-reactivity with PD-L2. In some instances, the huPD-Ll antibodies bind to PD-L1 with higher affinity and/or higher specificity than to PD-L2.
[0079] The present invention also features antibodies that have a specified percentage identity or similarity to the amino acid or nucleotide sequences of the huPD-Ll antibodies described herein. For example, the antibodies may have 60% , 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or higher identity when compared a specified region or the full length of any one of the huPD-Ll antibodies described herein. Sequence identity or similarity to the nucleic acids and proteins of the present invention can be determined by sequence comparison and/or alignment by methods known in the art. For example, sequence comparison algorithms (i.e. BLAST or BLAST 2.0), manual alignment or visual inspection can be utilized to determine percent sequence identity or similarity for the nucleic acids and proteins of the present invention.
[0080] As to amino acid sequences, one of skill in the art will readily recognize that individual substitutions, deletions or additions to a nucleic acid, peptide, polypeptide, or protein sequence which alters, adds, deletes, or substitutes a single amino acid or a small percentage of amino acids in the encoded sequence is collectively referred to herein as a "conservatively modified variant". In some embodiments the alteration results in the substitution of an amino acid with a chemically similar amino acid. Conservative substitution tables providing functionally similar amino acids are well known in the art. Such conservatively modified variants of the huPD-Ll antibody disclosed herein may exhibit increased cross-reactivity to PD-L2 in comparison to an unmodified huPD-Ll antibody. Antibodies
[0081] As used herein, the term "antibody" refers to immunoglobulin molecules and immunologically active portions of immunoglobulin (Ig) molecules, i.e. , molecules that contain an antigen binding site that specifically binds (immunoreacts with) an antigen. By "specifically binds" or "immunoreacts with" is meant that the antibody reacts with one or more antigenic determinants of the desired antigen and does not react with other
polypeptides. Antibodies include, but are not limited to, polyclonal, monoclonal, chimeric, dAb (domain antibody), single chain, Fa , Fa - and F(ab')2 fragments, scFvs, and Fa expression libraries. [0082] A single chain Fv ("scFv") polypeptide molecule is a covalently linked VH:VL heterodimer, which can be expressed from a gene fusion including VH- and "VY-encoding genes linked by a peptide-encoding linker. (See Huston et al. (1988) Proc Nat Acad Sci USA 85(16):5879-5883). A number of methods have been described to discern chemical structures for converting the naturally aggregated, but chemically separated, light and heavy polypeptide chains from an antibody V region into an scFv molecule, which will fold into a three dimensional structure substantially similar to the structure of an antigen-binding site. See, e.g., U.S. Patent Nos. 5,091,513; 5,132,405; and 4,946,778.
[0083] Very large naive human scFv libraries have been and can be created to offer a large source of rearranged antibody genes against a plethora of target molecules. Smaller libraries can be constructed from individuals with infectious diseases in order to isolate disease-specific antibodies. (See Barbas et al., Proc. Natl. Acad. Sci. USA 89:9339-43 (1992); Zebedee et al., Proc. Natl. Acad. Sci. USA 89:3175-79 (1992)).
[0084] In general, antibody molecules obtained from humans relate to any of the classes IgG, IgM, IgA, IgE and IgD, which differ from one another by the nature of the heavy chain present in the molecule. Certain classes have subclasses as well, such as IgGi, IgG2, and others. Furthermore, in humans, the light chain may be a kappa chain or a lambda chain. The term "antigen-binding site," or "binding portion" refers to the part of the immunoglobulin molecule that participates in antigen binding. The antigen binding site is formed by amino acid residues of the N-terminal variable ("V") regions of the heavy ("H") and light ("L") chains. Three highly divergent stretches within the V regions of the heavy and light chains, referred to as "hypervariable regions," are interposed between more conserved flanking stretches known as "framework regions," or "FRs". Thus, the term "FR" refers to amino acid sequences which are naturally found between, and adjacent to, hypervariable regions in immunoglobulins. In an antibody molecule, the three hypervariable regions of a light chain and the three hypervariable regions of a heavy chain are disposed relative to each other in three dimensional space to form an antigen-binding surface. The antigen-binding surface is complementary to the three-dimensional surface of a bound antigen, and the three hypervariable regions of each of the heavy and light chains are referred to as
"complementarity-determining regions," or "CDRs." CDRs for the VH and VL regions of the scFv antibodies are shown in Figure 2.
[0085] As used herein, the term "epitope" includes any protein determinant capable of specific binding to an immunoglobulin, a scFv, or a T-cell receptor. Epitopic determinants usually consist of chemically active surface groupings of molecules such as amino acids or sugar side chains and usually have specific three dimensional structural characteristics, as well as specific charge characteristics. For example, antibodies may be raised against N- terminal or C-terminal peptides of a polypeptide.
[0086] As used herein, the terms "immunological binding," and "immunological binding properties" refer to the non-covalent interactions of the type which occur between an immunoglobulin molecule and an antigen for which the immunoglobulin is specific. The strength, or affinity of immunological binding interactions can be expressed in terms of the dissociation constant (K< of the interaction, wherein a smaller K<j represents a greater affinity. Immunological binding properties of selected polypeptides can be quantified using methods well known in the art. One such method entails measuring the rates of antigen- binding site/antigen complex formation and dissociation, wherein those rates depend on the concentrations of the complex partners, the affinity of the interaction, and geometric parameters that equally influence the rate in both directions. Thus, both the "on rate constant" (Kon) and the "off rate constant" (Kcff) can be determined by calculation of the concentrations and the actual rates of association and dissociation. (See Nature 361: 186-87 (1993)). The ratio of Kcff /Kon enables the cancellation of all parameters not related to affinity, and is equal to the dissociation constant K<j. (See, generally, Davies et al. (1990) Annual Rev Biochem 59:439-473). An antibody of the present invention is said to specifically bind to a PD-L1 epitope when the equilibrium binding constant (K< is <10 μΜ, preferably < 10 nM, more preferably < 10 nM, and most preferably < 100 pM to about 1 pM, as measured by assays such as radioligand binding assays or similar assays known to those skilled in the art.
[0087] An PD-L1 protein of the invention, or a derivative, fragment, analog, homolog or ortholog thereof, may be utilized as an immunogen in the generation of antibodies that immunospecifically bind these protein components. A PD-L1 protein or a derivative, fragment, analog, homolog, or ortholog thereof, coupled to a proteoliposome may be utilized as an immunogen in the generation of antibodies that immunospecifically bind these protein components.
[0088] Those skilled in the art will recognize that it is possible to determine, without undue experimentation, if a human monoclonal antibody has the same specificity as a human monoclonal antibody of the invention by ascertaining whether the former prevents the latter from binding to PD-L1. If the human monoclonal antibody being tested competes with the human monoclonal antibody of the invention, as shown by a decrease in binding by the human monoclonal antibody of the invention, then it is likely that the two monoclonal antibodies bind to the same, or to a closely related, epitope.
[0089] Another way to determine whether a human monoclonal antibody has the specificity of a human monoclonal antibody of the invention is to pre-incubate the human monoclonal antibody of the invention with the PD-L1 protein, with which it is normally reactive, and then add the human monoclonal antibody being tested to determine if the human monoclonal antibody being tested is inhibited in its ability to bind PD-L1. If the human monoclonal antibody being tested is inhibited then, in all likelihood, it has the same, or functionally equivalent, epitopic specificity as the monoclonal antibody of the invention. Screening of human monoclonal antibodies of the invention can be also carried out by utilizing PD-L1 and determining whether the test monoclonal antibody is able to neutralize PD-L1.
[0090] Various procedures known within the art may be used for the production of polyclonal or monoclonal antibodies directed against a protein of the invention, or against derivatives, fragments, analogs homologs or orthologs thereof. (See, for example,
Antibodies: A Laboratory Manual, Harlow E, and Lane D, 1988, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, incorporated herein by reference).
[0091] Antibodies can be purified by well-known techniques, such as affinity chromatography using protein A or protein G, which provide primarily the IgG fraction of immune serum. Subsequently, or alternatively, the specific antigen which is the target of the immunoglobulin sought, or an epitope thereof, may be immobilized on a column to purify the immune specific antibody by immunoaffinity chromatography. Purification of
immunoglobulins is discussed, for example, by D. Wilkinson (The Scientist, published by The Scientist, Inc., Philadelphia PA, Vol. 14, No. 8 (April 17, 2000), pp. 25-28).
[0092] The term "monoclonal antibody" or "MAb" or "monoclonal antibody composition", as used herein, refers to a population of antibody molecules that contain only one molecular species of antibody molecule consisting of a unique light chain gene product and a unique heavy chain gene product. In particular, the complementarity determining regions (CDRs) of the monoclonal antibody are identical in all the molecules of the population. MAbs contain an antigen binding site capable of immunoreacting with a particular epitope of the antigen characterized by a unique binding affinity for it.
[0093] Monoclonal antibodies can be prepared using hybridoma methods, such as those described by Kohler and Milstein, Nature, 256:495 (1975). In a hybridoma method, a mouse, hamster, or other appropriate host animal, is typically immunized with an immunizing agent to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the immunizing agent. Alternatively, the lymphocytes can be immunized in vitro.
[0094] The immunizing agent will typically include the protein antigen, a fragment thereof or a fusion protein thereof. Generally, either peripheral blood lymphocytes are used if cells of human origin are desired, or spleen cells or lymph node cells are used if non-human mammalian sources are desired. The lymphocytes are then fused with an immortalized cell line using a suitable fusing agent, such as polyethylene glycol, to form a hybridoma cell (Coding, Monoclonal Antibodies: Principles and Practice, Academic Press, (1986) pp.
59-103). Immortalized cell lines are usually transformed mammalian cells, particularly myeloma cells of rodent, bovine and human origin. Usually, rat or mouse myeloma cell lines are employed. The hybridoma cells can be cultured in a suitable culture medium that preferably contains one or more substances that inhibit the growth or survival of the unfused, immortalized cells. For example, if the parental cells lack the enzyme hypoxanthine guanine phosphoribosyl transferase (HGPRT or HPRT), the culture medium for the hybridomas typically will include hypoxanthine, aminopterin, and thymidine ("HAT medium"), which substances prevent the growth of HGPRT-deficient cells.
[0095] Preferred immortalized cell lines are those that fuse efficiently, support stable high level expression of antibody by the selected antibody-producing cells, and are sensitive to a medium such as HAT medium. More preferred immortalized cell lines are murine myeloma lines, which can be obtained, for instance, from the Salk Institute Cell Distribution Center, San Diego, California and the American Type Culture Collection, Manassas, Virginia. Human myeloma and mouse-human heteromyeloma cell lines also have been described for the production of human monoclonal antibodies. (See Kozbor, J. Immunol., 133:3001 (1984); Brodeur et al., Monoclonal Antibody Production Techniques and
Applications, Marcel Dekker, Inc., New York, (1987) pp. 51-63)).
[0096] The culture medium in which the hybridoma cells are cultured can then be assayed for the presence of monoclonal antibodies directed against the antigen. Preferably, the binding specificity of monoclonal antibodies produced by the hybridoma cells is determined by immunoprecipitation or by an in vitro binding assay, such as
radioimmunoassay (RIA) or enzyme-linked immunoabsorbent assay (ELISA). Such techniques and assays are known in the art. The binding affinity of the monoclonal antibody can, for example, be determined by the Scatchard analysis of Munson and Pollard, Anal. Biochem., 107:220 (1980). Moreover, in therapeutic applications of monoclonal antibodies, it is important to identify antibodies having a high degree of specificity and a high binding affinity for the target antigen.
[0097] After the desired hybridoma cells are identified, the clones can be subcloned by limiting dilution procedures and grown by standard methods. (See Coding, Monoclonal Antibodies: Principles and Practice, Academic Press, (1986) pp. 59-103). Suitable culture media for this purpose include, for example, Dulbecco's Modified Eagle's Medium and RPMI-1640 medium. Alternatively, the hybridoma cells can be grown in vivo as ascites in a mammal.
[0098] The monoclonal antibodies secreted by the subclones can be isolated or purified from the culture medium or ascites fluid by conventional immunoglobulin purification procedures such as, for example, protein A-Sepharose, hydroxylapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography.
[0099] Monoclonal antibodies can also be made by recombinant DNA methods, such as those described in U.S. Patent No. 4,816,567. DNA encoding the monoclonal antibodies of the invention can be readily isolated and sequenced using conventional procedures (e.g. , by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of murine antibodies). The hybridoma cells of the invention serve as a preferred source of such DNA. Once isolated, the DNA can be placed into expression vectors, which are then transfected into host cells such as simian COS cells, Chinese hamster ovary (CHO) cells, or myeloma cells that do not otherwise produce immunoglobulin protein, to obtain the synthesis of monoclonal antibodies in the recombinant host cells. The DNA also can be modified, for example, by substituting the coding sequence for human heavy and light chain constant domains in place of the homologous murine sequences (see U.S. Patent No. 4,816,567; Morrison, Nature 368, 812-13 (1994)) or by covalently joining to the immunoglobulin coding sequence all or part of the coding sequence for a
non-immunoglobulin polypeptide. Such a non-immunoglobulin polypeptide can be substituted for the constant domains of an antibody of the invention, or can be substituted for the variable domains of one antigen-combining site of an antibody of the invention to create a chimeric bivalent antibody.
[00100] Fully human antibodies are antibody molecules in which the entire sequence of both the light chain and the heavy chain, including the CDRs, arise from human genes. Such antibodies are termed "humanized antibodies", "human antibodies", or "fully human antibodies" herein. Human monoclonal antibodies can be prepared by using trioma technique; the human B-cell hybridoma technique (see Kozbor, et al., 1983 Immunol Today 4: 72); and the EBV hybridoma technique to produce human monoclonal antibodies (see Cole, et al., 1985 In: MONOCLONAL ANTIBODIES AND CANCER THERAPY, Alan R. Liss, Inc., pp. 77-96). Human monoclonal antibodies may be utilized and may be produced by using human hybridomas (see Cote, et al., 1983. Proc Natl Acad Sci USA 80: 2026-2030) or by transforming human B-cells with Epstein Barr Virus in vitro (see Cole, et al., 1985 In:
MONOCLONAL ANTIBODIES AND CANCER THERAPY, Alan R. Liss, Inc., pp. 77-96).
[00101] In addition, human antibodies can also be produced using additional techniques, including phage display libraries. (See Hoogenboom and Winter, J. Mol. Biol., 227:381 (1991); Marks et al., J. Mol. Biol., 222:581 (1991)). Similarly, human antibodies can be made by introducing human immunoglobulin loci into transgenic animals, e.g. , mice in which the endogenous immunoglobulin genes have been partially or completely inactivated. Upon challenge, human antibody production is observed, which closely resembles that seen in humans in all respects, including gene rearrangement, assembly, and antibody repertoire. This approach is described, for example, in U.S. Patent Nos. 5,545,807; 5,545,806; 5,569,825; 5,625,126; 5,633,425; 5,661,016, and in Marks et al., Bio/Technology 10, 779-783 (1992); Lonberg et al., Nature 368 856-859 (1994); Morrison, Nature 368, 812-13 (1994); Fishwild et al, Nature Biotechnology 14, 845-51 (1996); Neuberger, Nature Biotechnology 14, 826 (1996); and Lonberg and Huszar, Intern. Rev. Immunol. 13 65-93 (1995).
[00102] Human antibodies may additionally be produced using transgenic nonhuman animals which are modified so as to produce fully human antibodies rather than the animal's endogenous antibodies in response to challenge by an antigen. (See PCT publication WO94/02602). The endogenous genes encoding the heavy and light immunoglobulin chains in the nonhuman host have been incapacitated, and active loci encoding human heavy and light chain immunoglobulins are inserted into the host's genome. The human genes are incorporated, for example, using yeast artificial chromosomes containing the requisite human DNA segments. An animal which provides all the desired modifications is then obtained as progeny by crossbreeding intermediate transgenic animals containing fewer than the full complement of the modifications. The preferred embodiment of such a nonhuman animal is a mouse, and is termed the Xenomouse™ as disclosed in PCT publications WO 96/33735 and WO 96/34096. This animal produces B cells which secrete fully human immunoglobulins. The antibodies can be obtained directly from the animal after immunization with an immunogen of interest, as, for example, a preparation of a polyclonal antibody, or alternatively from immortalized B cells derived from the animal, such as hybridomas producing monoclonal antibodies. Additionally, the genes encoding the immunoglobulins with human variable regions can be recovered and expressed to obtain the antibodies directly, or can be further modified to obtain analogs of antibodies such as, for example, single chain Fv (scFv) molecules.
[00103] An example of a method of producing a nonhuman host, exemplified as a mouse, lacking expression of an endogenous immunoglobulin heavy chain is disclosed in U.S. Patent No. 5,939,598. It can be obtained by a method, which includes deleting the J segment genes from at least one endogenous heavy chain locus in an embryonic stem cell to prevent rearrangement of the locus and to prevent formation of a transcript of a rearranged immunoglobulin heavy chain locus, the deletion being effected by a targeting vector containing a gene encoding a selectable marker; and producing from the embryonic stem cell a transgenic mouse whose somatic and germ cells contain the gene encoding the selectable marker.
[00104] One method for producing an antibody of interest, such as a human antibody, is disclosed in U.S. Patent No. 5,916,771. This method includes introducing an expression vector that contains a nucleotide sequence encoding a heavy chain into one mammalian host cell in culture, introducing an expression vector containing a nucleotide sequence encoding a light chain into another mammalian host cell, and fusing the two cells to form a hybrid cell. The hybrid cell expresses an antibody containing the heavy chain and the light chain.
[00105] In a further improvement on this procedure, a method for identifying a clinically relevant epitope on an immunogen and a correlative method for selecting an antibody that binds immunospecifically to the relevant epitope with high affinity, are disclosed in PCT publication WO 99/53049.
[00106] The antibody can be expressed by a vector containing a DNA segment encoding the single chain antibody described above.
[00107] These can include vectors, liposomes, naked DNA, adjuvant-assisted DNA, gene gun, catheters, etc. Vectors include chemical conjugates such as described in WO 93/64701, which has targeting moiety (e.g. a ligand to a cellular surface receptor), and a nucleic acid binding moiety (e.g. polylysine), viral vector (e.g. a DNA or RNA viral vector), fusion proteins such as described in PCT/US 95/02140 (WO 95/22618) which is a fusion protein containing a target moiety (e.g. an antibody specific for a target cell) and a nucleic acid binding moiety (e.g. a protamine), plasmids, phage, etc. The vectors can be
chromosomal, non-chromosomal or synthetic.
[00108] Preferred vectors include viral vectors, fusion proteins and chemical conjugates. Retroviral vectors include moloney murine leukemia viruses. DNA viral vectors are preferred. These vectors include pox vectors such as orthopox or avipox vectors, herpesvirus vectors such as a herpes simplex I virus (HSV) vector (see Geller, A. I. et al., J. Neurochem, 64:487 (1995); Lim, F., et al., in DNA Cloning: Mammalian Systems, D.
Glover, Ed. (Oxford Univ. Press, Oxford England) (1995); Geller, A. I. et al., Proc Natl. Acad. Sci.: U.S.A. 90:7603 (1993); Geller, A. I., et al., Proc Natl. Acad. Sci USA 87: 1149 (1990), Adenovirus Vectors (see LeGal LaSalle et al., Science, 259:988 (1993); Davidson, et al., Nat. Genet 3:219 (1993); Yang, et al., J. Virol. 69:2004 (1995) and Adeno-associated Virus Vectors (see Kaplitt, M. G.. et al., Nat. Genet. 8: 148 (1994).
[00109] Pox viral vectors introduce the gene into the cells cytoplasm. Avipox virus vectors result in only a short term expression of the nucleic acid. Adenovirus vectors, adeno- associated virus vectors and herpes simplex virus (HSV) vectors are preferred for introducing the nucleic acid into neural cells. The adenovirus vector results in a shorter term expression (about 2 months) than adeno-associated virus (about 4 months), which in turn is shorter than HSV vectors. The particular vector chosen will depend upon the target cell and the condition being treated. The introduction can be by standard techniques, e.g. infection, transfection, transduction or transformation. Examples of modes of gene transfer include e.g., naked DNA, CaP04 precipitation, DEAE dextran, electroporation, protoplast fusion, lipofection, cell microinjection, and viral vectors.
[00110] The vector can be employed to target essentially any desired target cell. For example, stereotaxic injection can be used to direct the vectors (e.g. adenovirus, HSV) to a desired location. Additionally, the particles can be delivered by intracerebroventricular (icv) infusion using a minipump infusion system, such as a SynchroMed Infusion System. A method based on bulk flow, termed convection, has also proven effective at delivering large molecules to extended areas of the brain and may be useful in delivering the vector to the target cell. (See Bobo et al., Proc. Natl. Acad. Sci. USA 91:2076-2080 (1994); Morrison et al., Am. J. Physiol. 266:292-305 (1994)). Other methods that can be used include catheters, intravenous, parenteral, intraperitoneal and subcutaneous injection, and oral or other known routes of administration.
[00111] These vectors can be used to express large quantities of antibodies that can be used in a variety of ways. For example, to detect the presence of PD-L1 in a sample. The antibody can also be used to try to bind to and disrupt a PD-L1 activity.
[00112] Techniques can be adapted for the production of single-chain antibodies specific to an antigenic protein of the invention (see e.g. , U.S. Patent No. 4,946,778). In addition, methods can be adapted for the construction of Fab expression libraries (see e.g. , Huse, et al., 1989 Science 246: 1275-1281) to allow rapid and effective identification of monoclonal Fab fragments with the desired specificity for a protein or derivatives, fragments, analogs or homologs thereof. Antibody fragments that contain the idiotypes to a protein antigen may be produced by techniques known in the art including, but not limited to: (i) an F(ab')2 fragment produced by pepsin digestion of an antibody molecule; (ii) an Fa fragment generated by reducing the disulfide bridges of an F(a )2 fragment; (iii) an Fab fragment generated by the treatment of the antibody molecule with papain and a reducing agent and (iv) Fv fragments.
[00113] Heteroconjugate antibodies are also within the scope of the present invention.
Heteroconjugate antibodies are composed of two covalently joined antibodies. Such antibodies have, for example, been proposed to target immune system cells to unwanted cells (see U.S. Patent No. 4,676,980), and for treatment of HIV infection (see WO 91/00360; WO 92/200373; EP 03089). It is contemplated that the antibodies can be prepared in vitro using known methods in synthetic protein chemistry, including those involving crosslinking agents. For example, immunotoxins can be constructed using a disulfide exchange reaction or by forming a thioether bond. Examples of suitable reagents for this purpose include
iminothiolate and methyl-4-mercaptobutyrimidate and those disclosed, for example, in U.S. Patent No. 4,676,980.
[00114] It can be desirable to modify the antibody of the invention with respect to effector function, so as to enhance, e.g. , the effectiveness of the antibody in treating cancer. For example, cysteine residue(s) can be introduced into the Fc region, thereby allowing interchain disulfide bond formation in this region. The homodimeric antibody thus generated can have improved internalization capability and/or increased complement-mediated cell killing and antibody-dependent cellular cytotoxicity (ADCC). (See Caron et al., J. Exp Med., 176: 1191-1195 (1992) and Shopes, J. Immunol., 148: 2918-2922 (1992)). Alternatively, an antibody can be engineered that has dual Fc regions and can thereby have enhanced complement lysis and ADCC capabilities. (See Stevenson et al., Anti-Cancer Drug Design, 3: 219-230 (1989)).
[00115] The invention also pertains to immunoconjugates comprising an antibody conjugated to a cytotoxic agent such as a toxin (e.g. , an enzymatically active toxin of bacterial, fungal, plant, or animal origin, or fragments thereof), or a radioactive isotope (i.e. , a radioconjugate).
[00116] Enzymatically active toxins and fragments thereof that can be used include diphtheria A chain, nonbinding active fragments of diphtheria toxin, exotoxin A chain (from Pseudomonas aeruginosa), ricin A chain, abrin A chain, modeccin A chain, alpha-sarcin, Aleurites fordii proteins, dianthin proteins, Phytolaca americana proteins (PAPI, PAPII, and PAP-S), momordica charantia inhibitor, curcin, crotin, sapaonaria officinalis inhibitor, gelonin, mitogellin, restrictocin, phenomycin, enomycin, and the tricothecenes. A variety of radionuclides are available for the production of radioconjugated antibodies. Examples include 212Bi, mI, mIn, 90Y, and 186Re.
[00117] Conjugates of the antibody and cytotoxic agent are made using a variety of bifunctional protein-coupling agents such as N-succinimidyl-3-(2-pyridyldithiol) propionate (SPDP), iminothiolane (IT), bifunctional derivatives of imidoesters (such as dimethyl adipimidate HCL), active esters (such as disuccinimidyl suberate), aldehydes (such as glutareldehyde), bis-azido compounds (such as bis (p-azidobenzoyl) hexanediamine), bis-diazonium derivatives (such as bis-(p-diazoniumbenzoyl)-ethylenediamine),
diisocyanates (such as tolyene 2,6-diisocyanate), and bis-active fluorine compounds (such as l,5-difluoro-2,4-dinitrobenzene). For example, a ricin immunotoxin can be prepared as described in Vitetta et al., Science 238: 1098 (1987). Carbon- 14-labeled
l-isothiocyanatobenzyl-3-methyldiethylene triaminepentaacetic acid (MX-DTPA) is an exemplary chelating agent for conjugation of radionucleotide to the antibody. (See
WO94/11026).
[00118] Those of ordinary skill in the art will recognize that a large variety of possible moieties can be coupled to the resultant antibodies or to other molecules of the invention. (See, for example, "Conjugate Vaccines", Contributions to Microbiology and Immunology, J. M. Cruse and R. E. Lewis, Jr (eds), Carger Press, New York, (1989), the entire contents of which are incorporated herein by reference). [00119] Coupling may be accomplished by any chemical reaction that will bind the two molecules so long as the antibody and the other moiety retain their respective activities. This linkage can include many chemical mechanisms, for instance covalent binding, affinity binding, intercalation, coordinate binding and complexation. The preferred binding is, however, covalent binding. Covalent binding can be achieved either by direct condensation of existing side chains or by the incorporation of external bridging molecules. Many bivalent or polyvalent linking agents are useful in coupling protein molecules, such as the antibodies of the present invention, to other molecules. For example, representative coupling agents can include organic compounds such as thioesters, carbodiimides, succinimide esters, diisocyanates, glutaraldehyde, diazobenzenes and hexamethylene diamines. This listing is not intended to be exhaustive of the various classes of coupling agents known in the art but, rather, is exemplary of the more common coupling agents. (See Killen and Lindstrom, Jour. Immun. 133: 1335-2549 (1984); Jansen et al., Immunological Reviews 62: 185-216 (1982); and Vitetta et al., Science 238: 1098 (1987)). Preferred linkers are described in the literature. (See, for example, Ramakrishnan, S. et al., Cancer Res. 44:201-208 (1984) describing use of MBS (M-maleimidobenzoyl-N-hydroxysuccinimide ester). See also, U.S. Patent No.
5,030,719, describing use of halogenated acetyl hydrazide derivative coupled to an antibody by way of an oligopeptide linker. Particularly preferred linkers include: (i) EDC (l-ethyl-3- (3-dimethylamino-propyl) carbodiimide hydrochloride; (ii) SMPT (4- succinimidyloxycarbonyl-alpha-methyl-alpha-(2-pridyl-dithio)-toluene (Pierce Chem. Co., Cat. (21558G); (iii) SPDP (succinimidyl-6 [3-(2-pyridyldithio) propionamidojhexanoate (Pierce Chem. Co., Cat #216510); (iv) Sulfo-LC-SPDP (sulfosuccinimidyl 6 [3-(2- pyridyldithio)-propianamide] hexanoate (Pierce Chem. Co. Cat. #2165-G); and (v) sulfo- NHS (N-hydroxysulfo- succinimide: Pierce Chem. Co., Cat. #24510) conjugated to EDC.
[00120] The linkers described above contain components that have different attributes, thus leading to conjugates with differing physio-chemical properties. For example, sulfo- NHS esters of alkyl carboxylates are more stable than sulfo-NHS esters of aromatic carboxylates. NHS-ester containing linkers are less soluble than sulfo-NHS esters. Further, the linker SMPT contains a sterically hindered disulfide bond, and can form conjugates with increased stability. Disulfide linkages, are in general, less stable than other linkages because the disulfide linkage is cleaved in vitro, resulting in less conjugate available. Sulfo-NHS, in particular, can enhance the stability of carbodimide couplings. Carbodimide couplings (such as EDC) when used in conjunction with sulfo-NHS, forms esters that are more resistant to hydrolysis than the carbodimide coupling reaction alone.
[00121] The antibodies disclosed herein can also be formulated as immunoliposomes.
Liposomes containing the antibody are prepared by methods known in the art, such as described in Epstein et al., Proc. Natl. Acad. Sci. USA, 82: 3688 (1985); Hwang et al., Proc. Natl Acad. Sci. USA, 77: 4030 (1980); and U.S. Pat. Nos. 4,485,045 and 4,544,545.
Liposomes with enhanced circulation time are disclosed in U.S. Patent No. 5,013,556.
[00122] Particularly useful liposomes can be generated by the reverse-phase evaporation method with a lipid composition comprising phosphatidylcholine, cholesterol, and PEG-derivatized phosphatidylethanolamine (PEG-PE). Liposomes are extruded through filters of defined pore size to yield liposomes with the desired diameter. Fab' fragments of the antibody of the present invention can be conjugated to the liposomes as described in Martin et al., J. Biol. Chem., 257: 286-288 (1982) via a disulfide-interchange reaction.
Use of Antibodies Against PD-Ll
[00123] Antibodies specifically binding a PD-Ll protein or a fragment thereof of the invention can be administered for the treatment of cancer or other proliferative disorders. Many cancers overexpress PD-Ll and the upregulation of PD-Ll is associated with high risk prognostic factors. Overexpression fo PD-Ll in tumor cells can also indicate a mechanism by which the tumor cells evade anti-tumor immunity, such as by inducing T cell exhaustion. Such cancers include renal cell carcinoma and breast cancer. Other exemplary cancers are those cancers that are associated with or utilize T cell exhaustion to evade anti-tumor T cell activity. Use of the antibody of the invention can enhance the ability of tumor antigen- specific T cells to proliferate and produce cytokines in response to stimulation with tumor antigen peptides, thereby augmenting T cell activity or anti-tumor immune response.
[00124] Antibodies specifically binding a PD-Ll protein or fragment thereof of the invention can be administered for the treatment of a chronic infection. Such chronic infections include, for example, viral, bacterial and parasitic infections. An exemplary chronic viral infection is HIV. During chronic HIV infection, HIV-specific CD8+ T cells are functionally impaired, showing a reduced capacity to produce cytokines and effector molecules as well as a diminished ability to proliferate. PD-1 is highly expressed on HIV- specific CD8+ T cells of HIV infected individuals. Use of the antibody of the invention can enhance the ability of HIV-specific T cells to proliferate and produce cytokines in response to stimulation with HIV peptides, thereby augmenting T cell activity or anti- viral immune response.
[00125] Antibodies of the invention, including bi-specific, polyclonal, monoclonal, humanized and fully human antibodies, may be used as therapeutic agents. Such agents will generally be employed to treat or prevent cancer in a subject, increase vaccine efficiency or augment a natural immune response. An antibody preparation, preferably one having high specificity and high affinity for its target antigen, is administered to the subject and will generally have an effect due to its binding with the target. Administration of the antibody may abrogate or inhibit or interfere with an activity of the PD-L1 protein.
[00126] Antibodies of the invention are capable of inducing cell death. Cell death is induced by either direct or indirect mechanisms. For instance, PD-L1 binding by the huPD- Ll antibody can lead to complement-dependent cytotoxicity (CDC). Alternatively, the huPD- Ll antibody binds PD-L1, and leads to the recruitment of a second cell type that will kill the PD-L14-expressing target cell. Exemplary mechanisms by which the huPD-Ll antibody mediates cell death by recruitment of a second cell type include, but are not limited to, antibody-dependent cellular toxicity (ADCC) and antibody dependent cellular phagocytosis (ADCP). Target PD-L1 -expressing cell types comprise tumor and T cells, for example, activated T cells.
[00127] Antibodies specifically binding a PD-L1 protein or fragment thereof of the invention can be administered for the treatment of a cancer or chronic infection in the form of pharmaceutical compositions. Principles and considerations involved in preparing therapeutic compositions comprising the antibody, as well as guidance in the choice of components are provided, for example, in Remington: The Science And Practice Of
Pharmacy 19th ed. (Alfonso R. Gennaro, et al., editors) Mack Pub. Co., Easton, Pa., 1995; Drug Absorption Enhancement: Concepts, Possibilities, Limitations, And Trends, Harwood Academic Publishers, Langhorne, Pa., 1994; and Peptide And Protein Drug Delivery (Advances In Parenteral Sciences, Vol. 4), 1991, M. Dekker, New York.
[00128] A therapeutically effective amount of an antibody of the invention relates generally to the amount needed to achieve a therapeutic objective. As noted above, this may be a binding interaction between the antibody and its target antigen that, in certain cases, interferes with the functioning of the target. The amount required to be administered will furthermore depend on the binding affinity of the antibody for its specific antigen, and will also depend on the rate at which an administered antibody is depleted from the free volume other subject to which it is administered. Common ranges for therapeutically effective dosing of an antibody or antibody fragment of the invention may be, by way of nonlimiting example, from about 0.1 mg/kg body weight to about 50 mg/kg body weight. Common dosing frequencies may range, for example, from twice daily to once a week.
[00129] Where antibody fragments are used, the smallest inhibitory fragment that specifically binds to the binding domain of the target protein is preferred. For example, based upon the variable-region sequences of an antibody, peptide molecules can be designed that retain the ability to bind the target protein sequence. Such peptides can be synthesized chemically and/or produced by recombinant DNA technology. (See, e.g. , Marasco et al., Proc. Natl. Acad. Sci. USA, 90: 7889-7893 (1993)). The formulation can also contain more than one active compound as necessary for the particular indication being treated, preferably those with complementary activities that do not adversely affect each other. Alternatively, or in addition, the composition can comprise an agent that enhances its function, such as, for example, a cytotoxic agent, cytokine, chemotherapeutic agent, or growth-inhibitory agent. Such molecules are suitably present in combination in amounts that are effective for the purpose intended.
[00130] The active ingredients can also be entrapped in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization, for example, hydroxymethylcellulose or gelatin-microcapsules and poly-(methylmethacrylate)
microcapsules, respectively, in colloidal drug delivery systems (for example, liposomes, albumin microspheres, microemulsions, nano-particles, and nanocapsules) or in
macroemulsions.
[00131] The formulations to be used for in vivo administration must be sterile. This is readily accomplished by filtration through sterile filtration membranes.
[00132] Sustained-release preparations can be prepared. Suitable examples of sustained-release preparations include semipermeable matrices of solid hydrophobic polymers containing the antibody, which matrices are in the form of shaped articles, e.g. , films, or microcapsules. Examples of sustained-release matrices include polyesters, hydrogels (for example, poly(2-hydroxyethyl-methacrylate), or poly(vinylalcohol)), polylactides (U.S. Pat. No. 3,773,919), copolymers of L-glutamic acid and γ
ethyl-L-glutamate, non-degradable ethylene-vinyl acetate, degradable lactic acid-glycolic acid copolymers such as the LUPRON DEPOT™ (injectable microspheres composed of lactic acid-glycolic acid copolymer and leuprolide acetate), and poly-D-(-)-3-hydroxybutyric acid. While polymers such as ethylene- vinyl acetate and lactic acid-glycolic acid enable release of molecules for over 100 days, certain hydrogels release proteins for shorter time periods.
[00133] An antibody according to the invention can be used as an agent for detecting the presence of PD-L1 (or a protein or a protein fragment thereof) in a sample. Preferably, the antibody contains a detectable label. Antibodies can be polyclonal, or more preferably, monoclonal. An intact antibody, or a fragment thereof (e.g. , Fab, scFv, or F(ab)2) can be used. The term "labeled", with regard to the probe or antibody, is intended to encompass direct labeling of the probe or antibody by coupling (i. e. , physically linking) a detectable substance to the probe or antibody, as well as indirect labeling of the probe or antibody by reactivity with another reagent that is directly labeled. Examples of indirect labeling include detection of a primary antibody using a fluorescently-labeled secondary antibody and end-labeling of a DNA probe with biotin such that it can be detected with fluorescently-labeled streptavidin. The term "biological sample" is intended to include tissues, cells and biological fluids isolated from a subject, as well as tissues, cells and fluids present within a subject. Included within the usage of the term "biological sample", therefore, is blood and a fraction or component of blood including blood serum, blood plasma, or lymph. That is, the detection method of the invention can be used to detect an analyte mRNA, protein, or genomic DNA in a biological sample in vitro as well as in vivo. For example, in vitro techniques for detection of an analyte mRNA includes Northern hybridizations and in situ hybridizations. In vitro techniques for detection of an analyte protein include enzyme linked immunosorbent assays (ELISAs), Western blots, immunoprecipitations, and immunofluorescence. In vitro techniques for detection of an analyte genomic DNA include Southern hybridizations.
Procedures for conducting immunoassays are described, for example in "ELISA: Theory and Practice: Methods in Molecular Biology", Vol. 42, J. R. Crowther (Ed.) Human Press, Totowa, NJ, 1995; "Immunoassay", E. Diamandis and T. Christopoulus, Academic Press, Inc., San Diego, CA, 1996; and "Practice and Theory of Enzyme Immunoassays", P. Tijssen, Elsevier Science Publishers, Amsterdam, 1985. Furthermore, in vivo techniques for detection of an analyte protein include introducing into a subject a labeled anti- analyte protein antibody. For example, the antibody can be labeled with a radioactive marker whose presence and location in a subject can be detected by standard imaging techniques.
[00134] Antibodies directed against a PD-L1 protein (or a fragment thereof) may be used in methods known within the art relating to the localization and/or quantitation of a PD- LI protein (e.g., for use in measuring levels of the PD-Ll protein within appropriate physiological samples, for use in diagnostic methods, for use in imaging the protein, and the like). In a given embodiment, antibodies specific to a PD-Ll protein, or derivative, fragment, analog or homolog thereof, that contain the antibody derived antigen binding domain, are utilized as pharmacologically active compounds (referred to hereinafter as "Therapeutics").
[00135] An antibody specific for a PD-Ll protein of the invention can be used to isolate a PD-Ll polypeptide by standard techniques, such as immunoaffinity,
chromatography or immunoprecipitation. Antibodies directed against a PD-Ll protein (or a fragment thereof) can be used diagnostically to monitor protein levels in tissue as part of a clinical testing procedure, e.g., to, for example, determine the efficacy of a given treatment regimen. Detection can be facilitated by coupling (i.e., physically linking) the antibody to a detectable substance. Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, and radioactive materials. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, β-galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; examples of bioluminescent materials include
125 luciferase, luciferin, and aequorin, and examples of suitable radioactive material include I, 1311, 35S or 3H.
Pharmaceutical compositions
[00136] The antibodies or agents of the invention (also referred to herein as "active compounds"), and derivatives, fragments, analogs and homologs thereof, can be incorporated into pharmaceutical compositions suitable for administration. Such compositions typically comprise the antibody or agent and a pharmaceutically acceptable carrier. As used herein, the term "pharmaceutically acceptable carrier" is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. Suitable carriers are described in the most recent edition of Remington' s Pharmaceutical Sciences, a standard reference text in the field, which is incorporated herein by reference. Preferred examples of such carriers or diluents include, but are not limited to, water, saline, ringer's solutions, dextrose solution, and 5% human serum albumin. Liposomes and non-aqueous vehicles such as fixed oils may also be used. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the compositions is contemplated. Supplementary active compounds can also be incorporated into the compositions.
[00137] A pharmaceutical composition of the invention is formulated to be compatible with its intended route of administration. Examples of routes of administration include parenteral, e.g. , intravenous, intradermal, subcutaneous, oral (e.g. , inhalation), transdermal (i.e., topical), transmucosal, and rectal administration. Solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid (EDTA); buffers such as acetates, citrates or phosphates, and agents for the adjustment of tonicity such as sodium chloride or dextrose. The pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide. The parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.
[00138] Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor
EL (BASF, Parsippany, N.J.) or phosphate buffered saline (PBS). In all cases, the composition must be sterile and should be fluid to the extent that easy syringeability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as manitol, sorbitol, sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.
[00139] Sterile injectable solutions can be prepared by incorporating the active compound in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle that contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, methods of preparation are vacuum drying and freeze-drying that yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.
[00140] Oral compositions generally include an inert diluent or an edible carrier. They can be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and used in the form of tablets, troches, or capsules. Oral compositions can also be prepared using a fluid carrier for use as a mouthwash, wherein the compound in the fluid carrier is applied orally and swished and expectorated or swallowed. Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition. The tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.
[00141] For administration by inhalation, the compounds are delivered in the form of an aerosol spray from pressured container or dispenser which contains a suitable propellant, e.g. , a gas such as carbon dioxide, or a nebulizer.
[00142] Systemic administration can also be by transmucosal or transdermal means.
For transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives. Transmucosal administration can be accomplished through the use of nasal sprays or suppositories. For transdermal administration, the active compounds are formulated into ointments, salves, gels, or creams as generally known in the art.
[00143] The compounds can also be prepared in the form of suppositories (e.g. , with conventional suppository bases such as cocoa butter and other glycerides) or retention enemas for rectal delivery.
[00144] In one embodiment, the active compounds are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, poly anhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art. The materials can also be obtained commercially from Alza Corporation and Nova Pharmaceuticals, Inc. Liposomal suspensions (including liposomes targeted to infected cells with monoclonal antibodies to viral antigens) can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Patent No. 4,522,811.
[00145] It is especially advantageous to formulate oral or parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the subject to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the dosage unit forms of the invention are dictated by and directly dependent on the unique characteristics of the active compound and the particular therapeutic effect to be achieved, and the limitations inherent in the art of compounding such an active compound for the treatment of individuals.
[00146] The pharmaceutical compositions can be included in a container, pack, or dispenser together with instructions for administration.
Diagnostic Assays
[00147] The huPD-Ll antibody of the invention, when joined to a detectable moiety, provides a way for detecting "cancerous tissue" or tissue subject to aberrant cell proliferation and therefore at risk for cancer. In addition to tissue that becomes cancerous due to an in situ neoplasm, for example, the antibody-detectable moiety conjugates also provides a method of detecting cancerous metastatic tissue present in distal organs and/or tissues. Thus such tissue may be detected by contacting tissue suspected of being cancerous with the antibody- detectable moiety under appropriate conditions to cause the detectable moiety to be detected in cancerous tissue, thereby detecting the presence of cancerous tissue.
[00148] The huPD-Ll antibody of the invention, when joined to a detectable moiety, provides a way for detecting T cell exhaustion in a subject suffering from a cancer or a chronic infection. For example, the huPD-Ll antibody can be used to detect the levels of PD- Ll in a subject, wherein the levels in comparison to a reference level can indicate whether the subject is suffering from T cell exhaustion. Thus, this method can also be used to determine whether or not treatment using the huPD-Ll antibody to augment the immune response by reversing or inhibiting T cell exhaustion would be beneficial to the subject.
[00149] The detectable moieties can be conjugated directly to the antibodies or fragments, or indirectly by using, for example, a fluorescent secondary antibody. Direct conjugation can be accomplished by standard chemical coupling of, for example, a fluorophore to the antibody or antibody fragment, or through genetic engineering. Chimeras, or fusion proteins can be constructed which contain an antibody or antibody fragment coupled to a fluorescent or bioluminescent protein. For example, Casadei, et al., describe a method of making a vector construct capable of expressing a fusion protein of aequorin and an antibody gene in mammalian cells.
[00150] As used herein, the term "labeled", with regard to the probe or antibody, is intended to encompass direct labeling of the probe or antibody by coupling (i.e. , physically linking) a detectable substance to the probe or antibody, as well as indirect labeling of the probe or antibody by reactivity with another reagent that is directly labeled. Examples of indirect labeling include detection of a primary antibody using a fluorescently-labeled secondary antibody and end-labeling of a DNA probe with biotin such that it can be detected with fluorescently-labeled streptavidin. The term "biological sample" is intended to include tissues, cells and biological fluids isolated from a subject (such as a biopsy), as well as tissues, cells and fluids present within a subject. That is, the detection method of the invention can be used to detect cancer, a cancer cell, or a cancer-associated cell (such as a stromal cell associated with a tumor or cancer cell) in a biological sample in vitro as well as in vivo. For example, in vitro techniques for detection of PD-L1 include enzyme linked immunosorbent assays (ELISAs), Western blots, immunoprecipitations, and immunofluorescence. Furthermore, in vivo techniques for detection of PD-L1 include introducing into a subject a labeled anti-PD-Ll antibody. For example, the antibody can be labeled with a radioactive marker whose presence and location in a subject can be detected by standard imaging techniques. In embodiments, the invention provides a non-invasive method of detecting a tumor or cancer cell in a subject. The subject is administered an antibody or scFv antibody of the invention, where the antibody is linked to a detectable moiety (i.e. , any moiety capable of being detected by, e.g., fluorescent, chemical, chemiluminescent, radioactive, or other means known in the art), the antibody is allowed to localize to the tumor then is detected by observation of the detectable moiety.
[00151] In the case of "targeted" conjugates, that is, conjugates which contain a targeting moiety-a molecule or feature designed to localize the conjugate within a subject or animal at a particular site or sites, localization refers to a state when an equilibrium between bound, "localized", and unbound, "free" entities within a subject has been essentially achieved. The rate at which such equilibrium is achieved depends upon the route of administration. For example, a conjugate administered by intravenous injection to localize thrombi may achieve localization, or accumulation at the thrombi, within minutes of injection. On the other hand, a conjugate administered orally to localize an infection in the intestine may take hours to achieve localization. Alternatively, localization may simply refer to the location of the entity within the subject or animal at selected time periods after the entity is administered. By way of another example, localization is achieved when an moiety becomes distributed following administration.
[00152] In all of the above cases, a reasonable estimate of the time to achieve localization may be made by one skilled in the art. Furthermore, the state of localization as a function of time may be followed by imaging the detectable moiety (e.g., a light-emitting conjugate) according to the methods of the invention, such as with a photodetector device. The "photodetector device" used should have a high enough sensitivity to enable the imaging of faint light from within a mammal in a reasonable amount of time, and to use the signal from such a device to construct an image.
[00153] In cases where it is possible to use light-generating moieties which are extremely bright, and/or to detect light-generating fusion proteins localized near the surface of the subject or animal being imaged, a pair of "night- vision" goggles or a standard high- sensitivity video camera, such as a Silicon Intensified Tube (SIT) camera (e.g., from Hammamatsu Photonic Systems, Bridgewater, N.J.), may be used. More typically, however, a more sensitive method of light detection is required.
[00154] In extremely low light levels the photon flux per unit area becomes so low that the scene being imaged no longer appears continuous. Instead, it is represented by individual photons which are both temporally and spatially distinct form one another. Viewed on a monitor, such an image appears as scintillating points of light, each representing a single detected photon. By accumulating these detected photons in a digital image processor over time, an image can be acquired and constructed. In contrast to conventional cameras where the signal at each image point is assigned an intensity value, in photon counting imaging the amplitude of the signal carries no significance. The objective is to simply detect the presence of a signal (photon) and to count the occurrence of the signal with respect to its position over time.
[00155] At least two types of photodetector devices, described below, can detect individual photons and generate a signal which can be analyzed by an image processor. Reduced-Noise Photodetection devices achieve sensitivity by reducing the background noise in the photon detector, as opposed to amplifying the photon signal. Noise is reduced primarily by cooling the detector array. The devices include charge coupled device (CCD) cameras referred to as "backthinned", cooled CCD cameras. In the more sensitive instruments, the cooling is achieved using, for example, liquid nitrogen, which brings the temperature of the CCD array to approximately -120°C. "Backthinned" refers to an ultra- thin backplate that reduces the path length that a photon follows to be detected, thereby increasing the quantum efficiency. A particularly sensitive backthinned cryogenic CCD camera is the "TECH 512", a series 200 camera available from Photometries, Ltd. (Tucson, Ariz.).
[00156] "Photon amplification devices" amplify photons before they hit the detection screen. This class includes CCD cameras with intensifiers, such as microchannel intensifiers. A microchannel intensifier typically contains a metal array of channels perpendicular to and co-extensive with the detection screen of the camera. The microchannel array is placed between the sample, subject, or animal to be imaged, and the camera. Most of the photons entering the channels of the array contact a side of a channel before exiting. A voltage applied across the array results in the release of many electrons from each photon collision. The electrons from such a collision exit their channel of origin in a "shotgun" pattern, and are detected by the camera.
[00157] Even greater sensitivity can be achieved by placing intensifying microchannel arrays in series, so that electrons generated in the first stage in turn result in an amplified signal of electrons at the second stage. Increases in sensitivity, however, are achieved at the expense of spatial resolution, which decreases with each additional stage of amplification. An exemplary microchannel intensifier-based single-photon detection device is the C2400 series, available from Hamamatsu.
[00158] Image processors process signals generated by photodetector devices which count photons in order to construct an image which can be, for example, displayed on a monitor or printed on a video printer. Such image processors are typically sold as part of systems which include the sensitive photon-counting cameras described above, and accordingly, are available from the same sources. The image processors are usually connected to a personal computer, such as an IBM-compatible PC or an Apple Macintosh (Apple Computer, Cupertino, Calif.), which may or may not be included as part of a purchased imaging system. Once the images are in the form of digital files, they can be manipulated by a variety of image processing programs (such as "ADOBE PHOTOSHOP", Adobe Systems, Adobe Systems, Mt. View, Calif.) and printed.
[00159] In one embodiment, the biological sample contains protein molecules from the test subject. One preferred biological sample is a peripheral blood leukocyte sample isolated by conventional means from a subject.
[00160] The invention also encompasses kits for detecting the presence of PD-Ll or a
PD-Ll -expressing cell in a biological sample. For example, the kit can comprise: a labeled compound or agent capable of detecting a cancer or tumor cell (e.g., an anti-PD-Ll scFv or monoclonal antibody) in a biological sample; means for determining the amount of PD-Ll in the sample; and means for comparing the amount of PD-Ll in the sample with a standard. The standard is, in some embodiments, a non-cancer cell or cell extract thereof. The compound or agent can be packaged in a suitable container. The kit can further comprise instructions for using the kit to detect cancer in a sample.
Bi- specific Antibodies
[00161] A bi-specific antibody (bsAb) is an antibody comprising two variable domains or scFv units such that the resulting antibody recognizes two different antigens. The present invention provides for bi-specific antibodies that recognize PD-L1 and a second antigen. Exemplary second antigens include tumor associated antigens, cytokines and cell surface receptors. In some embodiments, the second antigen can be CAIX (carbonic anhydrase IX, or G250), IL-10 or CCR4. In some embodiments, the second antigen can be a cell surface receptor, wherein the cell surface receptor is CCR4, IL21R, BTLA, HVEM or TIM3.
[00162] A bi-specific antibody of the present invention comprises a heavy chain and a light chain combination or scFv of the huPD-Ll antibodies disclosed herein.
Construction of bi-specific antibodies
[00163] Bi-specific antibodies of the present invention can be constructed using methods known art. In some embodiments, the bi-specific antibody is a single polypeptide wherein the two scFv fragments are joined by a long linker polypeptide, of sufficient length to allow intramolecular association between the two scFv units to form an antibody. In other embodiments, the bi-specific antibody is more than one polypeptide linked by covalent or non-covalent bonds.
[00164] In another embodiment, the bi-specific antibody is constructed using the
"knob into hole" method (Ridgway et al., Protein Eng 7:617-621 (1996)). In this method, the Ig heavy chains of the two different variable domains are reduced to selectively break the heavy chain pairing while retaining the heavy-light chain pairing. The two heavy-light chain heterodimers that recognize two different antigens are mixed to promote heteroligation pairing, which is mediated through the engineered "knob into holes" of the CH3 domains, as shown in Figure 5 and 6A.
[00165] In another embodiment, the bi-specific antibody can be constructed through exchange of heavy-light chain dimers from two or more different antibodies to generate a hybrid antibody where the first heavy-light chain dimer recognizes PD-L1 and the second heavy-light chain dimer recognizes a second antigen. The mechanism for heavy-light chain dimer is similar to the formation of human IgG4, which also functions as a bispecific molecule. Dimerization of IgG heavy chains is driven by intramolecular force, such as the pairing the CH3 domain of each heavy chain and disulfide bridges. Presence of a specific amino acid in the CH3 domain (R409) has been shown to promote dimer exchange and construction of the IgG4 molecules. Heavy chain pairing is also stabilized further by interheavy chain disulfide bridges in the hinge region of the antibody. Specifically, in IgG4, the hinge region contains the amino acid sequence Cys-Pro-Ser-Cys (in comparison to the stable IgGl hinge region which contains the sequence Cys-Pro-Pro-Cys) at amino acids 226- 230. This sequence difference of Serine at position 229 has been linked to the tendency of IgG4 to form novel intrachain disulfides in the hinge region (Van der Neut Kolfschoten, M. et al., 2007, Science 317: 1554-1557 and Labrijn, A.F. et al, 2011, Journal ofimmunol 187:3238-3246).
[00166] Therefore, bi-specific antibodies of the present invention can be created through introduction of the R409 residue in the CH3 domain and the Cys-Pro-Ser-Cys sequence in the hinge region of antibodies that recognize PD-Ll or a second antigen, so that the heavy-light chain dimers exchange to produce an antibody molecule with one heavy-light chain dimer recognizing PD-Ll and the second heavy-light chain dimer recognizing a second antigen, wherein the second antigen is any antigen disclosed herein. Preferably, the bi- specific antibody contains one anti-PD-Ll heavy-light chain dimer conjugated to one anti- CAIX (carbonic anhydrase IX, or 250) heavy-light chain dimer, as discussed in Examples 3 and 4. Heavy-light chain dimer exchange can also be enhanced with addition of a reducing agent, such as reduced glutathione, to promote the exchange. Known IgG4 molecules may also be altered such that the heavy and light chains recognize PD-Ll or a second antigen, as disclosed herein. Use of this method for constructing the bi-specific antibodies of the present invention may be beneficial due to the intrinsic characteristic of IgG4 molecules wherein the Fc region differs from other IgG subtypes in that it interacts poorly with effector systems of the immune response, such as complement and Fc receptors expressed by certain white blood cells. This specific property makes these IgG4-based bi-specific antibodies attractive for therapeutic applications, in which the antibody is required to bind the target(s) and functionally alter the signaling pathways associated with the target(s), however not trigger effector activities.
[00167] In some embodiments, mutations are introduced to the constant regions of the bsAb such that the antibody dependent cell-mediated cytotoxicity (ADCC) activity of the bsAb is altered. Such examples are depicted in Figure 6B. For example, the mutation is an LALA mutation in the CH2 domain. In one aspect, the bsAb contains mutations on one scFv unit of the heterodimeric bsAb, which reduces the ADCC activity. In another aspect, the bsAb contains mutations on both chains of the heterodimeric bsAb, which completely ablates the ADCC activity. For example, the mutations introduced one or both scFv units of the bsAb are LALA mutations in the CH2 domain. These bsAbs with variable ADCC activity can be optimized such that the bsAbs exhibits maximal selective killing towards cells that express one antigen that is recognized by the bsAb, however exhibits minimal killing towards the second antigen that is recognized by the bsAb.
Exemplary second antigens
[00168] The present invention provides for bi-specific antibodies that recognize PD-Ll and a second antigen.
[00169] In some embodiments, the second antigen is a tumor associated antigen. In some embodiments, the tumor associated antigen is carbonic anhydrase IX (CAIX). For example, a CAIX/PD-L1 bi-specific antibody may be constructed, comprising one heavy and one light chain combination of the huPD-Ll antibodies described herein and one heavy and one light chain combination that recognizes CAIX (Figure 5A). CAFX has been described as a prognostic marker for disease progression and a target for immunotherapy with IL-2. CAFX is a tumor-associated antigen that is highly expressed in cancers, such as renal cell carcinoma. In some cases, activation of the PDl/PD-Ll axis by tumor cells may induce T cell exhaustion for certain tumor- specific antigens, such as CAIX, whereby tumor cells expressing CAIX escape recognition by the immune system. The bsAb targeting both CAFX and PD-Ll serves as a novel cancer therapeutic. Treatment with a CAIX/PD-L1 bsAb would inhibit or reverse the PD-1/PD-L1 -mediated T-cell exhaustion for CAIX, and promote tumor surveillance and an immune response against CAIX-expressing tumor cells. For example, treatment with a CAIX/PD-L1 bsAb would promote an antigen-specific immune response against tumor cells, where the antigen targeted is CAIX.
[00170] In some instances, mutations may be introduced to the CAIX or the PD-Ll chains at the constant regions (e.g., CH2 domain) to reduce ADCC activity (Figure 5B). In some instances, mutations may be introduced into both the CAIX and the PD-Ll chains in the constant regions to completely ablate ADCC activity. Mutated bsAbs with variable ADCC activity can be assayed by methods known in the art for their specificity of killing tumor cells. Preferably, the CAFX/PD-L1 bsAb will exhibit maximal selective killing of CAIX- expressing tumor cells but exhibits only minimal killing of PD-Ll -expressing endogenous peripheral blood mononuclear cells (PBMCs).
[00171] In some embodiments, the second antigen is a cell surface receptor, wherein the cell surface receptor is interleukin 21 receptor (IL21R). For example, an IL21R/PD-L1 bi- specific antibody may be constructed, comprising one heavy and one light chain combination of the huPD-Ll antibodies described herein and one heavy and one light chain combination that binds IL21R in an agonistic manner. The cytokine IL21 is secreted by CD4+ T helper cells and binds to IL21R to promote several immune activation pathways, particularly, promoting the antigen- specific cytotoxicity of CTLs and the maturation, proliferation and cytotoxicity of NK cells (Sondergaard, H et al., 2009 Tissue antigens 74:467-479; Kasaian, M. T. et al, 2002 Immunity 16:559-569; and Coquet, J. M. et al, 2008 J Immunol 178:2827- 2834). In particular, IL21 has been shown to promote activation and cytotoxic capacity against melanoma antigens (Li, Y. et al, 2005, J Immunol 175:2261-2269). Systemic administration IL21 has been explored for use in treating cancer and has shown some efficacy (Schmidt, H. et al, 2010 Clinical cancer research, 16: 5312-5319), however, some data has also shown detrimental and undesirable side effects (Grunwald, V. et al, 2011, Acta Oncol 50: 121-126).
[00172] The IL21R/PD-L1 bsAb of the present invention binds to IL21R in an agonistic manner, thereby acting as a mimic or surrogate for the cytokine IL21. Binding by the IL21R/PD-L1 bsAb can result in activation of the IL21R-mediated pathways and subsequent promotion of antigen- specific cytotoxic immune responses against tumor cells that have induced PD-L1 -mediated T-cell exhaustion. One particular benefit of treatment with the bi-specific antibody of the invention is the localization of the IL21R activation to areas where PD-1/PD-L1 -mediated T cell exhaustion has occurred, for example, in the tumor microenvironment, for example near or within tumors that have induced T cell exhaustion to evade anti-tumor immune responses. In this manner, the ILR/PD-L1 bsAb promotes antitumor immune response in a two-pronged mechanism: 1) by reversing or inhibiting PD-l/PD- Ll-mediated T cell exhaustion, and 2) by promoting IL21/IL21R-mediated activation of cytotoxic immune response, thereby inducing antigen-specific or anti-tumor immune responses and cytotoxicity.
[00173] The IL21R/PD-L1 bi-specific antibody may also have use in a vaccine for vaccination of a subject, or as a vaccine adjuvant. In the germinal center reaction (OCR), in which high-affinity antibody-secreting plasma cells and memory B cells that ensure sustained immune protection and rapid recall responses against previously encountered foreign antigens are produced, PD1 is expressed by follicular T helper cells (TFH) while PDL1 is expressed by germinal center B cells (Crotty, S. et al, 2011, Annual review of Immunology, 29:621- 623). Overexpression of PD1 or PD-L1 inhibits the expansion of antibody-producing B cells. Use of the IL21R/PD-L1 bi-specific antibody, wherein the PD-L1 portion of the antibody inhibits the P D1/PD-L1 axis, would result in the preferential expansion of only high affinity antibodies. As IL-21 strongly promotes the transition of antigen-specific B cells to antibody- secreting plasma cells, as well as the formation and persistence of TFH activity (Crotty, S. et al, 2011, Annual review of Immunology , 29:621-623), a bsAb against PDL1 with IL21 surrogate or agonistic activity could act as a GCR-specific adjuvant towards promotion of high affinity antibody production against particular antigens, such as antigens administered through a vaccine, or antigens of infectious agents.
[00174] In some embodiments, the second antigen is BTLA (B and T lymphocyte attenuator protein) or HVEM (Herpesvirus entry mediator, also known as TNFRSF14). For example, a BTLA/PD-L1 bi-specific antibody may be constructed, comprising one heavy and one light chain combination of the huPD-Ll antibodies described herein and one heavy and one light chain combination that binds BTLA. For example, an HVEM/PD-L1 bi-specific antibody may be constructed, comprising one heavy and one light chain combination of the huPD-Ll antibodies described herein and one heavy and one light chain combination that binds HVEM, preferably, to those regions of HVEM that mediate binding with BTLA. BTLA binding to HVEM results in T cell inhibition, similar to PD1/PD-L1 interactions. The BTLA/PD-L1 or HVEM/PD-L1 bi-specific antibodies of the present invention would inhibit or prevent the association between BTLA and HVEM, and prevent BTLA/HVE-mediated T cell inhibition. BTLA inhibition promotes tumor- specific T cell responses. Therefore, treatment with the bi-specific antibodies of the present invention results in the simultaneous blockade of two distinct inhibitor pathways that limit T cell activity.
[00175] In some instances, the HVEM/PD-L1 bsAb antibody would also prevent the association between HVEM and another HVEM ligand, CD 160, which has been shown to be an agonist for the survival of B cell chronic lymphocytic leukemia (BCLL) cells, and strongly inhibits CD4+ T-cell activation and function. Treatment with the HVEM/PD-L1 bi-specific antibody that also prevents HVEM/CD160 binding of the present invention results in the simultaneous blockade of two inhibitor pathways that limit T cell activity and inhibition of CD160-mediated tumor survival pathways.
[00176] In some embodiments, the second antigen is TIM3 (T-cell immunoglobulin and mucin domain 3). For example, a TIM3/PD-L1 bi-specific antibody may be constructed, comprising one heavy and one light chain combination of the huPD-Ll antibodies described herein and one heavy and one light chain combination that binds TIM3. In one aspect, the antibodies of the present invention prevent or inhibit TIM3 binding with galectin-9 (GAL9). Interaction between TIM3 and GAL9 results in inhibition of T cell function and activation of macrophages (Sakuishi, K. et al, 2010, The Journal of experimental medicine, 207:2187-2194 and Zhang, Y. et al, 2012, Journal of leukocyte biology, 91 : 189-196). TIM3 has also been shown to promote the activity of myeloid derived suppressor cells (MDSC) (Dardalhon, V. et al., 2012 Journal of leukocyte biology, 185: 1383-1392). Therefore, treatment with a bispecific antibody of the present invention, such as the TIM3/PD-L1 bsAb, would reverse and prevent T-cell exhaustion, promote tumor surveillance and inhibit generation of MDSC. Use of the TIM3/PD-L1 bsAb may be particularly beneficial for treatment of subjects that suffer from cancers with polymorphisms in TIM3, such as renal cell carcinoma and metastatic renal cell carcinoma.
[00177] The bi-specific antibodies disclosed herein may be useful in treatment of diseases or medical conditions, for example, cancer. The bi-specific antibodies of the present invention may be particularly useful in diseases or medical conditions that are associated with T cell exhaustion. In some cases, the bi-specific antibodies disclosed herein may be used as a vaccine for promoting antigen-specific immune responses. The bi-specific antibodies of the present invention will target tumors that induce T-cell exhaustion.
Methods of Treatment
[00178] The invention provides for both prophylactic and therapeutic methods of treating a subject at risk of (or susceptible to) a cancer, or other cell proliferation-related diseases or disorders. Such diseases or disorders include but are not limited to, e.g., those diseases or disorders associated with aberrant expression of PD-L1. For example, the methods are used to treat, prevent or alleviate a symptom of renal cell carcinoma or breast cancer. Alternatively, the methods are used to treat, prevent or alleviate a symptom of a cancer in which PD-L1 plays a negative regulatory role in T cell response. Alternatively, the methods are used to treat, prevent or alleviate a symptom of a solid tumor such as breast cancer, lung cancer, ovarian cancer, prostate cancer, colon cancer, cervical cancer, brain cancer, liver cancer, pancreatic cancer or stomach cancer. Alternatively, the methods are used to treat, prevent or alleviate a symptom of a cancer that has metastasized.
[00179] The invention provides for both prophylactic and therapeutic methods of treating a subject at risk of (or susceptible to) a chronic viral, bacterial or parasitic infection. Particularly, the invention provides for both prophylactic and therapeutic methods of treating a subject at risk of (or susceptible to) HIV infection or AIDS.
[00180] The invention also provides for therapeutic methods for both prophylactic and therapeutic methods of treating a subject at risk of a disease or disorder or condition associated with T-cell exhaustion or a risk of developing T-cell exhaustion. The invention also provides for therapeutic methods for both prophylactic and therapeutic methods of treating a subject at risk of a disease or disorder or condition associated with T-cell exhaustion or a risk of developing T-cell exhaustion. Such diseases or disorder include, but are not limited to HIV, AIDS, and chronic bacterial, viral or parasitic infections. Other such chronic infections include those caused by, for example, hepatitis B virus (HBV), hepatitis C virus (HCV), herpes simplex virus 1 (HSV-1), H. pylori, or Toxoplasma gondii.
[00181] Accordingly, in one aspect, the invention provides methods for preventing, treating or alleviating a symptom cancer or a cell proliferative disease or disorder in a subject by administering to the subject a monoclonal antibody or scFv antibody of the invention. For example, a huPD-Ll antibody may be administered in therapeutically effective amounts.
[00182] Subjects at risk for cancer or cell proliferation-related diseases or disorders include patients who have a family history of cancer or a subject exposed to a known or suspected cancer-causing agent. Administration of a prophylactic agent can occur prior to the manifestation of cancer such that the disease is prevented or, alternatively, delayed in its progression.
[00183] In another aspect, tumor cell growth is inhibited or suppressor T cell activity is decreased by contacting a cell with a PD-L1 antibody of the invention. The cell is any cell that expresses PD-L1. For example the cell is T cell.
[00184] Also included in the invention are methods of increasing or enhancing an immune response to an antigen. An immune response is increased or enhanced by administering to the subject a monoclonal antibody or scFv antibody of the invention. The immune response is augmented for example by augmenting antigen specific T effector function. The antigen is a viral (e.g. HIV), bacterial, parasitic or tumor antigen. The immune response is a natural immune response. By natural immune response is meant an immune response that is a result of an infection. The infection is a chronic infection. Increasing or enhancing an immune response to an antigen can be measured by a number of methods known in the art. For example, an immune response can be measured by measuring any one of the following: T cell activity, T cell proliferation, T cell activation, production of effector cytokines, and T cell transcriptional profile.
[00185] Alternatively, the immune response is a response induced due to a vaccination.
Accordingly, in another aspect the invention provides a method of increasing vaccine efficiency by administering to the subject a monoclonal antibody or scFv antibody of the invention and a vaccine. The antibody and the vaccine are administered sequentially or concurrently. The vaccine is a tumor vaccine a bacterial vaccine or a viral vaccine.
Combinatory Methods
[00186] The invention provides treating cancer in a patient by administering two antibodies that bind to the same epitope of the PD-Ll protein or, alternatively, two different epitopes of the PD-Ll protein. Alternatively, the cancer is treated by administering a first antibody that binds to PD-Ll and a second antibody that binds to a protein other than PD-Ll. For example, the other protein other than PD-Ll may include, but is not limited to, CAIX, CCR4 and IL-10. For example, the other protein other than PD-Ll is a tumor-associated antigen.
[00187] In some embodiments, the invention provides administration of a huPD-Ll antibody alone or with an additional antibody that recognizes another protein other than PD- Ll, with cells that are capable of effecting or augmenting an immune response. For example, these cells may be peripheral blood mononuclear cells (PBMC), or any cell type that is found in PBMC, e.g., cytotoxic T cells, macrophages, and natural killer (NK) cells.
[00188] Additionally, the invention provides administration of an antibody that binds to the PD-Ll protein and an anti-neoplastic agent, such a small molecule, a growth factor, a cytokine or other therapeutics including biomolecules such as peptides, peptidomimetics, peptoids, polynucleotides, lipid-derived mediators, small biogenic amines, hormones, neuropeptides, and proteases. Small molecules include, but are not limited to, inorganic molecules and small organic molecules. Suitable growth factors or cytokines include an IL- 2, GM-CSF, IL-12, and TNF-alpha. Small molecule libraries are known in the art. (See, Lam, Anticancer Drug Des., 12: 145, 1997.)
[00189] The invention will be further described in the following examples, which do not limit the scope of the invention described in the claims.
EXAMPLES
[00190] EXAMPLE 1 : GENERATION OF HUMAN MABS AGAINST PD-Ll
[00191] Human mAbs against human PD-Ll were generated by panning against a 27- billion member human scFv phage display library. Using full length PD-Ll in the form of paramagnetic proteoliposomes (PMPL), which assure proper orientation of the extracellular domain of PD-Ll for presentation to the library, 14 unique scFv-phage were identified that bind PD-Ll. Human IgG constructs were constructed for these 14 unique scFv-phage: Ab- 14, Ab-16, Ab-22, Ab-30, Ab-31, Ab-32, Ab-38, Ab-42, Ab-46, Ab-50, Ab-52, Ab-55, Ab- 56 and Ab-65.
[00192] EXAMPLE 2: CHARACTERIZATION OF HUPD-L1 MABS BINDING TO PD-Ll
[00193] Binding analysis of huPD-Ll antibodies were performed using PD-Ll - expressing cells. Four types of cells were tested, including parental cell line 300.19, and transfected cell lines expressing human PD-Ll (hPD-Ll), human PD-L2 (HPD-L2), and human C-type lectin domain family 2 member (hCLEC2D). The binding assays were performed in duplicate, with the results summarized below in Tables 16-19 and Figure 2. Antibody affinity was tested by using four antibody concentrations: 10 g/ml, 1 g/ml, 0.1 μg/ml and 0.01 μg/ml. GF1538 and GF1757 antibodies were used as controls: GF1538 is a humanized Ab against hPD-Ll, and GF1757 is a humanized Ab against hPD-L2. The secondary antibody utilized was PE-goat anti-human IgG. All values represent mean fluorescence intensity (GMFI), as detected by FACs analysis.
[00194] Results from the binding assay show that the tested huPD-Ll antibodies show highly affinity and specificity for binding PD-Ll. Use of the parental cell line 300.19, which does not express human PD-Ll, as a control established the basal or non-specific fluorescence (Table 16 and Figure 2, top left). Staining of 300.19 cells that express human PD-Ll by transfection with huPD-Ll antibodies showed significantly higher mean fluorescence intensity (MFI), demonstrating that the antibodies can bind to PD-Ll.
Significant FMI values, even at the lowest dilution of 0.01 μg/ml of antibody, demonstrated the high affinity of the huPD-Ll for binding PD-Ll protein (Tables 17A, 17B and Figure 2, top right). HuPD-Ll antibodies demonstrated some capacity to bind human PD-L2 or CLEC2D when expressed in 300.19 cells, as demonstrated by Tables 18A, 18B, 19A, 19B and Figure 2, bottom two graphs). However, the MFI values obtained for staining of PD-L2 and CLE2D were not as high as the values obtained for PD-Ll. Moreover, at the lower dilutions, the MFI values were not significantly higher than the basal levels, indicating that the huPD-Ll antibodies did not have high affinity or specificity for PD-L2 or CLE2D. Although a few huPD-Ll antibodies, for example Ab-42, demonstrated some cross-reactivity with PD-L2, the antibodies have significantly higher affinity and specificity for PD-Ll.
[00195] Table 16. Staining using huPD-Ll on untransfected 300.19 cells
Cells PE-A Mean huPD-Ll approx
Well 1 ug/ml 0.1 ug/ml 0.01 ug/ml
Ab # 10 ug/ml
Al 14 358 186 91 73
A2 16 269 105 79 67
A3 30 75 78 74 66
A4 31 324 137 82 73
A5 42 771 315 119 82
A6 50 145 95 70 71
A7 52 324 124 85 72
A8 55 110 75 74 69
A9 1538 GF anti-hPD-Ll 79 72 75 71
A10 1757 GF anti-hPD-L2 108 74 70 71
Al l control hlgG 260 87 74 73
A12 Wash 81 73 73 73
[00196] Table 17A. Staining using huPD-Ll on hPD-Ll-transfected 300.19 cells, assay 1 results.
Figure imgf000053_0001
[00197] Table 17B. Staining using huPD-Ll on hPD-Ll-transfected 300.19 cells, assay 2 results.
Figure imgf000053_0002
Figure imgf000054_0001
[00198] Table 18A. Staining using huPD-Ll on hPD-L2-transfected 300.19 cells, assay 1 results.
Figure imgf000054_0002
[00199] Table 18B. Staining using huPD-Ll on hPD-L2-transfected 300.19 cells, assay 2 results.
Figure imgf000054_0003
[00200] Table 19A. Staining using huPD-Ll on hCLEC2D-transfected 300.19 cells, assay 1.
[00201]
Figure imgf000055_0001
Table 19B. Staining using huPD-Ll on hCLEC2- transfected 300.19 cells,
Figure imgf000055_0002
[00203] EXAMPLE 2: CHARACTERIZATION OF ANTI-PD-L1 PHAGE-ANTIBODIES BLOCKING PD/PD-L1 BINDING
[00204] A competitive FACS analysis was performed to characterize the inhibition of hPDl binding to hPD-Ll by anti-PD-Ll phage antibodies. All anti-hPD-Ll antibodies were in phage-scFv form. 293T cells were transfected with a vector encoding human PD-L1 fused to human Fc region for expression of hPD-Ll-Fc. In this assay, 1012 plaque-forming units (pfu) of phage-scFvs were mixed with about 0.25 mg/ml of soluble hPD-l-hFc fusion protein and then added to the hPD-Ll -expressing 293T cells. After washing, the cells were incubated with FITC- anti-human IgG antibody and analyzed by FACS to measure the binding of hPDl-hFc to hPD-Ll on the cell surface.
[00205] Fluorescence values were obtained by FACS analysis and used to generate a percentage of inhibition of binding of hPD-1 to hPD-Ll+ cells. These values are displayed in Figure 3. Almost all anti-PD-Ll phage scFvs demonstrated some ability to inhibit the binding of hPD-1 to hPD-Ll. Particularly, Ab-14, Ab-16, Ab-30, Ab-31, Ab-42, Ab-50, Ab- 52, and Ab-55 phage-scFvs demonstrated significant inhibition of hPD-l/hPD-Ll binding.
[00206] EXAMPLE 3: CHARACTERIZATION OF HUPD-L1 SOLUBLE MABS BLOCKING
PD/PD-L1 BINDING
[00207] A competitive FACS analysis was performed to characterize the inhibition of hPDl binding to hPD-Ll by the soluble huPD-Ll antibodies of the present invention. All huPD-Ll antibodies were tested for their ability to inhibit the binding of hPDl-IgG fusion protein with hPD-Ll -expressing 300.19 cells. In this assay, 50,000 cells expressing hPD-Ll were pre-incubated with the huPD-Ll or control antibodies for 30 minutes at the following concentrations: 10 g/ml, 1 g/ml, 0.1 μg/ml and 0.01 μg/ml. After the pre- incubation, 0.125 μg of human PD1 fused to mouse IgG2oc was added to the cells and incubated for another 30 minutes. The cells were washed twice, and then 0.125 μg of goat anti-mouse IgG2oc-PE antibody was added to the cells. After 30 minutes of incubation, the cells were washed twice and then analyzed by FACS. The values obtained from FACS analysis are represented as mean fluorescence intensity units (MFI) and are summarized in Table 20. MFI values from Table 20 are used to generate a percent inhibition of hPDl binding with hPD-Ll+ cells for Figure 4. As shown herein, all of the tested huPD-Ll soluble antibodies demonstrated nearly complete inhibition of hPDl binding with hPD-Ll at 10 μg/ml. At successively lower concentrations, most of the soluble antibodies still demonstrated very good inhibition of PD1/PD-L1 binding, particularly Ab-42 and Ab-50.
[00208] Table 20. Results from blocking of PD-1 binding using huPD-Ll
Figure imgf000056_0001
Al 14 696 11991 14859 15840
A2 16 1092 6660 11080 14783
A3 30 244 661 4775 11585
A4 31 157 623 7934 11908
A5 42 139 142 3137 11797
A6 50 207 156 2795 12517
A7 52 380 2070 6746 11856
A8 55 150 3625 9137 12926
A9 1538 GF anti-hPD-Ll 143 148 198 10145
A10 1757 GF anti-hPD-L2 10922 11447 11197 13167
Al l control hlgG 11355 11664 11571 12274
A12 wash 10339 10274 9842 12305 wash
El neg control 155 137 130
mIgG2a
E4 neg control 128 207 131
average positive control 11363
average negative control 155
[00209] EXAMPLE 4: FORMATION OF BI-SPECIFIC ANTIBODIES
[00210] Based on the role of the hinge in generating half-monomers of IgG4 molecules, it was hypothesized that that introducing charged mutations in the hinge region of human IgGi may not only facilitate half-monomer exchange but also potentially stabilize the bi-specific molecule. This example demonstrates that the combination of hinge and CH3 mutations increase bi-specific antibody formation.
[00211] To further stabilize the heterodimer formation, an oppositely charged mutation was further replaced in CH3 domain, which is a concept of "Knobs-into-holes". Formation of bispecific antibodies was achieved in the following steps. First, the two parental antibodies carrying the bispecific mutations were expressed and purified separately. Then the antibodies were mixed in the presence of a mild reducing agent. The mild reduction of the antibodies caused dissociation of the antibodies into two monomers, each with a variable heavy and light chain. The monomers were then mixed together, followed by an oxidation step which causes the formation of bi-specific antibody molecules.
[00212] Bi-specific antibodies that recognize PD-L1 and G250 (Carbonic Anhydrase
ΓΧ) were generated. Anti-G250 parental (G37 wild type, G37WT) and engineered (G37 KIHA) antibodies were generated and purified by two independent vectors. G37 KIHA, which conforms to a "knob-in-hole" concept and carried bispecific mutations, was altered in the sequence of immunoglobulin hinge region. [00213] To understand the dissociation activity of G37 KIHA, antibodies were mixed in the presence of mild reducing agent to interrupt to form antibody monomer by glutathione (GSH) in different concentrations (Figure 1A). Addition of increasing concentration of reducing agent (GSH) caused dissociation of the antibody into monomers, as indicated by the increase in the levels of the lower molecular weight species in Figure 1A.
[00214] Similarly, Anti-PD-Ll parental (PD-L1 wild type, PDL-1WT) and engineered
(PD-L1 KIHB) antibodies were generated and purified by two independent vectors. Using different concentrations of GSH verified the appropriate condition to obtain anti-PD-Ll monomers (Figure 7B). The best condition of GSH concentration was selected and resulting anti-PD-Ll monomers were incubated with the G37 KIHA monomers. The formation of bispecific antibody was observed at the same size of wild type IgG, indicating that antibodies containing two heavy-light chain monomers were generated, one PD-L1 -specific monomer and one G250- specific monomer.
[00215] EXAMPLE 5: BI-SPECIFIC ANTIBODY FUNCTION
[00216] The bi-specific antibodies generated in Example 3 were next tested for their ability to recognize both antigens, for example, PD-L1 and G250. The function of the PD-L1 and G250 bi-specific antibodies was tested using flow cytometry. CAIX+PD-L1" SKRC-52 express CALX (250) but not PD-L1, and therefore it was expected that cells could be recognized by only anti-CAIX antibody G37 and not PD-L1. To avoid the saturation of antibody binding, the concentration of antibody was low and in a reduced dose manner. Indeed, parental anti-G37 recognized SKRC-52 cells, while parental anti-PD-Ll did not (levels same as control). The bi-specific antibody, containing conjugated anti-G37 and anti- PD-Ll monomers, recognized SKRC-52 cells in a half reduced concentration compared to the parental G37 antibody, thereby demonstrating the functionality of a bi-specific antibody generated using the methods and antibodies described herein.
[00217] EXAMPLE 6: FUNCTIONAL CHARACTERIZATION OF MAB42
[00218] Further functional characterization of the monoclonal antibody against PD-L1
(mAb42) was performed. Peripheral blood mononuclear cells (PBMCs) were cultured from 4 different healthy donors (D1-D4). PBMCs were cultured either in the presence of mAb42 or in the presence of a control isotype IgG antibody. PMBCs were stimulated with 0. ^g/ml SEB (staphylococcal enterotoxin B) and TNFoc production was measured using MSD (Meso Scale Delivery). Sample analyses were performed in triplicate. [00219] As shown in Figure 8, culturing PBMCs in the presence of mAb42 caused an increase in production of TNFa in response to SEB when cultured in the presence of anti-PD- Ll antibody (mAb42) compared to control antibody in all four donor samples. Furthermore, the increase in TNFa production was statistically significant, with a p<0.0005. Thus, treatment with anti-PD-Ll antibody augments the immune response in response to an antigen, or infection, in humans.
OTHER EMBODIMENTS
[00220] While the invention has been described in conjunction with the detailed description thereof, the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims.

Claims

claimed is:
An isolated humanized monoclonal antibody having: a. a heavy chain with three CDRs comprising the amino acid sequences SYGIS (SEQ ID NO:57), WISAYNGNTNYAQKLED (SEQ ID NO:70), and ALPS GTILVGGWFDP (SEQ ID NO:86) respectively and a light chain with three CDRs comprising the amino acid sequences TRSSGNIASNYVQ (SEQ ID NO: 101), EDNQRPS (SEQ ID NO: 115), and QSYDSSNLWV (SEQ ID NO: 127) respectively; b. a heavy chain with three CDRs comprising the amino acid sequences SYALS (SEQ ID NO:58), AISGGGGSTYYADSVKD (SEQ ID NO:71), and
DVFPETFSMNYGMDV (SEQ ID NO: 87) respectively and a light chain with three CDRs comprising the amino acid sequences QGDSLRSYYAS (SEQ ID NO: 102), GKNNRPS (SEQ ID NO: 116), and NSRDSSGNHYV (SEQ ID NO: 128) respectively; c. a heavy chain with three CDRs comprising the amino acid sequences
DYAMH (SEQ ID NO:60), LISGDGGSTYYADSVKD (SEQ ID NO:73), and VLLPCSSTSCYGSVGAFDI (SEQ ID NO:88) respectively and a light chain with three CDRs comprising the amino acid sequences GGSDIGRKSVH (SEQ ID NO: 103), SDRDRPS (SEQ ID NO: 117), and QVWDNNSDHYV (SEQ ID NO: 129) respectively; d. a heavy chain with three CDRs comprising the amino acid sequences NYDMS (SEQ ID NO:61), RVNWNGGSTTYADAVKD (SEQ ID NO:74), and EFVGAYDL (SEQ ID NO: 89) respectively and a light chain with three CDRs comprising the amino acid sequences TGTSSDVGGYNYVS (SEQ ID
NO: 104), DVSNRPS (SEQ ID NO: 118), and SSYTSSTLP (SEQ ID NO: 130) respectively; e. a heavy chain with three CDRs comprising the amino acid sequences GLYIH (SEQ ID NO:62), WIIPIFGTANYAQKFED (SEQ ID NO:75), and
GLRWGIWGWFDP (SEQ ID NO: 90) respectively and a light chain with three CDRs comprising the amino acid sequences RASQSIGNSLA (SEQ ID NO: 105), GASSRAT (SEQ ID NO: 119), and QQHTIPTFS (SEQ ID NO: 131) respectively; f. a heavy chain with three CDRs comprising the amino acid sequences DNAIS (SEQ ID NO:63), WIIPIFGKPNYAQKFED (SEQ ID NO:76), and
TMVRGFLGVMDV (SEQ ID NO: 91) respectively and a light chain with three CDRs comprising the amino acid sequences RASQGIGSYLA (SEQ ID NO: 106), AASTLQS (SEQ ID NO: 120), and QQLNNYPIT (SEQ ID
NO: 132) respectively; g. a heavy chain with three CDRs comprising the amino acid sequences SYAMS (SEQ ID NO:64), AISGSGGSTYYADSVKD (SEQ ID NO:77), and
DQFVTIFGVPRYGMDV (SEQ ID NO: 92) respectively and a light chain with three CDRs comprising the amino acid sequences SGDKLGNKYAY (SEQ ID NO: 107), QDIKRPS (SEQ ID NO: 121), and QTWDNSVV (SEQ ID NO: 133) respectively; h. a heavy chain with three CDRs comprising the amino acid sequences SYAIS (SEQ ID NO:57), WIIPIFGTANYAQKFED (SEQ ID NO:78), and
GRQMFGAGIDF (SEQ ID NO:93) respectively and a light chain with three CDRs comprising the amino acid sequences TRSSGSIDSNYVQ (SEQ ID NO: 108), EDNQRPS (SEQ ID NO: 115), and QSYDSNNRHVI (SEQ ID NO: 134) respectively; i. a heavy chain with three CDRs comprising the amino acid sequences TYALN (SEQ ID NO:65), RIVPLIGLVNYAHNFED (SEQ ID NO:79), and
EVYGGNSDY (SEQ ID NO: 94) respectively and a light chain with three CDRs comprising the amino acid sequences TRSSGNIGTNYVQ (SEQ ID NO: 109), EDYRRPS (SEQ ID NO: 122), and QSYHSSGWE (SEQ ID
NO: 135) respectively; j. a heavy chain with three CDRs comprising the amino acid sequences SHGIT (SEQ ID NO:66), WISAHNGHASNAQKVED (SEQ ID NO:80), and VHAALYYGMDV (SEQ ID NO:95) respectively and a light chain with three CDRs comprising the amino acid sequences GGNNIGS KG VH (SEQ ID NO: 110), DDSDRPS (SEQ ID NO: 123), and QVWDSSSDHWV (SEQ ID NO: 136) respectively; k. a heavy chain with three CDRs comprising the amino acid sequences
RHGMH (SEQ ID NO:67), VISHDGSVKYYADSMKD (SEQ ID NO:81), and GLSYQVSGWFDP (SEQ ID NO:96) respectively and a light chain with three CDRs comprising the amino acid sequences TRSSGSIASNYVQ (SEQ ID NO: 111), EDNQRPS (SEQ ID NO: 115), and QSYDSTTPSV (SEQ ID NO: 137) respectively;
1. a heavy chain with three CDRs comprising the amino acid sequences SYGIS (SEQ ID NO:58), WTS PHNGLTAFAQILED (SEQ ID NO:82), and VHPVFSYALDV (SEQ ID NO: 97) respectively and a light chain with three CDRs comprising the amino acid sequences TRSSGSIASNYVQ (SEQ ID NO: 112), EDNQRPS (SEQ ID NO: 115), and QSYDGITVI (SEQ ID NO: 138) respectively; m. a heavy chain with three CDRs comprising the amino acid sequences TYAFS (SEQ ID NO:68), RIIPILGIANYAQKFED (SEQ ID NO:83), and DGYGSDPVL (SEQ ID NO: 98) respectively and a light chain with three CDRs comprising the amino acid sequences TRSSGSIASHYVQ (SEQ ID NO: 113), EDNKRPS (SEQ ID NO: 124), and QSYDSSNRWV (SEQ ID NO: 139) respectively; or n. a heavy chain with three CDRs comprising the amino acid sequences NYGIS (SEQ ID NO:69), WISAYNGNTNYAQKVED (SEQ ID NO:84), and GDFRKPFDY (SEQ ID NO: 99) respectively and a light chain with three CDRs comprising the amino acid sequences TLRS GLN VGS YRIY (SEQ ID NO: 114), YKSDSNKQQAS (SEQ ID NO: 125), and MIWYSSAVV (SEQ ID NO: 140) respectively; wherein said antibody binds human PD-L1.
2. The antibody of claim 1 , wherein said antibody is monovalent or bivalent.
3. The antibody of claim 1 , wherein said antibody is a single chain antibody.
4. A single chain antibody comprising: a. a VH nucleotide sequence comprising SEQ ID NO: 1 and a VL nucleotide sequence comprising SEQ ID NO: 3; b. a VH nucleotide sequence comprising SEQ ID NO: 5 and a VL nucleotide sequence comprising SEQ ID NO:7; c. a VH nucleotide sequence comprising SEQ ID NO: 9 and a VL nucleotide sequence comprising SEQ ID NO: 11; d. a VH nucleotide sequence comprising SEQ ID NO: 13 and a VL nucleotide sequence comprising SEQ ID NO: 15; e. a VH nucleotide sequence comprising SEQ ID NO: 17 and a VL nucleotide sequence comprising SEQ ID NO: 19; f. a VH nucleotide sequence comprising SEQ ID NO: 21 and a VL nucleotide sequence comprising SEQ ID NO:23; g. a VH nucleotide sequence comprising SEQ ID NO: 25 and a VL nucleotide sequence comprising SEQ ID NO:27; h. a VH nucleotide sequence comprising SEQ ID NO: 29 and a VL nucleotide sequence comprising SEQ ID NO:31; i. a VH nucleotide sequence comprising SEQ ID NO: 33 and a VL nucleotide sequence comprising SEQ ID NO:35; j. a VH nucleotide sequence comprising SEQ ID NO: 37 and a VL nucleotide sequence comprising SEQ ID NO:39; k. a VH nucleotide sequence comprising SEQ ID NO: 41 and a VL nucleotide sequence comprising SEQ ID NO:43;
1. a VH nucleotide sequence comprising SEQ ID NO: 45 and a VL nucleotide sequence comprising SEQ ID NO:47; a VH nucleotide sequence comprising SEQ ID NO: 49 and a VL nucleotide sequence comprising SEQ ID NO:51; or a VH nucleotide sequence comprising SEQ ID NO: 53 and a VL nucleotide sequence comprising SEQ ID NO:55. single chain antibody comprising a VH amino acid sequence comprising SEQ ID NO: 2 and a VL amino acid sequence comprising SEQ ID NO: 4; a VH amino acid sequence comprising SEQ ID NO: 6 and a VL amino acid sequence comprising SEQ ID NO: 8; a VH amino acid sequence comprising SEQ ID NO: 10 and a VL amino acid sequence comprising SEQ ID NO: 12; a VH amino acid sequence comprising SEQ ID NO: 14 and a VL amino acid sequence comprising SEQ ID NO: 16; a VH amino acid sequence comprising SEQ ID NO: 18 and a VL amino acid sequence comprising SEQ ID NO: 20; a VH amino acid sequence comprising SEQ ID NO: 22 and a VL amino acid sequence comprising SEQ ID NO: 24; a VH amino acid sequence comprising SEQ ID NO: 26 and a VL amino acid sequence comprising SEQ ID NO: 28; a VH amino acid sequence comprising SEQ ID NO: 30 and a VL amino acid sequence comprising SEQ ID NO: 32; a VH amino acid sequence comprising SEQ ID NO: 34 and a VL amino acid sequence comprising SEQ ID NO: 36; a VH amino acid sequence comprising SEQ ID NO: 38 and a VL amino acid sequence comprising SEQ ID NO: 40; k. a VH amino acid sequence comprising SEQ ID NO: 42 and a VL amino acid sequence comprising SEQ ID NO: 44;
1. a VH amino acid sequence comprising SEQ ID NO: 46 and a VL amino acid sequence comprising SEQ ID NO: 48; m. a VH amino acid sequence comprising SEQ ID NO: 50 and a VL amino acid sequence comprising SEQ ID NO: 52; or n. a VH amino acid sequence comprising SEQ ID NO: 54 and a VL amino acid sequence comprising SEQ ID NO: 56.
6. The antibody of claim 1 , wherein said antibody has a binding affinity within the range of 10"5 M to 10"12 M.
7. The antibody according to claim 1 wherein said antibody is a bi-specific antibody that also binds to a tumor-associated antigen, a cytokine or a cell surface receptor.
8. The antibody according to claim 7 wherein said tumor-associated antigen is
CAIX.
9. The antibody according to claim 7, wherein said cytokine is IL-10.
10. The antibody according to claim 7, wherein said cell surface receptor is CCR4, IL21R, BTLA, HVEM or TIM3.
11. The antibody according to any one of claims 1-8 linked to a therapeutic agent.
12. The antibody of claim 9, wherein said therapeutic agent is a toxin, a radiolabel, a siRNA, a small molecule, or a cytokine.
13. A cell producing the antibody of any one of claims 1-12.
14. A method of selectively killing a tumor cell comprising contacting said cell with the antibody of any one of claims 1-12.
15. The method of claim 14, wherein said selective killing occurs by antibody- dependent cellular toxicity (ADCC), complement-dependent cytotoxicity (CDC), antibody dependent cellular phagocytosis (ADCP).
16. The method of claim 14, wherein said tumor cell expresses PD-L1.
17. A method of preventing or reversing T cell exhaustion comprising administering to a subject in need thereof a composition comprising an antibody of any one of claims 1-12.
18. A method of augmenting an immune response to an antigen comprising
administering to a subject in need thereof a composition comprising an antibody of any one of claims 1-12.
19. The method of claim 18, wherein said antigen is a viral antigen, a bacterial antigen or a tumor associated antigen.
20. The method of claim 19, wherein said viral antigen is HIV.
21. The method of claim 19, wherein said tumor associated antigen is CAIX.
22. The method of claim 18, wherein said antibody is administered prior to or after exposure to the antigen.
23. The method of claim 17 or 18, wherein said administration of said antibody causes an increase in antigen specific T cell activity.
24. The method of claim 23, wherein said T-cell is an effector T cell.
25. A method of treating or alleviating a symptom of cancer, comprising
administering to a subject in need thereof a composition comprising an antibody according to any one of claims 1-12.
26. The method of claim 25, wherein said cancer is renal cell carcinoma or breast cancer.
27. The method of claim 25, wherein said cancer is a cancer in which PD-L1 is
overexpressed.
28. The method of claim 25, wherein said cancer is a cancer that induces T cell
exhaustion.
29. A method of treating or alleviating a symptom of a chronic viral infection, comprising administering to a subject in need thereof a composition comprising an antibody according to any one of claims 1-12.
30. The method of claim 29, wherein said chronic viral infection is an HIV infection.
31. The method of claim 29, wherein said chronic viral infection is a viral infection that induces T cell exhaustion.
32. A nucleic acid sequence comprising the nucleic acid sequence of SEQ ID NO: 1, 3, 5, 7, 9, 11, 13. 15. 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53 or 55.
33. A nucleic acid sequence encoding the polypeptide of SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54 or 56.
34. A polypeptide comprising the amino acid sequence of SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54 or 56.
35. A vector comprising the nucleic acid claims 32 or 33.
36. A cell comprising the vector of claim 35.
PCT/US2013/063509 2012-10-04 2013-10-04 Human monoclonal anti-pd-l1 antibodies and methods of use WO2014055897A2 (en)

Priority Applications (15)

Application Number Priority Date Filing Date Title
AU2013326901A AU2013326901B2 (en) 2012-10-04 2013-10-04 Human monoclonal anti-PD-L1 antibodies and methods of use
CN202111595551.3A CN114507282A (en) 2012-10-04 2013-10-04 Human monoclonal anti-PD-L1 antibodies and methods of use
US14/433,826 US9828434B2 (en) 2012-10-04 2013-10-04 Human monoclonal anti-PD-L1 antibodies and methods of use
CA2886433A CA2886433C (en) 2012-10-04 2013-10-04 Human monoclonal anti-pd-l1 antibodies and methods of use
EP13776696.0A EP2903641A2 (en) 2012-10-04 2013-10-04 Human monoclonal anti-pd-l1 antibodies and methods of use
CN201380063513.0A CN104994873B (en) 2012-10-04 2013-10-04 The anti-PD L1 antibody of human monoclonal and application method
BR112015007672A BR112015007672A2 (en) 2012-10-04 2013-10-04 human monoclonal anti-pd-l1 antibodies and methods of use
KR1020157008757A KR101947702B1 (en) 2012-10-04 2013-10-04 Human monoclonal anti-pd-l1 antibodies and methods of use
MX2015004105A MX370848B (en) 2012-10-04 2013-10-04 Human monoclonal anti-pd-l1 antibodies and methods of use.
JP2015535829A JP6461800B2 (en) 2012-10-04 2013-10-04 Human monoclonal anti-PD-L1 antibody and method of use
IL237737A IL237737B (en) 2012-10-04 2015-03-15 Human monoclonal anti-pd-l1 antibodies and methods of use
HK15112103.2A HK1211223A1 (en) 2012-10-04 2015-12-08 Human monoclonal anti-pd-l1 antibodies and methods of use -pd-l1
US15/821,087 US10604581B2 (en) 2012-10-04 2017-11-22 Human monoclonal anti-PD-L1 antibodies and methods of use
AU2018226425A AU2018226425B2 (en) 2012-10-04 2018-08-31 Human Monoclonal Anti-PD-L1 Antibodies and Methods of Use
US16/834,901 US20200385482A1 (en) 2012-10-04 2020-03-30 Human monoclonal anti-pd-l1 antibodies and methods of use

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261709731P 2012-10-04 2012-10-04
US61/709,731 2012-10-04
US201361779969P 2013-03-13 2013-03-13
US61/779,969 2013-03-13

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US14/433,826 A-371-Of-International US9828434B2 (en) 2012-10-04 2013-10-04 Human monoclonal anti-PD-L1 antibodies and methods of use
US15/821,087 Division US10604581B2 (en) 2012-10-04 2017-11-22 Human monoclonal anti-PD-L1 antibodies and methods of use

Publications (2)

Publication Number Publication Date
WO2014055897A2 true WO2014055897A2 (en) 2014-04-10
WO2014055897A3 WO2014055897A3 (en) 2014-06-05

Family

ID=49354980

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/063509 WO2014055897A2 (en) 2012-10-04 2013-10-04 Human monoclonal anti-pd-l1 antibodies and methods of use

Country Status (12)

Country Link
US (3) US9828434B2 (en)
EP (1) EP2903641A2 (en)
JP (1) JP6461800B2 (en)
KR (1) KR101947702B1 (en)
CN (3) CN107892719B (en)
AU (2) AU2013326901B2 (en)
BR (1) BR112015007672A2 (en)
CA (2) CA3139031A1 (en)
HK (2) HK1211223A1 (en)
IL (1) IL237737B (en)
MX (1) MX370848B (en)
WO (1) WO2014055897A2 (en)

Cited By (249)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015033299A1 (en) 2013-09-06 2015-03-12 Aurigene Discovery Technologies Limited 1,2,4-oxadiazole derivatives as immunomodulators
WO2015033301A1 (en) 2013-09-06 2015-03-12 Aurigene Discovery Technologies Limited 1,3,4-oxadiazole and 1,3,4-thiadiazole derivatives as immunomodulators
WO2015033303A1 (en) 2013-09-06 2015-03-12 Aurigene Discovery Technologies Limited Cyclic peptidomimetic compounds as immunomodulators
WO2016000619A1 (en) * 2014-07-03 2016-01-07 Beigene, Ltd. Anti-pd-l1 antibodies and their use as therapeutics and diagnostics
WO2016061142A1 (en) * 2014-10-14 2016-04-21 Novartis Ag Antibody molecules to pd-l1 and uses thereof
WO2016070051A2 (en) 2014-10-31 2016-05-06 Oncomed Pharmaceuticals, Inc. Combination therapy for treatment of disease
WO2016120789A1 (en) 2015-01-28 2016-08-04 Glaxosmithkline Intellectual Property Development Limited Agonistic icos binding proteins
WO2016142833A1 (en) 2015-03-10 2016-09-15 Aurigene Discovery Technologies Limited 1,2,4-oxadiazole and thiadiazole compounds as immunomodulators
WO2016149201A2 (en) 2015-03-13 2016-09-22 Cytomx Therapeutics, Inc. Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof
WO2016197367A1 (en) 2015-06-11 2016-12-15 Wuxi Biologics (Shanghai) Co. Ltd. Novel anti-pd-l1 antibodies
WO2017020858A1 (en) * 2015-08-06 2017-02-09 Wuxi Biologics (Shanghai) Co. Ltd. Novel anti-pd-l1 antibodies
WO2017025871A1 (en) 2015-08-07 2017-02-16 Glaxosmithkline Intellectual Property Development Limited Combination therapy comprising anti ctla-4 antibodies
WO2017055484A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for determining the metabolic status of lymphomas
CN106699891A (en) * 2017-01-25 2017-05-24 北京天广实生物技术股份有限公司 Anti-PD-L1 antibody as well as pharmaceutical composition and application of anti-PD-L1 antibody
WO2017084495A1 (en) * 2015-11-17 2017-05-26 江苏恒瑞医药股份有限公司 Pd-l1 antibody, antigen fragment binding thereof and pharmaceutical use thereof
WO2017093933A1 (en) 2015-12-03 2017-06-08 Glaxosmithkline Intellectual Property Development Limited Cyclic purine dinucleotides as modulators of sting
WO2017093942A1 (en) 2015-12-01 2017-06-08 Glaxosmithkline Intellectual Property Development Limited Combination treatments and uses and methods thereof
WO2017098421A1 (en) 2015-12-08 2017-06-15 Glaxosmithkline Intellectual Property Development Limited Benzothiadiazine compounds
JP2017518769A (en) * 2014-06-12 2017-07-13 ウニヴェルシダージ ド ポルト − レイトリア Vaccines for immunocompromised hosts
WO2017118634A1 (en) 2016-01-04 2017-07-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of pd-1 and tim-3 as a measure for cd8+ cells in predicting and treating renal cell carcinoma
WO2017153952A1 (en) 2016-03-10 2017-09-14 Glaxosmithkline Intellectual Property Development Limited 5-sulfamoyl-2-hydroxybenzamide derivatives
WO2017175147A1 (en) 2016-04-07 2017-10-12 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides useful as protein modulators
WO2017175156A1 (en) 2016-04-07 2017-10-12 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides useful as protein modulators
US9789183B1 (en) 2015-01-09 2017-10-17 Agency For Science, Technology And Research Anti-PD-L1 antibodies
WO2017191545A1 (en) 2016-05-05 2017-11-09 Glaxosmithkline Intellectual Property (No.2) Limited Enhancer of zeste homolog 2 inhibitors
WO2017205721A1 (en) 2016-05-27 2017-11-30 Agenus Inc. Anti-tim-3 antibodies and methods of use thereof
US9834606B2 (en) 2013-09-13 2017-12-05 Beigene, Ltd Anti-PD1 antibodies and their use as therapeutics and diagnostics
WO2017212423A1 (en) 2016-06-08 2017-12-14 Glaxosmithkline Intellectual Property Development Limited Chemcical compounds
WO2017212425A1 (en) 2016-06-08 2017-12-14 Glaxosmithkline Intellectual Property Development Limited Chemical compounds as atf4 pathway inhibitors
WO2017218533A1 (en) 2016-06-13 2017-12-21 Torque Therapeutics, Inc. Methods and compositions for promoting immune cell function
WO2017220988A1 (en) 2016-06-20 2017-12-28 Kymab Limited Multispecific antibodies for immuno-oncology
WO2018005682A2 (en) 2016-06-29 2018-01-04 Checkpoint Therapeutics, Inc. Pd-l1-specific antibodies and methods of using the same
WO2018015879A1 (en) 2016-07-20 2018-01-25 Glaxosmithkline Intellectual Property Development Limited Isoquinoline derivatives as perk inhibitors
WO2018029474A2 (en) 2016-08-09 2018-02-15 Kymab Limited Anti-icos antibodies
JP2018504894A (en) * 2014-12-19 2018-02-22 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Chimeric antigen receptor and method of use thereof
WO2018071913A2 (en) 2016-10-14 2018-04-19 Dana-Farber Cancer Institute, Inc. Modular tetrameric bispecific antibody platform
WO2018071500A1 (en) 2016-10-11 2018-04-19 Agenus Inc. Anti-lag-3 antibodies and methods of use thereof
EP3177649A4 (en) * 2014-08-05 2018-04-25 CB Therapeutics, Inc. Anti-pd-l1 antibodies
US9957323B2 (en) 2016-06-20 2018-05-01 Kymab Limited Anti-ICOS antibodies
JP2018512175A (en) * 2015-03-30 2018-05-17 エスティーキューブ，インコーポレイテッド Antibodies specific for glycosylated PD-L1 and methods of use thereof
WO2018100535A1 (en) 2016-12-01 2018-06-07 Glaxosmithkline Intellectual Property Development Limited Combination therapy
WO2018100534A1 (en) 2016-12-01 2018-06-07 Glaxosmithkline Intellectual Property Development Limited Combination therapy
WO2018106864A1 (en) 2016-12-07 2018-06-14 Agenus Inc. Antibodies and methods of use thereof
WO2018106862A1 (en) 2016-12-07 2018-06-14 Agenus Inc. Anti-ctla-4 antibodies and methods of use thereof
WO2018132739A2 (en) 2017-01-13 2018-07-19 Agenus Inc. T cell receptors that bind to ny-eso-1 and methods of use thereof
WO2018154520A1 (en) 2017-02-27 2018-08-30 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides as kinase inhibitors
WO2018172508A1 (en) 2017-03-24 2018-09-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating melanoma
WO2018191502A2 (en) 2017-04-13 2018-10-18 Agenus Inc. Anti-cd137 antibodies and methods of use thereof
WO2018191074A1 (en) * 2017-04-11 2018-10-18 Eli Lilly And Company Anti-pd-l1-anti-tim-3 bispecific antibodies
WO2018198091A1 (en) 2017-04-28 2018-11-01 Novartis Ag Antibody conjugates comprising toll-like receptor agonist and combination therapies
WO2018204363A1 (en) 2017-05-01 2018-11-08 Agenus Inc. Anti-tigit antibodies and methods of use thereof
US10144779B2 (en) 2015-05-29 2018-12-04 Agenus Inc. Anti-CTLA-4 antibodies and methods of use thereof
WO2018225093A1 (en) 2017-06-07 2018-12-13 Glaxosmithkline Intellectual Property Development Limited Chemical compounds as atf4 pathway inhibitors
WO2018225033A1 (en) 2017-06-09 2018-12-13 Glaxosmithkline Intellectual Property Development Limited Combination therapy
WO2018229715A1 (en) 2017-06-16 2018-12-20 Novartis Ag Compositions comprising anti-cd32b antibodies and methods of use thereof
WO2018234879A1 (en) 2017-06-22 2018-12-27 Novartis Ag Il-1beta binding antibodies for use in treating cancer
WO2018237157A1 (en) 2017-06-22 2018-12-27 Novartis Ag Antibody molecules to cd73 and uses thereof
WO2018237173A1 (en) 2017-06-22 2018-12-27 Novartis Ag Antibody molecules to cd73 and uses thereof
WO2018235056A1 (en) 2017-06-22 2018-12-27 Novartis Ag Il-1beta binding antibodies for use in treating cancer
WO2019006007A1 (en) 2017-06-27 2019-01-03 Novartis Ag Dosage regimens for anti-tim-3 antibodies and uses thereof
WO2019008506A1 (en) 2017-07-03 2019-01-10 Glaxosmithkline Intellectual Property Development Limited N-(3-(2-(4-chlorophenoxy)acetamido)bicyclo[1.1.1]pentan-1-yl)-2-cyclobutane-1-carboxamide derivatives and related compounds as atf4 inhibitors for treating cancer and other diseases
WO2019008507A1 (en) 2017-07-03 2019-01-10 Glaxosmithkline Intellectual Property Development Limited 2-(4-chlorophenoxy)-n-((1 -(2-(4-chlorophenoxy)ethynazetidin-3-yl)methyl)acetamide derivatives and related compounds as atf4 inhibitors for treating cancer and other diseases
WO2019018730A1 (en) 2017-07-20 2019-01-24 Novartis Ag Dosage regimens of anti-lag-3 antibodies and uses thereof
WO2019021208A1 (en) 2017-07-27 2019-01-31 Glaxosmithkline Intellectual Property Development Limited Indazole derivatives useful as perk inhibitors
US10214586B2 (en) 2015-08-24 2019-02-26 Eli Lilly And Company PD-L1 antibodies
WO2019046856A1 (en) 2017-09-04 2019-03-07 Agenus Inc. T cell receptors that bind to mixed lineage leukemia (mll)-specific phosphopeptides and methods of use thereof
WO2019049061A1 (en) 2017-09-07 2019-03-14 Glaxosmithkline Intellectual Property Development Limited 5-(1 h-benzo[d]imidazo-2-yl)-pyridin-2-amine and 5-(3h-imidazo[4,5-b]pyridin-6-yl)-pyridin-2-amine derivatives as c-myc and p300/cbp histone acetyltransferase inhibitors for treating cancer
WO2019053617A1 (en) 2017-09-12 2019-03-21 Glaxosmithkline Intellectual Property Development Limited Chemical compounds
WO2019069269A1 (en) 2017-10-05 2019-04-11 Glaxosmithkline Intellectual Property Development Limited Modulators of stimulator of interferon genes (sting) useful in treating hiv
WO2019069270A1 (en) 2017-10-05 2019-04-11 Glaxosmithkline Intellectual Property Development Limited Modulators of stimulator of interferon genes (sting)
WO2019081983A1 (en) 2017-10-25 2019-05-02 Novartis Ag Antibodies targeting cd32b and methods of use thereof
WO2019108900A1 (en) 2017-11-30 2019-06-06 Novartis Ag Bcma-targeting chimeric antigen receptor, and uses thereof
WO2019114235A1 (en) * 2017-12-11 2019-06-20 苏州银河生物医药有限公司 Pdl1 monoclonal antibody and application thereof
WO2019122884A1 (en) 2017-12-19 2019-06-27 Kymab Limited Antibodies to icos
WO2019136432A1 (en) 2018-01-08 2019-07-11 Novartis Ag Immune-enhancing rnas for combination with chimeric antigen receptor therapy
WO2019134946A1 (en) 2018-01-04 2019-07-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating melanoma resistant
WO2019137397A1 (en) 2018-01-10 2019-07-18 江苏恒瑞医药股份有限公司 Pd-l1 antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
WO2019148043A1 (en) 2018-01-26 2019-08-01 Exelixis, Inc. Compounds for the treatment of kinase-dependent disorders
WO2019148036A1 (en) 2018-01-26 2019-08-01 Exelixis, Inc. Compounds for the treatment of kinase-dependent disorders
WO2019148044A1 (en) 2018-01-26 2019-08-01 Exelixis, Inc. Compounds for the treatment of kinase-dependent disorders
WO2019152660A1 (en) 2018-01-31 2019-08-08 Novartis Ag Combination therapy using a chimeric antigen receptor
WO2019160956A1 (en) 2018-02-13 2019-08-22 Novartis Ag Chimeric antigen receptor therapy in combination with il-15r and il15
WO2019162325A1 (en) 2018-02-21 2019-08-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of sk1 as biomarker for predicting response to immunecheckpoint inhibitors
US10428146B2 (en) 2014-07-22 2019-10-01 Cb Therapeutics, Inc. Anti PD-1 antibodies
WO2019193540A1 (en) 2018-04-06 2019-10-10 Glaxosmithkline Intellectual Property Development Limited Heteroaryl derivatives of formula (i) as atf4 inhibitors
WO2019193541A1 (en) 2018-04-06 2019-10-10 Glaxosmithkline Intellectual Property Development Limited Bicyclic aromatic ring derivatives of formula (i) as atf4 inhibitors
WO2019200229A1 (en) 2018-04-13 2019-10-17 Novartis Ag Dosage regimens for anti-pd-l1 antibodies and uses thereof
WO2019210055A2 (en) 2018-04-26 2019-10-31 Agenus Inc. Heat shock protein-binding peptide compositions and methods of use thereof
US10472419B2 (en) 2014-01-31 2019-11-12 Novartis Ag Antibody molecules to TIM-3 and uses thereof
WO2019219820A1 (en) 2018-05-16 2019-11-21 Ctxt Pty Limited Substituted condensed thiophenes as modulators of sting
WO2019232244A2 (en) 2018-05-31 2019-12-05 Novartis Ag Antibody molecules to cd73 and uses thereof
WO2019229701A2 (en) 2018-06-01 2019-12-05 Novartis Ag Binding molecules against bcma and uses thereof
WO2019229658A1 (en) 2018-05-30 2019-12-05 Novartis Ag Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
WO2020012337A1 (en) 2018-07-10 2020-01-16 Novartis Ag 3-(5-amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and their use in the treatment of i karos family zinc finger 2 (ikzf2)-dependent diseases
WO2020012334A1 (en) 2018-07-10 2020-01-16 Novartis Ag 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and their use in the treatment of ikaros family zinc finger 2 (ikzf2)-dependent diseases
WO2020012339A1 (en) 2018-07-09 2020-01-16 Glaxosmithkline Intellectual Property Development Limited Chemical compounds
WO2020031107A1 (en) 2018-08-08 2020-02-13 Glaxosmithkline Intellectual Property Development Limited Chemical compounds
US10570204B2 (en) 2013-09-26 2020-02-25 The Medical College Of Wisconsin, Inc. Methods for treating hematologic cancers
WO2020044206A1 (en) 2018-08-29 2020-03-05 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides as kinase inhibitors for use in the treatment cancer
WO2020086476A1 (en) 2018-10-22 2020-04-30 Glaxosmithkline Intellectual Property Development Limited Dosing
WO2020089811A1 (en) 2018-10-31 2020-05-07 Novartis Ag Dc-sign antibody drug conjugates
WO2020102804A2 (en) 2018-11-16 2020-05-22 Arqule, Inc. Pharmaceutical combination for treatment of cancer
WO2020104479A1 (en) 2018-11-20 2020-05-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating cancers and resistant cancers with anti transferrin receptor 1 antibodies
WO2020104496A1 (en) 2018-11-20 2020-05-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Bispecific antibody targeting transferrin receptor 1 and soluble antigen
WO2020110056A1 (en) 2018-11-30 2020-06-04 Glaxosmithkline Intellectual Property Development Limited Compounds useful in hiv therapy
WO2020117988A1 (en) 2018-12-04 2020-06-11 Tolero Pharmaceuticals, Inc. Cdk9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
WO2020115261A1 (en) 2018-12-07 2020-06-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating melanoma
WO2020123800A1 (en) 2018-12-13 2020-06-18 Exelixis, Inc. Crystalline forms and salt forms of a kinase inhibitor
WO2020120592A1 (en) 2018-12-12 2020-06-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for predicting and treating melanoma
WO2020128972A1 (en) 2018-12-20 2020-06-25 Novartis Ag Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
WO2020128636A1 (en) 2018-12-21 2020-06-25 Novartis Ag Use of il-1 beta antibodies in the treatment or prevention of myelodysplastic syndrome
WO2020128637A1 (en) 2018-12-21 2020-06-25 Novartis Ag Use of il-1 binding antibodies in the treatment of a msi-h cancer
WO2020128613A1 (en) 2018-12-21 2020-06-25 Novartis Ag Use of il-1beta binding antibodies
WO2020127411A1 (en) 2018-12-19 2020-06-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating cancers by immuno-modulation using antibodies against cathespin-d
WO2020127885A1 (en) 2018-12-21 2020-06-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions for treating cancers and resistant cancers
WO2020132560A2 (en) 2018-12-21 2020-06-25 Aim Immunotech Inc. Compositions and methods for cancer therapy
WO2020127965A1 (en) 2018-12-21 2020-06-25 Onxeo New conjugated nucleic acid molecules and their uses
WO2020128620A1 (en) 2018-12-21 2020-06-25 Novartis Ag Use of il-1beta binding antibodies
CN111363041A (en) * 2016-03-23 2020-07-03 迈博斯生物医药(苏州)有限公司 Novel anti-PD-L1 antibodies
WO2020154610A1 (en) 2019-01-25 2020-07-30 Exelixis, Inc. Compounds for the treatment of kinase-dependent disorders
WO2020157131A1 (en) 2019-01-30 2020-08-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for identifying whether a subject suffering from a cancer will achieve a response with an immune-checkpoint inhibitor
WO2020160375A1 (en) 2019-02-01 2020-08-06 Glaxosmithkline Intellectual Property Development Limited Combination treatments for cancer comprising belantamab mafodotin and an anti ox40 antibody and uses and methods thereof
WO2020161083A1 (en) 2019-02-04 2020-08-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for modulating blood-brain barrier
WO2020165370A1 (en) 2019-02-13 2020-08-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for selecting a cancer treatment in a subject suffering from cancer
WO2020167990A1 (en) 2019-02-12 2020-08-20 Tolero Pharmaceuticals, Inc. Formulations comprising heterocyclic protein kinase inhibitors
WO2020165833A1 (en) 2019-02-15 2020-08-20 Novartis Ag 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
WO2020165834A1 (en) 2019-02-15 2020-08-20 Novartis Ag Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
US10752687B2 (en) 2014-01-24 2020-08-25 Novartis Ag Antibody molecules to PD-1 and uses thereof
WO2020198077A1 (en) 2019-03-22 2020-10-01 Sumitomo Dainippon Pharma Oncology, Inc. Compositions comprising pkm2 modulators and methods of treatment using the same
WO2020216379A1 (en) * 2019-04-26 2020-10-29 I-Mab Human pd-l1 antibodies
WO2020221796A1 (en) 2019-04-30 2020-11-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating melanoma
WO2020232378A1 (en) 2019-05-16 2020-11-19 Silicon Swat, Inc. Benzo[b][1,8]naphthyridine acetic acid derivatives and methods of use
WO2020232375A1 (en) 2019-05-16 2020-11-19 Silicon Swat, Inc. Oxoacridinyl acetic acid derivatives and methods of use
US10858432B2 (en) 2015-12-02 2020-12-08 Stcube, Inc. Antibodies specific to glycosylated PD-1 and methods of use thereof
WO2020247418A1 (en) 2019-06-04 2020-12-10 Exelixis, Inc. Compounds for the treatment of kinase-dependent disorders
WO2020247019A1 (en) 2019-06-03 2020-12-10 Exelixis, Inc. Crystalline salt forms of a kinase inhibitor
US10864203B2 (en) 2016-07-05 2020-12-15 Beigene, Ltd. Combination of a PD-1 antagonist and a RAF inhibitor for treating cancer
US10875864B2 (en) 2011-07-21 2020-12-29 Sumitomo Dainippon Pharma Oncology, Inc. Substituted imidazo[1,2-B]pyridazines as protein kinase inhibitors
WO2020261097A1 (en) 2019-06-26 2020-12-30 Glaxosmithkline Intellectual Property Development Limited Il1rap binding proteins
WO2021003417A1 (en) 2019-07-03 2021-01-07 Sumitomo Dainippon Pharma Oncology, Inc. Tyrosine kinase non-receptor 1 (tnk1) inhibitors and uses thereof
WO2021009365A1 (en) 2019-07-18 2021-01-21 Ctxt Pty Limited Benzothiophene, thienopyridine and thienopyrimidine derivatives for the modulation of sting
WO2021009267A1 (en) 2019-07-15 2021-01-21 Capella Bioscience Ltd Anti-pd-l1 antibodies
WO2021009362A1 (en) 2019-07-18 2021-01-21 Ctxt Pty Limited Benzothiophene, thienopyridine and thienopyrimidine derivatives for the modulation of sting
EP3613770A4 (en) * 2017-04-17 2021-01-27 Joint Stock Company "Biocad" Monoclonal antibody to pd-l1
WO2021042019A1 (en) 2019-08-30 2021-03-04 Agenus Inc. Anti-cd96 antibodies and methods of use thereof
WO2021043961A1 (en) 2019-09-06 2021-03-11 Glaxosmithkline Intellectual Property Development Limited Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and chemotherapy
WO2021048292A1 (en) 2019-09-11 2021-03-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating melanoma
WO2021053559A1 (en) 2019-09-18 2021-03-25 Novartis Ag Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
WO2021053560A1 (en) 2019-09-18 2021-03-25 Novartis Ag Combination therapy with entpd2 and cd73 antibodies
WO2021058711A2 (en) 2019-09-27 2021-04-01 Glaxosmithkline Intellectual Property Development Limited Antigen binding proteins
WO2021064180A1 (en) 2019-10-03 2021-04-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for modulating macrophages polarization
WO2021074391A1 (en) 2019-10-17 2021-04-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing nasal intestinal type adenocarcinomas
WO2021079188A1 (en) 2019-10-21 2021-04-29 Novartis Ag Combination therapies with venetoclax and tim-3 inhibitors
WO2021079195A1 (en) 2019-10-21 2021-04-29 Novartis Ag Tim-3 inhibitors and uses thereof
WO2021083959A1 (en) 2019-10-29 2021-05-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating uveal melanoma
WO2021102343A1 (en) 2019-11-22 2021-05-27 Sumitomo Dainippon Pharma Oncology, Inc. Solid dose pharmaceutical composition
EP3630148A4 (en) * 2017-05-26 2021-06-16 The Johns Hopkins University Multifunctional antibody-ligand traps to modulate immune tolerance
US11040948B2 (en) 2017-09-29 2021-06-22 Curis, Inc. Crystal forms of immunomodulators
WO2021127200A1 (en) 2019-12-19 2021-06-24 Ngm Biopharmaceuticals, Inc. Ilt3-binding agents and methods of use thereof
WO2021123996A1 (en) 2019-12-20 2021-06-24 Novartis Ag Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases
WO2021123243A1 (en) 2019-12-19 2021-06-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and vaccine compositions to treat cancers
EP3634994A4 (en) * 2017-06-05 2021-06-30 Janssen Biotech, Inc. Methods of engineering surface charge for bispecific antibody production
WO2021144657A1 (en) 2020-01-17 2021-07-22 Novartis Ag Combination comprising a tim-3 inhibitor and a hypomethylating agent for use in treating myelodysplastic syndrome or chronic myelomonocytic leukemia
WO2021144426A1 (en) 2020-01-17 2021-07-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating melanoma
WO2021152005A1 (en) 2020-01-28 2021-08-05 Universite De Strasbourg Antisense oligonucleotide targeting linc00518 for treating melanoma
WO2021152495A1 (en) 2020-01-28 2021-08-05 Glaxosmithkline Intellectual Property Development Limited Combination treatments and uses and methods thereof
WO2021156360A1 (en) 2020-02-05 2021-08-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for discontinuing a treatment with a tyrosine kinase inhibitor (tki)
WO2021170777A1 (en) 2020-02-28 2021-09-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing, prognosing and managing treatment of breast cancer
US11136300B2 (en) 2017-10-11 2021-10-05 Aurigene Discovery Technologies Limited Crystalline forms of 3-substituted 1,2,4-oxadiazole
WO2021209358A1 (en) 2020-04-14 2021-10-21 Glaxosmithkline Intellectual Property Development Limited Combination treatment for cancer based upon an icos antibody and a pd-l1 antibody tgf-beta-receptor fusion protein
EP3733706A4 (en) * 2017-12-27 2021-11-03 Pharmabcine Inc. Anti-pd-l1 antibody and use thereof
WO2021222544A1 (en) 2020-05-01 2021-11-04 Ngm Biopharmaceuticals, Inc. Ilt-binding agents and methods of use thereof
US11168144B2 (en) 2017-06-01 2021-11-09 Cytomx Therapeutics, Inc. Activatable anti-PDL1 antibodies, and methods of use thereof
WO2021255223A1 (en) 2020-06-19 2021-12-23 Onxeo New conjugated nucleic acid molecules and their uses
WO2021260528A1 (en) 2020-06-23 2021-12-30 Novartis Ag Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
WO2021262597A2 (en) 2020-06-22 2021-12-30 Ngm Biopharmaceuticals, Inc. Lair-1-binding agents and methods of use thereof
EP3778635A4 (en) * 2018-04-09 2022-01-26 Origincell Therapeutics Co., Ltd. Anti-pd-l1 antibody and use thereof
WO2022023379A1 (en) 2020-07-28 2022-02-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for preventing and treating a cancer
WO2022026706A1 (en) 2020-07-31 2022-02-03 Exelixis, Inc. Combinations for the treatment of cancer
WO2022029573A1 (en) 2020-08-03 2022-02-10 Novartis Ag Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
WO2022040555A2 (en) 2020-08-21 2022-02-24 Exelixis, Inc. Method of treating cancer
US11279694B2 (en) 2016-11-18 2022-03-22 Sumitomo Dainippon Pharma Oncology, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
WO2022074206A1 (en) 2020-10-08 2022-04-14 Affimed Gmbh Trispecific binders
WO2022081886A1 (en) * 2020-10-14 2022-04-21 Xencor, Inc. Bispecific antibodies that bind pd-l1 and cd28
WO2022084531A1 (en) 2020-10-23 2022-04-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating glioma
WO2022097060A1 (en) 2020-11-06 2022-05-12 Novartis Ag Cd19 binding molecules and uses thereof
WO2022101484A1 (en) 2020-11-16 2022-05-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for predicting and treating uveal melanoma
WO2022101481A1 (en) 2020-11-16 2022-05-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for predicting and treating uveal melanoma
US11344620B2 (en) 2014-09-13 2022-05-31 Novartis Ag Combination therapies
WO2022162569A1 (en) 2021-01-29 2022-08-04 Novartis Ag Dosage regimes for anti-cd73 and anti-entpd2 antibodies and uses thereof
WO2022185160A1 (en) 2021-03-02 2022-09-09 Glaxosmithkline Intellectual Property Development Limited Substituted pyridines as dnmt1 inhibitors
US11440960B2 (en) 2017-06-20 2022-09-13 Kymab Limited TIGIT antibodies, encoding nucleic acids and methods of using said antibodies in vivo
WO2022195551A1 (en) 2021-03-18 2022-09-22 Novartis Ag Biomarkers for cancer and methods of use thereof
WO2022194908A1 (en) 2021-03-17 2022-09-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating melanoma
US11459394B2 (en) 2017-02-24 2022-10-04 Macrogenics, Inc. Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof
WO2022208353A1 (en) 2021-03-31 2022-10-06 Glaxosmithkline Intellectual Property Development Limited Antigen binding proteins and combinations thereof
WO2022215011A1 (en) 2021-04-07 2022-10-13 Novartis Ag USES OF ANTI-TGFβ ANTIBODIES AND OTHER THERAPEUTIC AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISEASES
WO2022221227A1 (en) 2021-04-13 2022-10-20 Nuvalent, Inc. Amino-substituted heterocycles for treating cancers with egfr mutations
WO2022219080A1 (en) 2021-04-14 2022-10-20 INSERM (Institut National de la Santé et de la Recherche Médicale) New method to improve nk cells cytotoxicity
WO2022223791A1 (en) 2021-04-23 2022-10-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating cell senescence accumulation related disease
US11497756B2 (en) 2017-09-12 2022-11-15 Sumitomo Pharma Oncology, Inc. Treatment regimen for cancers that are insensitive to BCL-2 inhibitors using the MCL-1 inhibitor alvocidib
US11497735B2 (en) 2017-11-06 2022-11-15 Aurigene Discovery Technologies Limited Conjoint therapies for immunomodulation
US11497734B2 (en) 2017-11-03 2022-11-15 Aurigene Discovery Technologies Limited Dual inhibitors of TIM-3 and PD-1 pathways
WO2022243846A1 (en) 2021-05-18 2022-11-24 Novartis Ag Combination therapies
WO2022243378A1 (en) 2021-05-18 2022-11-24 Kymab Limited Uses of anti-icos antibodies
WO2022254227A1 (en) 2021-06-04 2022-12-08 Kymab Limited Treatment of pd-l1 negative or low expressing cancer with anti-icos antibodies
US11555038B2 (en) 2017-01-25 2023-01-17 Beigene, Ltd. Crystalline forms of (S)-7-(1-(but-2-ynoyl)piperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
WO2023007023A1 (en) 2021-07-30 2023-02-02 Affimed Gmbh Duplexbodies
US11597768B2 (en) 2017-06-26 2023-03-07 Beigene, Ltd. Immunotherapy for hepatocellular carcinoma
US11629189B2 (en) 2017-12-19 2023-04-18 Kymab Limited Bispecific antibody for ICOS and PD-L1
US11634506B2 (en) 2013-01-14 2023-04-25 Xencor, Inc. Heterodimeric proteins
WO2023078900A1 (en) 2021-11-03 2023-05-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating triple negative breast cancer (tnbc)
US11660352B2 (en) 2016-03-29 2023-05-30 Stcube, Inc. Dual function antibodies specific to glycosylated PD-L1 and methods of use thereof
US11673972B2 (en) 2014-11-26 2023-06-13 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
WO2023111203A1 (en) 2021-12-16 2023-06-22 Onxeo New conjugated nucleic acid molecules and their uses
WO2023118165A1 (en) 2021-12-21 2023-06-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating melanoma
WO2023122739A1 (en) 2021-12-22 2023-06-29 Exelixis, Inc. Crystalline forms and salt forms of a kinase inhibitor
US11701357B2 (en) 2016-08-19 2023-07-18 Beigene Switzerland Gmbh Treatment of B cell cancers using a combination comprising Btk inhibitors
US11739144B2 (en) 2021-03-09 2023-08-29 Xencor, Inc. Heterodimeric antibodies that bind CD3 and CLDN6
US11746152B2 (en) 2016-07-20 2023-09-05 Stcube, Inc. Methods of cancer treatment and therapy using a combination of antibodies that bind glycosylated PD-L1
US11746103B2 (en) 2020-12-10 2023-09-05 Sumitomo Pharma Oncology, Inc. ALK-5 inhibitors and uses thereof
US11753479B2 (en) 2014-03-04 2023-09-12 Kymab Limited Nucleic acids encoding anti-OX40L antibodies
WO2023173091A1 (en) 2022-03-11 2023-09-14 Ngm Biopharmaceuticals, Inc. Osteoclast-associated ig-like receptor (oscar) and methods of use thereof
WO2023174210A1 (en) 2022-03-14 2023-09-21 Laekna Limited Combination treatment for cancer
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
WO2023194656A1 (en) 2022-04-08 2023-10-12 Tilt Biotherapeutics Oy Monoclonal pd-l1 antibodies
US11786529B2 (en) 2017-11-29 2023-10-17 Beigene Switzerland Gmbh Treatment of indolent or aggressive B-cell lymphomas using a combination comprising BTK inhibitors
US11793802B2 (en) 2019-03-20 2023-10-24 Sumitomo Pharma Oncology, Inc. Treatment of acute myeloid leukemia (AML) with venetoclax failure
WO2023214325A1 (en) 2022-05-05 2023-11-09 Novartis Ag Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
US11814423B2 (en) 2013-03-15 2023-11-14 Xencor, Inc. Heterodimeric proteins
WO2023222854A1 (en) 2022-05-18 2023-11-23 Kymab Limited Uses of anti-icos antibodies
WO2023230541A1 (en) 2022-05-27 2023-11-30 Viiv Healthcare Company Piperazine derivatives useful in hiv therapy
US11858996B2 (en) 2016-08-09 2024-01-02 Kymab Limited Anti-ICOS antibodies
US11859012B2 (en) 2021-03-10 2024-01-02 Xencor, Inc. Heterodimeric antibodies that bind CD3 and GPC3
WO2024033399A1 (en) 2022-08-10 2024-02-15 Institut National de la Santé et de la Recherche Médicale Sigmar1 ligand for the treatment of pancreatic cancer
WO2024033400A1 (en) 2022-08-10 2024-02-15 Institut National de la Santé et de la Recherche Médicale Sk2 inhibitor for the treatment of pancreatic cancer
US11919956B2 (en) 2020-05-14 2024-03-05 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
US11919958B2 (en) 2020-08-19 2024-03-05 Xencor, Inc. Anti-CD28 compositions
US11933786B2 (en) 2015-03-30 2024-03-19 Stcube, Inc. Antibodies specific to glycosylated PD-L1 and methods of use thereof
WO2024056716A1 (en) 2022-09-14 2024-03-21 Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical compositions for the treatment of dilated cardiomyopathy
US11945880B2 (en) 2014-11-26 2024-04-02 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
WO2024084034A1 (en) 2022-10-21 2024-04-25 Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical compositions for the treatment of osteoarthritis
US12006345B2 (en) 2019-02-21 2024-06-11 Xencor, Inc. Untargeted and targeted IL-10 Fc-fusion proteins
US12054545B2 (en) 2016-06-28 2024-08-06 Xencor, Inc. Heterodimeric antibodies that bind somatostatin receptor 2
WO2024160721A1 (en) 2023-01-30 2024-08-08 Kymab Limited Antibodies
US12059474B2 (en) 2016-03-29 2024-08-13 Stcube & Co., Inc. Methods for selecting antibodies that specifically bind glycosylated immune checkpoint proteins
WO2024200571A1 (en) 2023-03-28 2024-10-03 Institut National de la Santé et de la Recherche Médicale Method for discriminating mono-immunotherapy from combined immunotherapy in cancers
WO2024216028A1 (en) 2023-04-12 2024-10-17 Agenus Inc. Methods of treating cancer using an anti-ctla4 antibody and an enpp1 inhibitor
US12129309B2 (en) 2014-11-26 2024-10-29 Xencor, Inc. Heterodimeric antibodies that bind CD3 and CD38

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2717641C2 (en) 2014-04-21 2020-03-24 Натера, Инк. Detection of mutations and ploidy in chromosomal segments
CN106939047B (en) * 2016-01-04 2021-08-31 江苏怀瑜药业有限公司 PD-L1 antibody and preparation method thereof
US20190178888A1 (en) 2016-01-11 2019-06-13 Technion Research & Development Foundation Limited Methods of determining prognosis of sepsis and treating same
SG11201806496SA (en) 2016-01-29 2018-08-30 Heyue Zhou Antigen binding proteins that bind pd-l1
ES2801873T3 (en) 2016-03-04 2021-01-14 Sichuan Kelun Biotech Biopharmaceutical Co Ltd PDL-1 antibody, its pharmaceutical composition and its uses
CN105968200B (en) * 2016-05-20 2019-03-15 瑞阳(苏州)生物科技有限公司 Anti human PD-L 1 Humanized monoclonal antibodies and its application
CN106008714B (en) 2016-05-24 2019-03-15 瑞阳(苏州)生物科技有限公司 Anti-human PD-1 Humanized monoclonal antibodies and its application
CN106243223B (en) * 2016-07-28 2019-03-05 北京百特美博生物科技有限公司 Anti-human PDL1 antibody and application thereof
JP2019525934A (en) * 2016-07-29 2019-09-12 イーライ リリー アンド カンパニー Combination therapy with melestinib and anti-PD-L1 or anti-PD-1 inhibitor for use in the treatment of cancer
JP2019526595A (en) 2016-09-09 2019-09-19 ティージー セラピューティクス，インコーポレイテッド Combination of anti-CD20 antibody, PI3 kinase-delta inhibitor and anti-PD-1 antibody or anti-PD-L1 antibody for treating blood cancer
CN106496327B (en) * 2016-11-18 2019-01-15 昆山百尔泰生物科技有限公司 Human antibody or antibody fragment and purposes, nucleotide sequence and carrier for PD-L1 extracellular fragment
EP3554561B1 (en) 2016-12-14 2023-06-28 Janssen Biotech, Inc. Cd137 binding fibronectin type iii domains
WO2018111976A1 (en) 2016-12-14 2018-06-21 Janssen Biotech, Inc. Pd-l1 binding fibronectin type iii domains
EP3554562A4 (en) 2016-12-14 2020-11-04 Janssen Biotech, Inc. Cd8a-binding fibronectin type iii domains
EP3592769B1 (en) * 2017-03-09 2024-05-08 Genmab A/S Antibodies against pd-l1
AU2018252193A1 (en) 2017-04-14 2019-10-17 Tallac Therapeutics, Inc. Immunomodulating polynucleotides, antibody conjugates thereof, and methods of their use
JOP20190248A1 (en) 2017-04-21 2019-10-20 Amgen Inc Trem2 antigen binding proteins and uses thereof
DE102017125019B4 (en) * 2017-10-25 2019-10-17 Epiontis Gmbh PDCD1 as an epigenetic marker for the identification of immune cells, in particular PD1 + cells
CN109929037B (en) * 2019-04-01 2023-03-17 华博生物医药技术（上海）有限公司 Conjugates to programmed death ligands and uses thereof
CN112300279A (en) * 2019-07-26 2021-02-02 上海复宏汉霖生物技术股份有限公司 Methods and compositions directed to anti-CD 73 antibodies and variants
US20220411513A1 (en) * 2019-09-30 2022-12-29 Harbour Biomed (Shanghai) Co., Ltd Anti-pd-l1 antigen binding protein and application thereof
CN114786682B (en) 2019-10-14 2024-07-16 Aro生物疗法公司 Fibronectin type III domain binding CD71
US11781138B2 (en) 2019-10-14 2023-10-10 Aro Biotherapeutics Company FN3 domain-siRNA conjugates and uses thereof
EP4069294A4 (en) * 2019-12-02 2024-07-10 Dana Farber Cancer Inst Inc Antibodies against pd-l1 and methods of use thereof
CN111378042A (en) * 2020-01-15 2020-07-07 哈尔滨医科大学 Cerenkov fluorescence imaging probe and preparation method and application thereof
JP2023515566A (en) 2020-02-28 2023-04-13 タラック セラピューティクス，インク． Transglutaminase-mediated conjugation
WO2022221505A2 (en) 2021-04-14 2022-10-20 Aro Biotherapeutics Company Cd71 binding fibronectin type iii domains

Citations (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
EP0003089A1 (en) 1978-01-06 1979-07-25 Bernard David Drier for silkscreen printed sheets
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
WO1991000360A1 (en) 1989-06-29 1991-01-10 Medarex, Inc. Bispecific reagents for aids therapy
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5030719A (en) 1986-08-28 1991-07-09 Teijin Limited Cytotoxic antibody conjugates and a process for preparation thereof
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
WO1992020373A1 (en) 1991-05-14 1992-11-26 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
WO1993004701A1 (en) 1991-09-05 1993-03-18 University Of Connecticut Targeted delivery of poly- or oligonucleotides to cells
WO1994002602A1 (en) 1992-07-24 1994-02-03 Cell Genesys, Inc. Generation of xenogeneic antibodies
WO1994011026A2 (en) 1992-11-13 1994-05-26 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma
WO1995022618A1 (en) 1994-02-22 1995-08-24 Dana-Farber Cancer Institute Nucleic acid delivery system, method of synthesis and uses thereof
US5545807A (en) 1988-10-12 1996-08-13 The Babraham Institute Production of antibodies from transgenic animals
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5569825A (en) 1990-08-29 1996-10-29 Genpharm International Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
WO1996033735A1 (en) 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
US5939598A (en) 1990-01-12 1999-08-17 Abgenix, Inc. Method of making transgenic mice lacking endogenous heavy chains
WO1999053049A1 (en) 1998-04-15 1999-10-21 Abgenix, Inc. Epitope-driven human antibody production and gene expression profiling

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1907424E (en) * 2005-07-01 2015-10-09 Squibb & Sons Llc Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
JP2009055928A (en) 2005-12-19 2009-03-19 T S Tec Kk Skin-integrated foam-molded seat for vehicle
CN101104640A (en) * 2006-07-10 2008-01-16 苏州大学 Preparation for anti human PD-L1 monoclonal antibody and application thereof
EP3721903A1 (en) 2006-12-27 2020-10-14 Emory University Compositions and methods for the treatment of infections and tumors
EP3530672B1 (en) * 2008-09-26 2024-05-01 Dana-Farber Cancer Institute, Inc. Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses thereof
CA2992770A1 (en) * 2009-11-24 2011-06-03 Medimmune Limited Targeted binding agents against b7-h1
WO2016054638A1 (en) * 2014-10-03 2016-04-07 Dana-Farber Cancer Institute, Inc. Glucocorticoid-induced tumor necrosis factor receptor (gitr) antibodies and methods of use thereof
AU2015338974B2 (en) * 2014-10-31 2021-08-26 Oncomed Pharmaceuticals, Inc. Combination therapy for treatment of disease
IL252295B2 (en) * 2014-12-19 2023-10-01 Dana Farber Cancer Inst Inc Chimeric antigen receptors and methods of use thereof
MA41460A (en) * 2015-02-03 2017-12-12 Oncomed Pharm Inc TNFRSF LIAISON AGENTS AND THEIR USES
BR112017019559B1 (en) * 2015-03-13 2020-08-04 Cytomx Therapeutics, Inc ANTI-PDL1 ANTIBODIES, ACTIVABLE ANTI-PDL1 ANTIBODIES, AND METHODS OF USE OF THESE

Patent Citations (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
EP0003089A1 (en) 1978-01-06 1979-07-25 Bernard David Drier for silkscreen printed sheets
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5030719A (en) 1986-08-28 1991-07-09 Teijin Limited Cytotoxic antibody conjugates and a process for preparation thereof
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5545807A (en) 1988-10-12 1996-08-13 The Babraham Institute Production of antibodies from transgenic animals
WO1991000360A1 (en) 1989-06-29 1991-01-10 Medarex, Inc. Bispecific reagents for aids therapy
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5939598A (en) 1990-01-12 1999-08-17 Abgenix, Inc. Method of making transgenic mice lacking endogenous heavy chains
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5569825A (en) 1990-08-29 1996-10-29 Genpharm International Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
WO1992020373A1 (en) 1991-05-14 1992-11-26 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
WO1993004701A1 (en) 1991-09-05 1993-03-18 University Of Connecticut Targeted delivery of poly- or oligonucleotides to cells
WO1994002602A1 (en) 1992-07-24 1994-02-03 Cell Genesys, Inc. Generation of xenogeneic antibodies
WO1994011026A2 (en) 1992-11-13 1994-05-26 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma
WO1995022618A1 (en) 1994-02-22 1995-08-24 Dana-Farber Cancer Institute Nucleic acid delivery system, method of synthesis and uses thereof
WO1996033735A1 (en) 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
WO1999053049A1 (en) 1998-04-15 1999-10-21 Abgenix, Inc. Epitope-driven human antibody production and gene expression profiling

Non-Patent Citations (67)

* Cited by examiner, † Cited by third party
Title
"Advances In Parenteral Sciences", vol. 4, 1991, M. DEKKER, article "Peptide And Protein Drug Delivery"
"Drug Absorption Enhancement: Concepts, Possibilities, Limitations, And Trends", 1994, HARWOOD ACADEMIC PUBLISHERS
"ELISA: Theory and Practice: Methods in Molecular Biology", vol. 42, 1995, HUMAN PRESS
"Salk Institute Cell Distribution Center, San Diego", CALIFORNIA AND THE AMERICAN TYPE CULTURE COLLECTION
ALFONSO R. GENNARO, ET AL.: "Remington: The Science And Practice Of Pharmacy 19th ed.", 1995, MACK PUB. CO.
BARBAS ET AL., PROC. NATL. ACAD. SCI. USA, vol. 89, 1992, pages 9339 - 43
BOBO ET AL., PROC. NATL. ACAD. SCI. USA, vol. 91, 1994, pages 2076 - 2080
BRODEUR ET AL.: "Monoclonal Antibody Production Techniques and Applications", 1987, MARCEL DEKKER, INC., pages: 51 - 63
CARON ET AL., J. EXP MED., vol. 176, 1992, pages 1191 - 1195
COLE ET AL.: "MONOCLONAL ANTIBODIES AND CANCER THERAPY", 1985, ALAN R. LISS, INC., pages: 77 - 96
COQUET, J. M. ET AL., J IMMUNOL, vol. 178, 2008, pages 2827 - 2834
COTE ET AL., PROC NATL ACAD SCI USA, vol. 80, 1983, pages 2026 - 2030
CROTTY, S. ET AL., ANNUAL REVIEW OF IMMUNOLOGY, vol. 29, 2011, pages 621 - 623
D. WILKINSON: "The Scientist", vol. 14, 17 April 2000, THE SCIENTIST, INC., pages: 25 - 28
DARDALHON, V. ET AL., JOURNAL OF LEUKOCYTE BIOLOGY, vol. 185, 2012, pages 1383 - 1392
DAVIDSON ET AL., NAT. GENET, vol. 3, 1993, pages 219
DAVIES ET AL., ANNUAL REV BIOCHEM, vol. 59, 1990, pages 439 - 473
E. DIAMANDIS; T. CHRISTOPOULUS: "Immunoassay", 1996, ACADEMIC PRESS, INC.
EPSTEIN ET AL., PROC. NATL. ACAD. SCI. USA, vol. 82, 1985, pages 3688
FISHWILD ET AL., NATURE BIOTECHNOLOGY, vol. 14, 1996, pages 845 - 51
GELLER, A. 1. ET AL., J. NEUROCHEM, vol. 64, 1995, pages 487
GELLER, A. I. ET AL., PROC NATL. ACAD. SCI USA, vol. 87, pages 1149
GELLER, A. I. ET AL., PROC NATL. ACAD. SCI.: U.S.A., vol. 90, 1993, pages 7603
GODING: "Monoclonal Antibodies: Principles and Practice", 1986, ACADEMIC PRESS, pages: 59 - 103
GRUNWALD, V. ET AL., ACTA ONCOL, vol. 50, 2011, pages 121 - 126
HARLOW E; LANE D: "Antibodies: A Laboratory Manual", 1988, COLD SPRING HARBOR LABORATORY PRESS
HOOGENBOOM; WINTER, J. MOL. BIOL., vol. 227, 1991, pages 381
HUSE ET AL., SCIENCE, vol. 246, 1989, pages 1275 - 1281
HUSTON ET AL., PROC NAT ACAD SCI USA, vol. 85, no. 16, 1988, pages 5879 - 5883
HWANG ET AL., PROC. NATL ACAD. SCI. USA, vol. 77, 1980, pages 4030
J. M. CRUSE AND R. E. LEWIS, JR: "Contributions to Microbiology and Immunology", 1989, CARGER PRESS, article "Conjugate Vaccines"
JANSEN ET AL., IMMUNOLOGICAL REVIEWS, vol. 62, 1982, pages 185 - 216
KAPLITT, M. G. ET AL., NAT. GENET., vol. 8, 1994, pages 148
KASAIAN, M. T. ET AL., IMMUNITY, vol. 16, 2002, pages 559 - 569
KILLEN; LINDSTROM, JOUR. IMMUN., vol. 133, 1984, pages 1335 - 2549
KOHLER; MILSTEIN, NATURE, vol. 256, 1975, pages 495
KOZBOR ET AL., IMMUNOL TODAY, vol. 4, 1983, pages 72
KOZBOR, J. IMMUNOL., vol. 133, 1984, pages 3001
LABRIJN, A.F. ET AL., JOURNAL OF IMMUNOL, vol. 187, 2011, pages 3238 - 3246
LAM, ANTICANCER DRUG DES., vol. 12, 1997, pages 145
LEGAL LASALLE ET AL., SCIENCE, vol. 259, 1993, pages 988
LI, Y. ET AL., J IMMUNOL, vol. 175, 2005, pages 2261 - 2269
LIM, F. ET AL.: "DNA Cloning: Mammalian Systems", 1995, OXFORD UNIV. PRESS
LONBERG ET AL., NATURE, vol. 368, 1994, pages 856 - 859
LONBERG; HUSZAR, INTERN. REV. IMMUNOL., vol. 13, 1995, pages 65 - 93
MARASCO ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 7889 - 7893
MARKS ET AL., BIO/TECHNOLOGY, vol. 10, 1992, pages 779 - 783
MARKS ET AL., J. MOL. BIOL., vol. 222, 1991, pages 581
MARTIN ET AL., J. BIOL. CHEM., vol. 257, 1982, pages 286 - 288
MORRISON ET AL., AM. J. PHYSIOL., vol. 266, 1994, pages 292 - 305
MORRISON, NATURE, vol. 368, 1994, pages 812 - 13
MUNSON; POLLARD, ANAL. BIOCHEM., vol. 107, 1980, pages 220
NATURE, vol. 361, 1993, pages 186 - 87
NEUBERGER, NATURE BIOTECHNOLOGY, vol. 14, 1996, pages 826
P. TIJSSEN: "Practice and Theory of Enzyme Immunoassays", 1985, ELSEVIER SCIENCE PUBLISHERS
RAMAKRISHNAN, S. ET AL., CANCER RES., vol. 44, 1984, pages 201 - 208
RIDGWAY ET AL., PROTEIN ENG, vol. 7, 1996, pages 617 - 621
SAKUISHI, K. ET AL., THE JOURNAL OF EXPERIMENTAL MEDICINE, vol. 207, 2010, pages 2187 - 2194
SCHMIDT, H. ET AL., CLINICAL CANCER RESEARCH, vol. 16, 2010, pages 5312 - 5319
SHOPES, J. IMMUNOL., vol. 148, 1992, pages 2918 - 2922
SONDERGAARD, H ET AL., TISSUE ANTIGENS, vol. 74, 2009, pages 467 - 479
STEVENSON ET AL., ANTI-CANCER DRUG DESIGN, vol. 3, 1989, pages 219 - 230
VAN DER NEUT KOLFSCHOTEN, M. ET AL., SCIENCE, vol. 317, 2007, pages 1554 - 1557
VITETTA ET AL., SCIENCE, vol. 238, 1987, pages 1098
YANG ET AL., J. VIROL., vol. 69, 1995, pages 2004
ZEBEDEE ET AL., PROC. NATL. ACAD. SCI. USA, vol. 89, 1992, pages 3175 - 79
ZHANG, Y. ET AL., JOURNAL OF LEUKOCYTE BIOLOGY, vol. 91, 2012, pages 189 - 196

Cited By (368)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10875864B2 (en) 2011-07-21 2020-12-29 Sumitomo Dainippon Pharma Oncology, Inc. Substituted imidazo[1,2-B]pyridazines as protein kinase inhibitors
US11634506B2 (en) 2013-01-14 2023-04-25 Xencor, Inc. Heterodimeric proteins
US11814423B2 (en) 2013-03-15 2023-11-14 Xencor, Inc. Heterodimeric proteins
US9776978B2 (en) 2013-09-06 2017-10-03 Aurigene Discovery Technologies Limited 1,3,4-oxadiazole and 1,3,4-thiadiazole derivatives as immunomodulators
US10106581B2 (en) 2013-09-06 2018-10-23 Aurigene Discovery Technologies Limited Cyclic peptidomimetic compounds as immunomodulators
US11512060B2 (en) 2013-09-06 2022-11-29 Aurigene Discovery Technologies Limited 1,2,4-oxadiazole derivatives as immunomodulators
US10160736B2 (en) 2013-09-06 2018-12-25 Aurigene Discovery Technologies Limited 1,3,4-oxadiazole and 1,3,4-thiadiazole derivatives as immunomodulators
WO2015033301A1 (en) 2013-09-06 2015-03-12 Aurigene Discovery Technologies Limited 1,3,4-oxadiazole and 1,3,4-thiadiazole derivatives as immunomodulators
WO2015033303A1 (en) 2013-09-06 2015-03-12 Aurigene Discovery Technologies Limited Cyclic peptidomimetic compounds as immunomodulators
US9771338B2 (en) 2013-09-06 2017-09-26 Auirgene Discovery Technologies Limited 1,2,4-oxadiazole derivatives as immunomodulators
US10173989B2 (en) 2013-09-06 2019-01-08 Aurigene Discovery Technologies Limited 1,2,4-oxadiazole derivatives as immunomodulators
US12037321B2 (en) 2013-09-06 2024-07-16 Aurigene Oncology Limited 1,2,4-oxadiazole derivatives as immunomodulators
EP3385257A1 (en) 2013-09-06 2018-10-10 Aurigene Discovery Technologies Limited 1,3,4-oxadiazole and 1,3,4-thiadiazole derivatives as immunomodulators
WO2015033299A1 (en) 2013-09-06 2015-03-12 Aurigene Discovery Technologies Limited 1,2,4-oxadiazole derivatives as immunomodulators
EP3363790A1 (en) 2013-09-06 2018-08-22 Aurigene Discovery Technologies Limited 1,2,4-oxadiazole derivatives as immunomodulators
US10590093B2 (en) 2013-09-06 2020-03-17 Aurigene Discovery Technologies Limited 1,2,4-oxadiazole derivatives as immunomodulators
EP3366289A1 (en) 2013-09-06 2018-08-29 Aurigene Discovery Technologies Limited Cyclic peptidomimetic compounds as immunomodulators
US10961205B2 (en) 2013-09-06 2021-03-30 Aurigene Discovery Technologies Limited 1,2,4-oxadiazole derivatives as immunomodulators
US10519235B2 (en) 2013-09-13 2019-12-31 Beigene Switzerland Gmbh Anti-PD1 antibodies and their use as therapeutics and diagnostics
US11673951B2 (en) 2013-09-13 2023-06-13 Beigene Switzerland Gmbh Anti-PD1 antibodies and their use as therapeutics and diagnostics
US9834606B2 (en) 2013-09-13 2017-12-05 Beigene, Ltd Anti-PD1 antibodies and their use as therapeutics and diagnostics
US11186637B2 (en) 2013-09-13 2021-11-30 Beigene Switzerland Gmbh Anti-PD1 antibodies and their use as therapeutics and diagnostics
US9988450B2 (en) 2013-09-13 2018-06-05 Beigene Switzerland Gmbh Anti-PD1 antibodies and their use as therapeutics and diagnostics
US11708412B2 (en) 2013-09-26 2023-07-25 Novartis Ag Methods for treating hematologic cancers
US10570204B2 (en) 2013-09-26 2020-02-25 The Medical College Of Wisconsin, Inc. Methods for treating hematologic cancers
US10752687B2 (en) 2014-01-24 2020-08-25 Novartis Ag Antibody molecules to PD-1 and uses thereof
US11827704B2 (en) 2014-01-24 2023-11-28 Novartis Ag Antibody molecules to PD-1 and uses thereof
US10472419B2 (en) 2014-01-31 2019-11-12 Novartis Ag Antibody molecules to TIM-3 and uses thereof
US10981990B2 (en) 2014-01-31 2021-04-20 Novartis Ag Antibody molecules to TIM-3 and uses thereof
US11155620B2 (en) 2014-01-31 2021-10-26 Novartis Ag Method of detecting TIM-3 using antibody molecules to TIM-3
US11753479B2 (en) 2014-03-04 2023-09-12 Kymab Limited Nucleic acids encoding anti-OX40L antibodies
US11773175B2 (en) 2014-03-04 2023-10-03 Kymab Limited Antibodies, uses and methods
JP2017518769A (en) * 2014-06-12 2017-07-13 ウニヴェルシダージ ド ポルト − レイトリア Vaccines for immunocompromised hosts
US11066652B2 (en) 2014-06-12 2021-07-20 Universidade do Porto—Reitoria Vaccine for immunocompromised hosts
US11834684B2 (en) 2014-06-12 2023-12-05 Universidade do Porto—Reitoria Vaccine for immunocompromised hosts
WO2016000619A1 (en) * 2014-07-03 2016-01-07 Beigene, Ltd. Anti-pd-l1 antibodies and their use as therapeutics and diagnostics
CN110156892A (en) * 2014-07-03 2019-08-23 百济神州有限公司 Anti- PD-L1 antibody and its purposes as therapeutic agent and diagnosticum
CN106604742A (en) * 2014-07-03 2017-04-26 百济神州有限公司 Anti-PD-L1 antibodies and their use as therapeutics and diagnostics
US11512132B2 (en) 2014-07-03 2022-11-29 Beigene, Ltd. Anti-PD-L1 antibodies and their use as therapeutics and diagnostics
CN110156892B (en) * 2014-07-03 2023-05-16 百济神州有限公司 anti-PD-L1 antibodies and their use as therapeutic and diagnostic agents
US10544225B2 (en) 2014-07-03 2020-01-28 Beigene, Ltd. Anti-PD-L1 antibodies and their use as therapeutics and diagnostics
US10428146B2 (en) 2014-07-22 2019-10-01 Cb Therapeutics, Inc. Anti PD-1 antibodies
US11560429B2 (en) 2014-07-22 2023-01-24 Apollomics Inc. Anti PD-1 antibodies
US10981994B2 (en) 2014-07-22 2021-04-20 Apollomics Inc. Anti PD-1 antibodies
US10435470B2 (en) 2014-08-05 2019-10-08 Cb Therapeutics, Inc. Anti-PD-L1 antibodies
EP3177649A4 (en) * 2014-08-05 2018-04-25 CB Therapeutics, Inc. Anti-pd-l1 antibodies
US11827707B2 (en) 2014-08-05 2023-11-28 Apollomics Inc. Anti PD-L1 antibodies
US11111300B2 (en) 2014-08-05 2021-09-07 Apollomics Inc. Anti PD-L1 antibodies
US11344620B2 (en) 2014-09-13 2022-05-31 Novartis Ag Combination therapies
AU2015333687B2 (en) * 2014-10-14 2021-03-18 Dana-Farber Cancer Institute, Inc. Antibody molecules to PD-L1 and uses thereof
JP2017536099A (en) * 2014-10-14 2017-12-07 ノバルティス アーゲー Antibody molecule against PD-L1 and use thereof
KR102513870B1 (en) 2014-10-14 2023-03-23 노파르티스 아게 Antibody molecules to pd-l1 and uses thereof
US10851165B2 (en) 2014-10-14 2020-12-01 Novartis Ag Antibody molecules to PD-L1 and methods of treating cancer
US9988452B2 (en) 2014-10-14 2018-06-05 Novartis Ag Antibody molecules to PD-L1 and uses thereof
TWI716362B (en) * 2014-10-14 2021-01-21 瑞士商諾華公司 Antibody molecules to pd-l1 and uses thereof
WO2016061142A1 (en) * 2014-10-14 2016-04-21 Novartis Ag Antibody molecules to pd-l1 and uses thereof
KR20170069257A (en) * 2014-10-14 2017-06-20 노파르티스 아게 Antibody molecules to pd-l1 and uses thereof
EP4245376A3 (en) * 2014-10-14 2023-12-13 Novartis AG Antibody molecules to pd-l1 and uses thereof
WO2016070051A2 (en) 2014-10-31 2016-05-06 Oncomed Pharmaceuticals, Inc. Combination therapy for treatment of disease
US11859011B2 (en) 2014-11-26 2024-01-02 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
US11673972B2 (en) 2014-11-26 2023-06-13 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
US11945880B2 (en) 2014-11-26 2024-04-02 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
US12129309B2 (en) 2014-11-26 2024-10-29 Xencor, Inc. Heterodimeric antibodies that bind CD3 and CD38
JP2018504894A (en) * 2014-12-19 2018-02-22 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Chimeric antigen receptor and method of use thereof
US10517949B2 (en) 2015-01-09 2019-12-31 Agency For Science, Technology And Research Anti-PD-L1 antibodies
US11534489B2 (en) 2015-01-09 2022-12-27 Agency For Science, Technology And Research Anti-PD-L1 antibodies
US9789183B1 (en) 2015-01-09 2017-10-17 Agency For Science, Technology And Research Anti-PD-L1 antibodies
EP3572432A1 (en) 2015-01-28 2019-11-27 GlaxoSmithKline Intellectual Property Development Limited Icos binding proteins
EP3575324A1 (en) 2015-01-28 2019-12-04 GlaxoSmithKline Intellectual Property Development Limited Icos binding proteins
WO2016120789A1 (en) 2015-01-28 2016-08-04 Glaxosmithkline Intellectual Property Development Limited Agonistic icos binding proteins
EP4023645A1 (en) 2015-03-10 2022-07-06 Aurigene Discovery Technologies Limited 1,2,4-oxadiazole and thiadiazole compounds as immunomodulators
WO2016142833A1 (en) 2015-03-10 2016-09-15 Aurigene Discovery Technologies Limited 1,2,4-oxadiazole and thiadiazole compounds as immunomodulators
US10781189B2 (en) 2015-03-10 2020-09-22 Aurigene Discovery Technologies Limited 1,2,4-Oxadiazole and thiadiazole compounds as immunomodulators
US11465976B2 (en) 2015-03-10 2022-10-11 Aurigene Discovery Technologies Limited 1,2,4-oxadiazole and thiadiazole compounds as immunomodulators
US10336824B2 (en) 2015-03-13 2019-07-02 Cytomx Therapeutics, Inc. Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of thereof
WO2016149201A2 (en) 2015-03-13 2016-09-22 Cytomx Therapeutics, Inc. Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof
US10669339B2 (en) 2015-03-13 2020-06-02 Cytomx Therapeutics, Inc. Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of use thereof
US11174316B2 (en) 2015-03-13 2021-11-16 Cytomx Therapeutics, Inc. Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of use thereof
JP2021129572A (en) * 2015-03-30 2021-09-09 エスティーキューブ，インコーポレイテッド Antibodies specific to glycosylated pd-l1 and methods of use thereof
US11933786B2 (en) 2015-03-30 2024-03-19 Stcube, Inc. Antibodies specific to glycosylated PD-L1 and methods of use thereof
EP3277320A4 (en) * 2015-03-30 2018-08-01 Stcube, Inc. Antibodies specific to glycosylated pd-l1 and methods of use thereof
US10836827B2 (en) 2015-03-30 2020-11-17 Stcube, Inc. Antibodies specific to glycosylated PD-L1 and methods of use thereof
JP2018512175A (en) * 2015-03-30 2018-05-17 エスティーキューブ，インコーポレイテッド Antibodies specific for glycosylated PD-L1 and methods of use thereof
US10479833B2 (en) 2015-05-29 2019-11-19 Agenus Inc. Anti-CTLA-4 antibodies and methods of use thereof
US11267889B2 (en) 2015-05-29 2022-03-08 Agenus Inc. Anti-CTLA-4 antibodies and methods of use thereof
EP3736290A1 (en) 2015-05-29 2020-11-11 Agenus Inc. Anti-ctla-4 antibodies and methods of use thereof
US10144779B2 (en) 2015-05-29 2018-12-04 Agenus Inc. Anti-CTLA-4 antibodies and methods of use thereof
US10696745B2 (en) 2015-06-11 2020-06-30 Wuxi Biologics (Shanghai) Co. Ltd. Anti-PD-L1 antibodies
WO2016197367A1 (en) 2015-06-11 2016-12-15 Wuxi Biologics (Shanghai) Co. Ltd. Novel anti-pd-l1 antibodies
EP3307777A4 (en) * 2015-06-11 2019-02-13 Wuxi Biologics (Shanghai) Co. Ltd. Novel anti-pd-l1 antibodies
RU2736151C2 (en) * 2015-08-06 2020-11-12 Уси Байолоджикс (Шанхай) Ко. Лтд. Novel anti-pd-l1 antibodies
US10981995B2 (en) 2015-08-06 2021-04-20 Wuxi Biologies Ireland Limited Anti-PD-L1 antibodies
WO2017020858A1 (en) * 2015-08-06 2017-02-09 Wuxi Biologics (Shanghai) Co. Ltd. Novel anti-pd-l1 antibodies
EP3332006A4 (en) * 2015-08-06 2019-01-09 Wuxi Biologics (Shanghai) Co. Ltd. Novel anti-pd-l1 antibodies
WO2017025871A1 (en) 2015-08-07 2017-02-16 Glaxosmithkline Intellectual Property Development Limited Combination therapy comprising anti ctla-4 antibodies
US10214586B2 (en) 2015-08-24 2019-02-26 Eli Lilly And Company PD-L1 antibodies
WO2017055484A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for determining the metabolic status of lymphomas
US10815304B2 (en) 2015-11-17 2020-10-27 Suzhou Suncadia Biopharmaceuticals Co., Ltd. PD-L1 antibody, antigen-binding fragment thereof and medical application thereof
WO2017084495A1 (en) * 2015-11-17 2017-05-26 江苏恒瑞医药股份有限公司 Pd-l1 antibody, antigen fragment binding thereof and pharmaceutical use thereof
US11780923B2 (en) 2015-11-17 2023-10-10 Suzhou Suncadia Biopharmaceuticals Co., Ltd. PD-L1 antibody, antigen-binding fragment thereof and medical application thereof
WO2017093942A1 (en) 2015-12-01 2017-06-08 Glaxosmithkline Intellectual Property Development Limited Combination treatments and uses and methods thereof
EP4015537A1 (en) 2015-12-01 2022-06-22 GlaxoSmithKline Intellectual Property Development Limited Combination treatments and uses and methods thereof
US10858432B2 (en) 2015-12-02 2020-12-08 Stcube, Inc. Antibodies specific to glycosylated PD-1 and methods of use thereof
US11981736B2 (en) 2015-12-02 2024-05-14 St Cube Inc. Antibodies specific to glycosylated PD-1 and methods of use thereof
WO2017093933A1 (en) 2015-12-03 2017-06-08 Glaxosmithkline Intellectual Property Development Limited Cyclic purine dinucleotides as modulators of sting
EP3366691A1 (en) 2015-12-03 2018-08-29 GlaxoSmithKline Intellectual Property Development Limited Cyclic purine dinucleotides as modulators of sting
WO2017098421A1 (en) 2015-12-08 2017-06-15 Glaxosmithkline Intellectual Property Development Limited Benzothiadiazine compounds
WO2017118634A1 (en) 2016-01-04 2017-07-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of pd-1 and tim-3 as a measure for cd8+ cells in predicting and treating renal cell carcinoma
WO2017153952A1 (en) 2016-03-10 2017-09-14 Glaxosmithkline Intellectual Property Development Limited 5-sulfamoyl-2-hydroxybenzamide derivatives
US11753473B2 (en) 2016-03-23 2023-09-12 Suzhou Transcenta Therapeutics Co., Ltd. Anti-PD-L1 antibodies
CN111363041B (en) * 2016-03-23 2022-02-22 苏州创胜医药集团有限公司 Novel anti-PD-L1 antibodies
CN111363041A (en) * 2016-03-23 2020-07-03 迈博斯生物医药(苏州)有限公司 Novel anti-PD-L1 antibodies
US11660352B2 (en) 2016-03-29 2023-05-30 Stcube, Inc. Dual function antibodies specific to glycosylated PD-L1 and methods of use thereof
US12059474B2 (en) 2016-03-29 2024-08-13 Stcube & Co., Inc. Methods for selecting antibodies that specifically bind glycosylated immune checkpoint proteins
WO2017175156A1 (en) 2016-04-07 2017-10-12 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides useful as protein modulators
WO2017175147A1 (en) 2016-04-07 2017-10-12 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides useful as protein modulators
EP4032885A1 (en) 2016-04-07 2022-07-27 GlaxoSmithKline Intellectual Property Development Limited Heterocyclic amides useful as protein modulators
WO2017191545A1 (en) 2016-05-05 2017-11-09 Glaxosmithkline Intellectual Property (No.2) Limited Enhancer of zeste homolog 2 inhibitors
WO2017205721A1 (en) 2016-05-27 2017-11-30 Agenus Inc. Anti-tim-3 antibodies and methods of use thereof
WO2017212423A1 (en) 2016-06-08 2017-12-14 Glaxosmithkline Intellectual Property Development Limited Chemcical compounds
WO2017212425A1 (en) 2016-06-08 2017-12-14 Glaxosmithkline Intellectual Property Development Limited Chemical compounds as atf4 pathway inhibitors
WO2017218533A1 (en) 2016-06-13 2017-12-21 Torque Therapeutics, Inc. Methods and compositions for promoting immune cell function
WO2017220989A1 (en) 2016-06-20 2017-12-28 Kymab Limited Anti-pd-l1 and il-2 cytokines
US9957323B2 (en) 2016-06-20 2018-05-01 Kymab Limited Anti-ICOS antibodies
US11965026B2 (en) 2016-06-20 2024-04-23 Kymab Limited Anti-PD-L1 and IL-2 cytokines
US10604576B2 (en) 2016-06-20 2020-03-31 Kymab Limited Antibodies and immunocytokines
WO2017220988A1 (en) 2016-06-20 2017-12-28 Kymab Limited Multispecific antibodies for immuno-oncology
WO2017220990A1 (en) 2016-06-20 2017-12-28 Kymab Limited Anti-pd-l1 antibodies
US12054545B2 (en) 2016-06-28 2024-08-06 Xencor, Inc. Heterodimeric antibodies that bind somatostatin receptor 2
WO2018005682A3 (en) * 2016-06-29 2018-02-08 Checkpoint Therapeutics, Inc. Pd-l1-specific antibodies and methods of using the same
US10590199B2 (en) 2016-06-29 2020-03-17 Checkpoint Therapeutics, Inc. PD-L1-specific antibodies and methods of using the same
US11834505B2 (en) 2016-06-29 2023-12-05 Checkpoint Therapeutics, Inc. PD-L1-specific antibodies and methods of using the same
WO2018005682A2 (en) 2016-06-29 2018-01-04 Checkpoint Therapeutics, Inc. Pd-l1-specific antibodies and methods of using the same
US10864203B2 (en) 2016-07-05 2020-12-15 Beigene, Ltd. Combination of a PD-1 antagonist and a RAF inhibitor for treating cancer
US11534431B2 (en) 2016-07-05 2022-12-27 Beigene Switzerland Gmbh Combination of a PD-1 antagonist and a RAF inhibitor for treating cancer
US11746152B2 (en) 2016-07-20 2023-09-05 Stcube, Inc. Methods of cancer treatment and therapy using a combination of antibodies that bind glycosylated PD-L1
WO2018015879A1 (en) 2016-07-20 2018-01-25 Glaxosmithkline Intellectual Property Development Limited Isoquinoline derivatives as perk inhibitors
US11858996B2 (en) 2016-08-09 2024-01-02 Kymab Limited Anti-ICOS antibodies
WO2018029474A2 (en) 2016-08-09 2018-02-15 Kymab Limited Anti-icos antibodies
US11701357B2 (en) 2016-08-19 2023-07-18 Beigene Switzerland Gmbh Treatment of B cell cancers using a combination comprising Btk inhibitors
US10844119B2 (en) 2016-10-11 2020-11-24 Agenus Inc. Anti-LAG-3 antibodies and methods of use thereof
US11993651B2 (en) 2016-10-11 2024-05-28 Agenus Inc. Anti-lag-3 antibodies and methods of use thereof
US10882908B2 (en) 2016-10-11 2021-01-05 Agenus Inc. Anti-LAG-3 antibodies and methods of use thereof
WO2018071500A1 (en) 2016-10-11 2018-04-19 Agenus Inc. Anti-lag-3 antibodies and methods of use thereof
WO2018071913A2 (en) 2016-10-14 2018-04-19 Dana-Farber Cancer Institute, Inc. Modular tetrameric bispecific antibody platform
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
US11279694B2 (en) 2016-11-18 2022-03-22 Sumitomo Dainippon Pharma Oncology, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
WO2018100534A1 (en) 2016-12-01 2018-06-07 Glaxosmithkline Intellectual Property Development Limited Combination therapy
WO2018100535A1 (en) 2016-12-01 2018-06-07 Glaxosmithkline Intellectual Property Development Limited Combination therapy
US11638755B2 (en) 2016-12-07 2023-05-02 Agenus Inc. Anti-CTLA-4 antibodies and methods of use thereof
WO2018106864A1 (en) 2016-12-07 2018-06-14 Agenus Inc. Antibodies and methods of use thereof
EP4289484A2 (en) 2016-12-07 2023-12-13 Agenus Inc. Anti-ctla-4 antibodies and methods of use thereof
WO2018106862A1 (en) 2016-12-07 2018-06-14 Agenus Inc. Anti-ctla-4 antibodies and methods of use thereof
US10912831B1 (en) 2016-12-07 2021-02-09 Agenus Inc. Anti-CTLA-4 antibodies and methods of use thereof
US11013802B2 (en) 2016-12-07 2021-05-25 Agenus Inc. Anti-CTLA-4 antibodies and methods of use thereof
WO2018132739A2 (en) 2017-01-13 2018-07-19 Agenus Inc. T cell receptors that bind to ny-eso-1 and methods of use thereof
US11555038B2 (en) 2017-01-25 2023-01-17 Beigene, Ltd. Crystalline forms of (S)-7-(1-(but-2-ynoyl)piperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
CN106699891A (en) * 2017-01-25 2017-05-24 北京天广实生物技术股份有限公司 Anti-PD-L1 antibody as well as pharmaceutical composition and application of anti-PD-L1 antibody
EP4389226A2 (en) 2017-02-24 2024-06-26 MacroGenics, Inc. Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof
US11942149B2 (en) 2017-02-24 2024-03-26 Macrogenics, Inc. Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof
US11459394B2 (en) 2017-02-24 2022-10-04 Macrogenics, Inc. Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof
WO2018154520A1 (en) 2017-02-27 2018-08-30 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides as kinase inhibitors
WO2018172508A1 (en) 2017-03-24 2018-09-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating melanoma
JP2019522624A (en) * 2017-04-11 2019-08-15 イーライ リリー アンド カンパニー Anti-PD-L1-anti-TIM-3 bispecific antibody
US11351251B2 (en) 2017-04-11 2022-06-07 Eli Lilly And Company Anti-PD-L1-anti-TIM-3 bispecific antibodies
KR102261582B1 (en) 2017-04-11 2021-06-08 일라이 릴리 앤드 캄파니 Anti-PD-L1-anti-TIM-3 bispecific antibody
WO2018191074A1 (en) * 2017-04-11 2018-10-18 Eli Lilly And Company Anti-pd-l1-anti-tim-3 bispecific antibodies
KR20190127791A (en) * 2017-04-11 2019-11-13 일라이 릴리 앤드 캄파니 Anti-PD-L1-anti-TIM-3 bispecific antibody
US10279034B2 (en) 2017-04-11 2019-05-07 Eli Lilly And Company Anti-PD-L1-anti-TIM-3 bispecific antibodies
WO2018191502A2 (en) 2017-04-13 2018-10-18 Agenus Inc. Anti-cd137 antibodies and methods of use thereof
US11236167B2 (en) 2017-04-17 2022-02-01 Joint Stock Company “Biocad” Monoclonal antibody to PD-L1
EP3613770A4 (en) * 2017-04-17 2021-01-27 Joint Stock Company "Biocad" Monoclonal antibody to pd-l1
WO2018198091A1 (en) 2017-04-28 2018-11-01 Novartis Ag Antibody conjugates comprising toll-like receptor agonist and combination therapies
EP4275698A2 (en) 2017-05-01 2023-11-15 Agenus Inc. Anti-tigit antibodies and methods of use thereof
WO2018204363A1 (en) 2017-05-01 2018-11-08 Agenus Inc. Anti-tigit antibodies and methods of use thereof
EP3630148A4 (en) * 2017-05-26 2021-06-16 The Johns Hopkins University Multifunctional antibody-ligand traps to modulate immune tolerance
US11168144B2 (en) 2017-06-01 2021-11-09 Cytomx Therapeutics, Inc. Activatable anti-PDL1 antibodies, and methods of use thereof
EP3634994A4 (en) * 2017-06-05 2021-06-30 Janssen Biotech, Inc. Methods of engineering surface charge for bispecific antibody production
US11192951B2 (en) 2017-06-05 2021-12-07 Janseen Biotech, Inc. Methods of engineering surface charge for bispecific antibody production
WO2018225093A1 (en) 2017-06-07 2018-12-13 Glaxosmithkline Intellectual Property Development Limited Chemical compounds as atf4 pathway inhibitors
WO2018225033A1 (en) 2017-06-09 2018-12-13 Glaxosmithkline Intellectual Property Development Limited Combination therapy
WO2018229715A1 (en) 2017-06-16 2018-12-20 Novartis Ag Compositions comprising anti-cd32b antibodies and methods of use thereof
US11440960B2 (en) 2017-06-20 2022-09-13 Kymab Limited TIGIT antibodies, encoding nucleic acids and methods of using said antibodies in vivo
WO2018234879A1 (en) 2017-06-22 2018-12-27 Novartis Ag Il-1beta binding antibodies for use in treating cancer
WO2018235056A1 (en) 2017-06-22 2018-12-27 Novartis Ag Il-1beta binding antibodies for use in treating cancer
WO2018237173A1 (en) 2017-06-22 2018-12-27 Novartis Ag Antibody molecules to cd73 and uses thereof
WO2018237157A1 (en) 2017-06-22 2018-12-27 Novartis Ag Antibody molecules to cd73 and uses thereof
US11597768B2 (en) 2017-06-26 2023-03-07 Beigene, Ltd. Immunotherapy for hepatocellular carcinoma
WO2019006007A1 (en) 2017-06-27 2019-01-03 Novartis Ag Dosage regimens for anti-tim-3 antibodies and uses thereof
WO2019008506A1 (en) 2017-07-03 2019-01-10 Glaxosmithkline Intellectual Property Development Limited N-(3-(2-(4-chlorophenoxy)acetamido)bicyclo[1.1.1]pentan-1-yl)-2-cyclobutane-1-carboxamide derivatives and related compounds as atf4 inhibitors for treating cancer and other diseases
WO2019008507A1 (en) 2017-07-03 2019-01-10 Glaxosmithkline Intellectual Property Development Limited 2-(4-chlorophenoxy)-n-((1 -(2-(4-chlorophenoxy)ethynazetidin-3-yl)methyl)acetamide derivatives and related compounds as atf4 inhibitors for treating cancer and other diseases
WO2019018730A1 (en) 2017-07-20 2019-01-24 Novartis Ag Dosage regimens of anti-lag-3 antibodies and uses thereof
WO2019021208A1 (en) 2017-07-27 2019-01-31 Glaxosmithkline Intellectual Property Development Limited Indazole derivatives useful as perk inhibitors
WO2019046856A1 (en) 2017-09-04 2019-03-07 Agenus Inc. T cell receptors that bind to mixed lineage leukemia (mll)-specific phosphopeptides and methods of use thereof
WO2019049061A1 (en) 2017-09-07 2019-03-14 Glaxosmithkline Intellectual Property Development Limited 5-(1 h-benzo[d]imidazo-2-yl)-pyridin-2-amine and 5-(3h-imidazo[4,5-b]pyridin-6-yl)-pyridin-2-amine derivatives as c-myc and p300/cbp histone acetyltransferase inhibitors for treating cancer
US11497756B2 (en) 2017-09-12 2022-11-15 Sumitomo Pharma Oncology, Inc. Treatment regimen for cancers that are insensitive to BCL-2 inhibitors using the MCL-1 inhibitor alvocidib
WO2019053617A1 (en) 2017-09-12 2019-03-21 Glaxosmithkline Intellectual Property Development Limited Chemical compounds
US11939306B2 (en) 2017-09-29 2024-03-26 Curis, Inc. Crystal forms of immunomodulators
US11040948B2 (en) 2017-09-29 2021-06-22 Curis, Inc. Crystal forms of immunomodulators
US11643401B2 (en) 2017-09-29 2023-05-09 Curis, Inc. Crystal forms of immunomodulators
WO2019069269A1 (en) 2017-10-05 2019-04-11 Glaxosmithkline Intellectual Property Development Limited Modulators of stimulator of interferon genes (sting) useful in treating hiv
WO2019069270A1 (en) 2017-10-05 2019-04-11 Glaxosmithkline Intellectual Property Development Limited Modulators of stimulator of interferon genes (sting)
US11136300B2 (en) 2017-10-11 2021-10-05 Aurigene Discovery Technologies Limited Crystalline forms of 3-substituted 1,2,4-oxadiazole
US11680051B2 (en) 2017-10-11 2023-06-20 Aurigene Discovery Technologies Limited Crystalline forms of 3-substituted 1,2,4-oxadiazole
WO2019081983A1 (en) 2017-10-25 2019-05-02 Novartis Ag Antibodies targeting cd32b and methods of use thereof
US11497734B2 (en) 2017-11-03 2022-11-15 Aurigene Discovery Technologies Limited Dual inhibitors of TIM-3 and PD-1 pathways
US12064418B2 (en) 2017-11-06 2024-08-20 Curis, Inc. Conjoint therapies for immunomodulation
US11497735B2 (en) 2017-11-06 2022-11-15 Aurigene Discovery Technologies Limited Conjoint therapies for immunomodulation
US11786529B2 (en) 2017-11-29 2023-10-17 Beigene Switzerland Gmbh Treatment of indolent or aggressive B-cell lymphomas using a combination comprising BTK inhibitors
WO2019108900A1 (en) 2017-11-30 2019-06-06 Novartis Ag Bcma-targeting chimeric antigen receptor, and uses thereof
WO2019114235A1 (en) * 2017-12-11 2019-06-20 苏州银河生物医药有限公司 Pdl1 monoclonal antibody and application thereof
US11629189B2 (en) 2017-12-19 2023-04-18 Kymab Limited Bispecific antibody for ICOS and PD-L1
WO2019122884A1 (en) 2017-12-19 2019-06-27 Kymab Limited Antibodies to icos
EP3733706A4 (en) * 2017-12-27 2021-11-03 Pharmabcine Inc. Anti-pd-l1 antibody and use thereof
WO2019134946A1 (en) 2018-01-04 2019-07-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating melanoma resistant
WO2019136432A1 (en) 2018-01-08 2019-07-11 Novartis Ag Immune-enhancing rnas for combination with chimeric antigen receptor therapy
WO2019137397A1 (en) 2018-01-10 2019-07-18 江苏恒瑞医药股份有限公司 Pd-l1 antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
US11359021B2 (en) 2018-01-10 2022-06-14 Jiangsu Hengrui Medicine Co., Ltd. PD-L1 antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
WO2019148036A1 (en) 2018-01-26 2019-08-01 Exelixis, Inc. Compounds for the treatment of kinase-dependent disorders
WO2019148044A1 (en) 2018-01-26 2019-08-01 Exelixis, Inc. Compounds for the treatment of kinase-dependent disorders
WO2019148043A1 (en) 2018-01-26 2019-08-01 Exelixis, Inc. Compounds for the treatment of kinase-dependent disorders
WO2019152660A1 (en) 2018-01-31 2019-08-08 Novartis Ag Combination therapy using a chimeric antigen receptor
WO2019160956A1 (en) 2018-02-13 2019-08-22 Novartis Ag Chimeric antigen receptor therapy in combination with il-15r and il15
WO2019162325A1 (en) 2018-02-21 2019-08-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of sk1 as biomarker for predicting response to immunecheckpoint inhibitors
WO2019193541A1 (en) 2018-04-06 2019-10-10 Glaxosmithkline Intellectual Property Development Limited Bicyclic aromatic ring derivatives of formula (i) as atf4 inhibitors
WO2019193540A1 (en) 2018-04-06 2019-10-10 Glaxosmithkline Intellectual Property Development Limited Heteroaryl derivatives of formula (i) as atf4 inhibitors
EP3778635A4 (en) * 2018-04-09 2022-01-26 Origincell Therapeutics Co., Ltd. Anti-pd-l1 antibody and use thereof
US11993655B2 (en) 2018-04-09 2024-05-28 Oricell Therapeutics Co., Ltd. Anti-PD-L1 antibody and use thereof
WO2019200229A1 (en) 2018-04-13 2019-10-17 Novartis Ag Dosage regimens for anti-pd-l1 antibodies and uses thereof
WO2019210055A2 (en) 2018-04-26 2019-10-31 Agenus Inc. Heat shock protein-binding peptide compositions and methods of use thereof
WO2019219820A1 (en) 2018-05-16 2019-11-21 Ctxt Pty Limited Substituted condensed thiophenes as modulators of sting
US11613525B2 (en) 2018-05-16 2023-03-28 Ctxt Pty Limited Substituted condensed thiophenes as modulators of sting
WO2019229658A1 (en) 2018-05-30 2019-12-05 Novartis Ag Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
WO2019232244A2 (en) 2018-05-31 2019-12-05 Novartis Ag Antibody molecules to cd73 and uses thereof
WO2019229701A2 (en) 2018-06-01 2019-12-05 Novartis Ag Binding molecules against bcma and uses thereof
WO2020012339A1 (en) 2018-07-09 2020-01-16 Glaxosmithkline Intellectual Property Development Limited Chemical compounds
WO2020012334A1 (en) 2018-07-10 2020-01-16 Novartis Ag 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and their use in the treatment of ikaros family zinc finger 2 (ikzf2)-dependent diseases
WO2020012337A1 (en) 2018-07-10 2020-01-16 Novartis Ag 3-(5-amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and their use in the treatment of i karos family zinc finger 2 (ikzf2)-dependent diseases
EP4306111A2 (en) 2018-07-10 2024-01-17 Novartis AG 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
WO2020031107A1 (en) 2018-08-08 2020-02-13 Glaxosmithkline Intellectual Property Development Limited Chemical compounds
WO2020044206A1 (en) 2018-08-29 2020-03-05 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides as kinase inhibitors for use in the treatment cancer
WO2020086476A1 (en) 2018-10-22 2020-04-30 Glaxosmithkline Intellectual Property Development Limited Dosing
WO2020086479A1 (en) 2018-10-22 2020-04-30 Glaxosmithkline Intellectual Property Development Limited Dosing
WO2020089811A1 (en) 2018-10-31 2020-05-07 Novartis Ag Dc-sign antibody drug conjugates
WO2020102804A2 (en) 2018-11-16 2020-05-22 Arqule, Inc. Pharmaceutical combination for treatment of cancer
WO2020104479A1 (en) 2018-11-20 2020-05-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating cancers and resistant cancers with anti transferrin receptor 1 antibodies
WO2020104496A1 (en) 2018-11-20 2020-05-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Bispecific antibody targeting transferrin receptor 1 and soluble antigen
WO2020110056A1 (en) 2018-11-30 2020-06-04 Glaxosmithkline Intellectual Property Development Limited Compounds useful in hiv therapy
EP4342473A2 (en) 2018-11-30 2024-03-27 GlaxoSmithKline Intellectual Property Development Limited Compounds useful in hiv therapy
US11530231B2 (en) 2018-12-04 2022-12-20 Sumitomo Pharma Oncology, Inc. CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
US12077554B2 (en) 2018-12-04 2024-09-03 Sumitomo Pharma Oncology, Inc. CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
US11034710B2 (en) 2018-12-04 2021-06-15 Sumitomo Dainippon Pharma Oncology, Inc. CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
WO2020117988A1 (en) 2018-12-04 2020-06-11 Tolero Pharmaceuticals, Inc. Cdk9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
WO2020115261A1 (en) 2018-12-07 2020-06-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating melanoma
WO2020120592A1 (en) 2018-12-12 2020-06-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for predicting and treating melanoma
WO2020123800A1 (en) 2018-12-13 2020-06-18 Exelixis, Inc. Crystalline forms and salt forms of a kinase inhibitor
WO2020127411A1 (en) 2018-12-19 2020-06-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating cancers by immuno-modulation using antibodies against cathespin-d
WO2020128972A1 (en) 2018-12-20 2020-06-25 Novartis Ag Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
WO2020128613A1 (en) 2018-12-21 2020-06-25 Novartis Ag Use of il-1beta binding antibodies
WO2020128637A1 (en) 2018-12-21 2020-06-25 Novartis Ag Use of il-1 binding antibodies in the treatment of a msi-h cancer
WO2020128636A1 (en) 2018-12-21 2020-06-25 Novartis Ag Use of il-1 beta antibodies in the treatment or prevention of myelodysplastic syndrome
WO2020127885A1 (en) 2018-12-21 2020-06-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions for treating cancers and resistant cancers
WO2020132560A2 (en) 2018-12-21 2020-06-25 Aim Immunotech Inc. Compositions and methods for cancer therapy
WO2020127965A1 (en) 2018-12-21 2020-06-25 Onxeo New conjugated nucleic acid molecules and their uses
WO2020128620A1 (en) 2018-12-21 2020-06-25 Novartis Ag Use of il-1beta binding antibodies
WO2020154610A1 (en) 2019-01-25 2020-07-30 Exelixis, Inc. Compounds for the treatment of kinase-dependent disorders
WO2020157131A1 (en) 2019-01-30 2020-08-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for identifying whether a subject suffering from a cancer will achieve a response with an immune-checkpoint inhibitor
WO2020160375A1 (en) 2019-02-01 2020-08-06 Glaxosmithkline Intellectual Property Development Limited Combination treatments for cancer comprising belantamab mafodotin and an anti ox40 antibody and uses and methods thereof
WO2020160365A1 (en) 2019-02-01 2020-08-06 Glaxosmithkline Intellectual Property Development Limited Belantamab mafodotin in combination with pembrolizumab for treating cancer
WO2020161083A1 (en) 2019-02-04 2020-08-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for modulating blood-brain barrier
US11471456B2 (en) 2019-02-12 2022-10-18 Sumitomo Pharma Oncology, Inc. Formulations comprising heterocyclic protein kinase inhibitors
WO2020167990A1 (en) 2019-02-12 2020-08-20 Tolero Pharmaceuticals, Inc. Formulations comprising heterocyclic protein kinase inhibitors
WO2020165370A1 (en) 2019-02-13 2020-08-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for selecting a cancer treatment in a subject suffering from cancer
WO2020165834A1 (en) 2019-02-15 2020-08-20 Novartis Ag Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
WO2020165833A1 (en) 2019-02-15 2020-08-20 Novartis Ag 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
US12006345B2 (en) 2019-02-21 2024-06-11 Xencor, Inc. Untargeted and targeted IL-10 Fc-fusion proteins
US11793802B2 (en) 2019-03-20 2023-10-24 Sumitomo Pharma Oncology, Inc. Treatment of acute myeloid leukemia (AML) with venetoclax failure
US11712433B2 (en) 2019-03-22 2023-08-01 Sumitomo Pharma Oncology, Inc. Compositions comprising PKM2 modulators and methods of treatment using the same
WO2020198077A1 (en) 2019-03-22 2020-10-01 Sumitomo Dainippon Pharma Oncology, Inc. Compositions comprising pkm2 modulators and methods of treatment using the same
IL281397A (en) * 2019-04-26 2021-04-29 I Mab Biopharma Us Ltd Human pd-l1 antibodies
WO2020216379A1 (en) * 2019-04-26 2020-10-29 I-Mab Human pd-l1 antibodies
US11208486B2 (en) 2019-04-26 2021-12-28 I-Mab Biopharma Us Limited Human PD-L1 antibodies
WO2020221796A1 (en) 2019-04-30 2020-11-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating melanoma
WO2020232375A1 (en) 2019-05-16 2020-11-19 Silicon Swat, Inc. Oxoacridinyl acetic acid derivatives and methods of use
WO2020232378A1 (en) 2019-05-16 2020-11-19 Silicon Swat, Inc. Benzo[b][1,8]naphthyridine acetic acid derivatives and methods of use
WO2020247019A1 (en) 2019-06-03 2020-12-10 Exelixis, Inc. Crystalline salt forms of a kinase inhibitor
WO2020247418A1 (en) 2019-06-04 2020-12-10 Exelixis, Inc. Compounds for the treatment of kinase-dependent disorders
WO2020261097A1 (en) 2019-06-26 2020-12-30 Glaxosmithkline Intellectual Property Development Limited Il1rap binding proteins
US11529350B2 (en) 2019-07-03 2022-12-20 Sumitomo Pharma Oncology, Inc. Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof
WO2021003417A1 (en) 2019-07-03 2021-01-07 Sumitomo Dainippon Pharma Oncology, Inc. Tyrosine kinase non-receptor 1 (tnk1) inhibitors and uses thereof
WO2021009267A1 (en) 2019-07-15 2021-01-21 Capella Bioscience Ltd Anti-pd-l1 antibodies
WO2021009365A1 (en) 2019-07-18 2021-01-21 Ctxt Pty Limited Benzothiophene, thienopyridine and thienopyrimidine derivatives for the modulation of sting
WO2021009362A1 (en) 2019-07-18 2021-01-21 Ctxt Pty Limited Benzothiophene, thienopyridine and thienopyrimidine derivatives for the modulation of sting
WO2021042019A1 (en) 2019-08-30 2021-03-04 Agenus Inc. Anti-cd96 antibodies and methods of use thereof
WO2021043961A1 (en) 2019-09-06 2021-03-11 Glaxosmithkline Intellectual Property Development Limited Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and chemotherapy
WO2021048292A1 (en) 2019-09-11 2021-03-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating melanoma
WO2021053559A1 (en) 2019-09-18 2021-03-25 Novartis Ag Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
WO2021053560A1 (en) 2019-09-18 2021-03-25 Novartis Ag Combination therapy with entpd2 and cd73 antibodies
WO2021058711A2 (en) 2019-09-27 2021-04-01 Glaxosmithkline Intellectual Property Development Limited Antigen binding proteins
WO2021064180A1 (en) 2019-10-03 2021-04-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for modulating macrophages polarization
WO2021074391A1 (en) 2019-10-17 2021-04-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing nasal intestinal type adenocarcinomas
WO2021079195A1 (en) 2019-10-21 2021-04-29 Novartis Ag Tim-3 inhibitors and uses thereof
WO2021079188A1 (en) 2019-10-21 2021-04-29 Novartis Ag Combination therapies with venetoclax and tim-3 inhibitors
WO2021083959A1 (en) 2019-10-29 2021-05-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating uveal melanoma
WO2021102343A1 (en) 2019-11-22 2021-05-27 Sumitomo Dainippon Pharma Oncology, Inc. Solid dose pharmaceutical composition
WO2021123243A1 (en) 2019-12-19 2021-06-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and vaccine compositions to treat cancers
WO2021127200A1 (en) 2019-12-19 2021-06-24 Ngm Biopharmaceuticals, Inc. Ilt3-binding agents and methods of use thereof
US11760802B2 (en) 2019-12-19 2023-09-19 Ngm Biopharmaceuticals, Inc. ILT3-binding agents and methods of use thereof
WO2021123902A1 (en) 2019-12-20 2021-06-24 Novartis Ag Combination of anti tim-3 antibody mbg453 and anti tgf-beta antibody nis793, with or without decitabine or the anti pd-1 antibody spartalizumab, for treating myelofibrosis and myelodysplastic syndrome
WO2021123996A1 (en) 2019-12-20 2021-06-24 Novartis Ag Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases
WO2021144426A1 (en) 2020-01-17 2021-07-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating melanoma
WO2021144657A1 (en) 2020-01-17 2021-07-22 Novartis Ag Combination comprising a tim-3 inhibitor and a hypomethylating agent for use in treating myelodysplastic syndrome or chronic myelomonocytic leukemia
WO2021152005A1 (en) 2020-01-28 2021-08-05 Universite De Strasbourg Antisense oligonucleotide targeting linc00518 for treating melanoma
WO2021152495A1 (en) 2020-01-28 2021-08-05 Glaxosmithkline Intellectual Property Development Limited Combination treatments and uses and methods thereof
WO2021156360A1 (en) 2020-02-05 2021-08-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for discontinuing a treatment with a tyrosine kinase inhibitor (tki)
WO2021170777A1 (en) 2020-02-28 2021-09-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing, prognosing and managing treatment of breast cancer
WO2021209358A1 (en) 2020-04-14 2021-10-21 Glaxosmithkline Intellectual Property Development Limited Combination treatment for cancer based upon an icos antibody and a pd-l1 antibody tgf-beta-receptor fusion protein
WO2021222544A1 (en) 2020-05-01 2021-11-04 Ngm Biopharmaceuticals, Inc. Ilt-binding agents and methods of use thereof
US11802155B2 (en) 2020-05-01 2023-10-31 Ngm Biopharmaceuticals, Inc. ILT-binding agents and methods of use thereof
US11919956B2 (en) 2020-05-14 2024-03-05 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
WO2021255223A1 (en) 2020-06-19 2021-12-23 Onxeo New conjugated nucleic acid molecules and their uses
WO2021262597A2 (en) 2020-06-22 2021-12-30 Ngm Biopharmaceuticals, Inc. Lair-1-binding agents and methods of use thereof
WO2021260528A1 (en) 2020-06-23 2021-12-30 Novartis Ag Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
WO2022023379A1 (en) 2020-07-28 2022-02-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for preventing and treating a cancer
WO2022026706A1 (en) 2020-07-31 2022-02-03 Exelixis, Inc. Combinations for the treatment of cancer
WO2022029573A1 (en) 2020-08-03 2022-02-10 Novartis Ag Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
US11919958B2 (en) 2020-08-19 2024-03-05 Xencor, Inc. Anti-CD28 compositions
WO2022040555A2 (en) 2020-08-21 2022-02-24 Exelixis, Inc. Method of treating cancer
WO2022074206A1 (en) 2020-10-08 2022-04-14 Affimed Gmbh Trispecific binders
WO2022081886A1 (en) * 2020-10-14 2022-04-21 Xencor, Inc. Bispecific antibodies that bind pd-l1 and cd28
WO2022084531A1 (en) 2020-10-23 2022-04-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating glioma
WO2022097060A1 (en) 2020-11-06 2022-05-12 Novartis Ag Cd19 binding molecules and uses thereof
WO2022101484A1 (en) 2020-11-16 2022-05-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for predicting and treating uveal melanoma
WO2022101481A1 (en) 2020-11-16 2022-05-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for predicting and treating uveal melanoma
US11746103B2 (en) 2020-12-10 2023-09-05 Sumitomo Pharma Oncology, Inc. ALK-5 inhibitors and uses thereof
WO2022162569A1 (en) 2021-01-29 2022-08-04 Novartis Ag Dosage regimes for anti-cd73 and anti-entpd2 antibodies and uses thereof
WO2022185160A1 (en) 2021-03-02 2022-09-09 Glaxosmithkline Intellectual Property Development Limited Substituted pyridines as dnmt1 inhibitors
US11739144B2 (en) 2021-03-09 2023-08-29 Xencor, Inc. Heterodimeric antibodies that bind CD3 and CLDN6
US11859012B2 (en) 2021-03-10 2024-01-02 Xencor, Inc. Heterodimeric antibodies that bind CD3 and GPC3
WO2022194908A1 (en) 2021-03-17 2022-09-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating melanoma
WO2022195551A1 (en) 2021-03-18 2022-09-22 Novartis Ag Biomarkers for cancer and methods of use thereof
WO2022208353A1 (en) 2021-03-31 2022-10-06 Glaxosmithkline Intellectual Property Development Limited Antigen binding proteins and combinations thereof
WO2022215011A1 (en) 2021-04-07 2022-10-13 Novartis Ag USES OF ANTI-TGFβ ANTIBODIES AND OTHER THERAPEUTIC AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISEASES
US12037346B2 (en) 2021-04-13 2024-07-16 Nuvalent, Inc. Amino-substituted heteroaryls for treating cancers with EGFR mutations
WO2022221227A1 (en) 2021-04-13 2022-10-20 Nuvalent, Inc. Amino-substituted heterocycles for treating cancers with egfr mutations
WO2022219080A1 (en) 2021-04-14 2022-10-20 INSERM (Institut National de la Santé et de la Recherche Médicale) New method to improve nk cells cytotoxicity
WO2022223791A1 (en) 2021-04-23 2022-10-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating cell senescence accumulation related disease
WO2022243846A1 (en) 2021-05-18 2022-11-24 Novartis Ag Combination therapies
WO2022243378A1 (en) 2021-05-18 2022-11-24 Kymab Limited Uses of anti-icos antibodies
WO2022254227A1 (en) 2021-06-04 2022-12-08 Kymab Limited Treatment of pd-l1 negative or low expressing cancer with anti-icos antibodies
WO2023007023A1 (en) 2021-07-30 2023-02-02 Affimed Gmbh Duplexbodies
WO2023078900A1 (en) 2021-11-03 2023-05-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating triple negative breast cancer (tnbc)
WO2023111203A1 (en) 2021-12-16 2023-06-22 Onxeo New conjugated nucleic acid molecules and their uses
WO2023118165A1 (en) 2021-12-21 2023-06-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating melanoma
WO2023122739A1 (en) 2021-12-22 2023-06-29 Exelixis, Inc. Crystalline forms and salt forms of a kinase inhibitor
WO2023173091A1 (en) 2022-03-11 2023-09-14 Ngm Biopharmaceuticals, Inc. Osteoclast-associated ig-like receptor (oscar) and methods of use thereof
WO2023174210A1 (en) 2022-03-14 2023-09-21 Laekna Limited Combination treatment for cancer
WO2023194656A1 (en) 2022-04-08 2023-10-12 Tilt Biotherapeutics Oy Monoclonal pd-l1 antibodies
WO2023214325A1 (en) 2022-05-05 2023-11-09 Novartis Ag Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
WO2023222854A1 (en) 2022-05-18 2023-11-23 Kymab Limited Uses of anti-icos antibodies
WO2023230541A1 (en) 2022-05-27 2023-11-30 Viiv Healthcare Company Piperazine derivatives useful in hiv therapy
WO2024033399A1 (en) 2022-08-10 2024-02-15 Institut National de la Santé et de la Recherche Médicale Sigmar1 ligand for the treatment of pancreatic cancer
WO2024033400A1 (en) 2022-08-10 2024-02-15 Institut National de la Santé et de la Recherche Médicale Sk2 inhibitor for the treatment of pancreatic cancer
WO2024056716A1 (en) 2022-09-14 2024-03-21 Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical compositions for the treatment of dilated cardiomyopathy
WO2024084034A1 (en) 2022-10-21 2024-04-25 Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical compositions for the treatment of osteoarthritis
WO2024160721A1 (en) 2023-01-30 2024-08-08 Kymab Limited Antibodies
WO2024200571A1 (en) 2023-03-28 2024-10-03 Institut National de la Santé et de la Recherche Médicale Method for discriminating mono-immunotherapy from combined immunotherapy in cancers
WO2024216028A1 (en) 2023-04-12 2024-10-17 Agenus Inc. Methods of treating cancer using an anti-ctla4 antibody and an enpp1 inhibitor

Also Published As

Publication number Publication date
EP2903641A2 (en) 2015-08-12
JP2015535691A (en) 2015-12-17
US20200385482A1 (en) 2020-12-10
AU2013326901B2 (en) 2018-05-31
AU2013326901A1 (en) 2015-04-02
CA2886433C (en) 2022-01-04
US10604581B2 (en) 2020-03-31
HK1211223A1 (en) 2016-05-20
AU2018226425A1 (en) 2018-09-20
US9828434B2 (en) 2017-11-28
BR112015007672A2 (en) 2017-08-08
MX370848B (en) 2020-01-08
HK1253723A1 (en) 2019-06-28
IL237737A0 (en) 2015-05-31
CA3139031A1 (en) 2014-04-10
US20180346587A1 (en) 2018-12-06
CN107892719B (en) 2022-01-14
CA2886433A1 (en) 2014-04-10
CN104994873A (en) 2015-10-21
MX2015004105A (en) 2015-10-26
CN104994873B (en) 2017-12-22
KR20150060750A (en) 2015-06-03
JP6461800B2 (en) 2019-01-30
IL237737B (en) 2020-09-30
KR101947702B1 (en) 2019-02-14
WO2014055897A3 (en) 2014-06-05
US20150274835A1 (en) 2015-10-01
AU2018226425B2 (en) 2020-04-23
CN107892719A (en) 2018-04-10
CN114507282A (en) 2022-05-17

Similar Documents

Publication Publication Date Title
AU2018226425B2 (en) Human Monoclonal Anti-PD-L1 Antibodies and Methods of Use
US20200261578A1 (en) Glucocorticoid-induced tumor necrosis factor receptor (gitr) antibodies and methods of use thereof
US11723973B2 (en) Humanized CC chemokine receptor 4 (CCR4) antibodies and methods of use thereof
US20220098314A1 (en) Glucocorticoid-induced tumor necrosis factor receptor (gitr) antibodies and methods of use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13776696

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 237737

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2013776696

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2886433

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: MX/A/2015/004105

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2013326901

Country of ref document: AU

Date of ref document: 20131004

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2015535829

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20157008757

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 14433826

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 15089268

Country of ref document: CO

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112015007672

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112015007672

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20150406